Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
WO 2021/257728
PCT/US2021/037667
.
,
PACKAGES COMPRISING ANTI-MICROBIAL COATINGS FOR
PREVENTING CONTAMINATION, E.G. AFTER FIRST USE OF THE
PRODUCT
[0001] The present application claims priority to United States
Provisional Patent Application
No. 63/039,666, filed on June 16, 2020, and United States Provisional Patent
Application No.
63/125,231, filed on December 14, 2020, the entireties of which are
incorporated herein by
reference.
FIELD OF THE INVENTION
[0002] The present invention relates to the technical field of multi-
dose packages containing
products that are used over a period of time, rather than all at once. The
packages include but
are not limited to multi-dose medicine containers, multi-dose eye drop
bottles, multi-dose nasal
spray bottles, multi-dose inhalers, cosmetic containers, skin cream or
ointment containers,
fragrance containers, and the like. In particular, the interior surfaces of
these multi-dose packages
may be treated with an anti-microbial coating that prevents contamination of
the container
contents, once the container has been opened.
[0003] The present invention also relates to the technical field of
barrier coated surfaces, for
example interior surfaces of fragrance and/or cosmetic packages, including for
example the mult-
dose containers described above. Examples of suitable fluids include
fragrances, perfumes, dry
powder cosmetics, moist cosmetics, solutions, and liquids. The present
invention also relates to
a fragrance and/or cosmetic package or other vessel and to a method for making
a fragrance
and/or cosmetic package with a pH protective coating or layer between the
contents and the
barrier coating or layer.
[0004] The present disclosure also relates to improved methods for
processing multi-dose
packages, fragrance, and/or cosmetic packages, for example multiple identical
multi-dose,
fragrance, and/or cosmetic packages. The resulting packages are also claimed.
Such multi-dose,
fragrance, and/or cosmetic packages are used in large numbers, and must be
relatively
economical to manufacture and yet highly reliable in storage and use.
BACKGROUND OF THE INVENTION
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
[0005] One important consideration for multi-dose packages is that the
product within the
package remains uncontaminated by microbes, such as bacteria and the like.
Many products are
aseptic or sterile when packaged but, after one or more uses, can become
contaminated with
bacteria. As a result, many multi-dose product packages have a limited shelf-
life after first
opening/use.
[0006] To avoid contamination, it is typically recommended that a user
of a multi-dose
cosmetic package wash his/her hands prior to application. However, in the
United States, there
are no requirements that a cosmetic manufacturer print a post-opening shelf
life or expiration
date on a cosmetic package. In Europe, cosmetic products with a lifespan
longer than 30 months
must show a "period after opening" (POA) time, i.e. a post-opening shelf-life,
which is the time
(usually in months) when the product will remain in good condition after the
consumer has opened
and used the product for the first time. The POA is typically provided as a
number ¨ which
identifies the number of months ¨ positioned on a symbol of an open cream jar.
This symbol is
sometimes used on cosmetic products in the United States as well. Similarly,
in Europe, any
cosmetic product that has a lifespan less than 30 months (which are less
common) must show a
"best before the end of" date, which is typically shown using an "egg timer"
symbol followed by
the date, or the words, which can be abbreviated to BBE or Exp, followed by
the date.
[0007] For instance, many cosmetics packages for creams and lotions
require a user to dip
his/her fingers into the container to extract an amount of the product, which
directly introduces
microorganisms, e.g. bacteria, fungi, etc., into the product. To combat this,
cosmetic
manufacturers will often include preservatives in the product. However,
preservatives break down
over time and/or can cause adverse reactions by certain users.
[0008] The shelf life for certain products, including for example eye-
area products and
cosmetics, e.g. eye drops, mascara, eye liner, etc., is also often limited
because the applicators
are susceptible to microbial infection during use, which increases the risk of
causing an eye
infection. For example, manufacturers usually recommend discarding mascara
three to six
months after purchase. The same may be true of products applied to the lips,
e.g. lip glosses,
lipsticks, etc.
[0009] A recent study of used lipstick, lip gloss, eyeliner, and mascara
products showed that
about 79-90% of those products were contaminated with significant levels of
microbial
contamination, with bacterial loads ranging between 102 and 103 CFU per mL.
Detected bacteria
included Staphylococcus aureus, Escherichia coli and Citrobacter freundii.
Enterobacteriaceae
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
and fungi were also detected in the used products. See Bashir et al.,
"Microbiological study of
used cosmetic products: highlighting possible impact on consumer health," J.
Appl. Microbiol.,
vol. 128(2), pp. 598-605 (2020).
[0010] Embodiments of the present disclosure are therefore directed to
a multi-dose (also
referred to as multi-use) product packages comprising an anti-microbial
coating to protect the
product from microbial, e.g. bacterial, fungal, etc., contamination during use
and to extend the
shelf-life of the product package after first opening/use.
[0011] Another important consideration for many multi-dose product
packages, cosmetic,
and/or fragrance packages, is that the contents of the package have a
substantial pre-opening
shelf life. During this pre-opening shelf life, it may be desirable to isolate
the product from the
vessel wall containing it, or from barrier layers or other functional layers
applied to the vessel wall
to avoid leaching material from the vessel wall, barrier layer, or other
functional layers into the
prefilled contents or vice versa.
[0012] Traditional glass multi-dose, fragrance, and/or cosmetic
packages or other vessels are
prone to breakage or degradation during manufacture, filling operations,
shipping and use, which
means that glass particulates may enter the multi-dose, fragrance, and/or
cosmetic. The
presence of glass particles has led to many FDA Warning Letters and to product
recalls. As a
result, some companies have turned to plastic multi-dose, fragrance, and/or
cosmetic packages,
which provide greater dimensional tolerance and less breakage than glass, but
their use may
remain limited due to their gas (oxygen) permeability: plastic allows small
molecule gases to
permeate into (or out of) the article, decreasing the pre-opening shelf-life
of the package. The
permeability of plastics to gases is significantly greater than that of glass
and, in many cases,
plastics have been unacceptable for that reason.
[0013] Fragrance and/or cosmetic compositions contained in the novel
packages of the
present invention may be suitable for application to a wide variety of
substrates but particularly
to the skin and hair. The compositions, in particular cosmetic compositions,
may comprise a
mascara composition, such as that of the type commonly used to enhance
lenghthening and
beautiful curvature on eyelashes, or a crème, such as a face or body crème or
a hair crème.
Such mascara compositions or crèmes may contain one or more waxes, a film-
forming polymer,
a silicone, a natural or synthetic latex or pseudolatex, and agents for
suspending the latex and
the silicone and/or a thickening agent, among other compositional materials or
admixtures.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
, [0014] Other cosmetic compositions, more particularly fragrance
compositions, may comprise
a fragrance oil, an entrapment material and greater than 50% volatile solvent,
wherein the
fragrance oil comprises both "top note" and "middle and base note" perfume raw
materials
wherein the weight ratio of the two types of fragrance raw materials is in the
range from about
1:20 to about 20:1. More particularly, the fragrance character of the "top
note" perfume raw
materials remains detectable on the substrate for at least 2 hours after
application.
SUMMARY OF THE INVENTION
[0015] An aspect of the invention is a vessel having a lumen defined at
least in part by a
wall, the wall having an interior surface facing the lumen, an outer surface,
and a coating set
on the interior surface comprising an anti-microbial coating and optionally a
barrier coating.
[0016] Embodiments of the present disclosure are directed to a package
comprising: a vessel
comprising one or more walls that enclose at least a portion of a lumen; a
fluid within the lumen,
the fluid being present in an amount that is configured for a plurality of
doses or applications,
optionally wherein the fluid is a drug or medical product, optionally wherein
the fluid is a cosmetic
product, optionally wherein the fluid is a skin care product; an anti-
microbial coating on an interior
surface of the one or more walls, wherein the anti-microbial coating is in
contact with the fluid;
and wherein the anti-microbial coating is effective to inhibit the growth of
microbes, such as
bacteria, in the fluid within the lumen.
[0017] Embodiments of the present disclosure are directed to a package
comprising: a vessel
comprising one or more walls that enclose at least a portion of a lumen; an
aseptic or sterile fluid
within the lumen, the fluid being present in an amount that is configured for
a plurality of doses
or applications, optionally wherein the fluid is a drug or medical product,
optionally wherein the
fluid is a cosmetic product, optionally wherein the fluid is a skin care
product; an anti-microbial
coating on an interior surface of the one or more walls, wherein the anti-
microbial coating is in
contact with the fluid; and wherein the anti-microbial coating is effective to
inactivate or kill
bacteria introduced into the lumen.
[0018] Embodiments of the present disclosure are directed to a package
comprising: a vessel
comprising one or more walls that enclose at least a portion of a lumen; an
aseptic or sterile fluid
within the lumen, the fluid being present in an amount that is configured for
a plurality of doses
or applications, optionally wherein the fluid is a drug or medical product,
optionally wherein the
fluid is a cosmetic product, optionally wherein the fluid is a skin care
product; an applicator for
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
the fluid, wherein the applicator is susceptible to bacterial contamination
upon use; and an anti-
microbial coating on an interior surface of the one or more walls, wherein the
anti-microbial
coating is in contact with the fluid; wherein the anti-microbial coating is
effective to increase the
shelf-life of the package after first use, optionally by at least one week
(also referred to herein as
the post-opening shelf life), optionally at least two weeks, optionally at
least one month, optionally
at least two months, optionally at least three months, optionally at least
four months, optionally
at least five months, optionally at least six months, optionally at least nine
months, optionally at
least one year.
[0019] Embodiments of the present disclosure are directed to a multi-
dose eye drop bottle
comprising: a vessel comprising one or more walls that enclose at least a
portion of a lumen; a
dropper tip at the opening of the lumen; an ophthalmic medical fluid within
the lumen; and an
anti-microbial coating on an interior surface of the one or more walls and in
contact with the fluid;
wherein the anti-microbial coating is effective to inactivate or kill bacteria
introduced into the
lumen.
[0020] Embodiments of the present disclosure are directed to a multi-
dose eye drop bottle
comprising: a vessel comprising one or more walls that enclose at least a
portion of a lumen; a
dropper tip at the opening of the lumen; an ophthalmic medical fluid within
the lumen; and an
anti-microbial coating on an interior surface of the one or more walls and in
contact with the fluid;
and wherein the anti-microbial coating is effective to increase the shelf-life
of the multi-dose eye
drop bottle after first use (also referred to herein as the post-opening shelf
life), optionally by at
least one week, optionally at least two weeks, optionally at least one month,
optionally at least
two months, optionally at least three months, optionally at least four months,
optionally at least
five months, optionally at least six months, optionally at least nine months,
optionally at least one
year.
[0021] Many additional and alternative aspects and embodiments of the
invention are also
contemplated, and are described in the specification and claims that follow.
Some optional
features include the following:
[0022] A package as previously described is contemplated in any
embodiment, in which the
package further comprises an applicator for the fluid, and wherein the
applicator is susceptible to
bacterial contamination.
[0023] A package as previously described is contemplated in any
embodiment, in which the
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
package comprises a dropper tip, a dropper cap, a dropper, or a plunger-
operated applicator.
[0024] A package as previously described is contemplated in any
embodiment, in which the
vessel comprises a nasal spray applicator, such as spray top, such as wherein
the vessel is a
nasal spray bottle.
[0025] A package as previously described is contemplated in any
embodiment, in which the
vessel is a multi-dose eye dropper bottle.
[0026] A package as previously described is contemplated in any
embodiment, in which the
fluid is a liquid formulation of a drug, optionally a liquid formulation of a
drug configured for ocular
or nasal administration, optionally a liquid formulation of a drug configured
for ocular
administration, optionally a liquid formulation of a drug configured for nasal
administration.
[0027] A package as previously described is contemplated in any
embodiment, in which the
fluid comprises an ophthalmic drug formulation.
[0028] A package as previously described is contemplated in any
embodiment, in which the
fluid comprises a locally-acting nasal drug, optionally a nasal decongestant.
[0029] A package as previously described is contemplated in any
embodiment, in which the
vessel is a multi-dose inhaler, e.g. a pressurized metered dose inhaler.
[0030] A package as previously described is contemplated in any
embodiment, in which the
anti-microbial coating is effective to increase the shelf-life of the package
after first use (also
referred to herein as the post-opening shelf life), optionally wherein the
anti-microbial coating is
effective to increase the shelf-life of the package after first use by at
least one week, optionally
at least two weeks, optionally at least one month, optionally at least two
months, optionally at
least three months, optionally at least four months, optionally at least five
months, optionally at
least six months, optionally at least nine months, optionally at least one
year.
[0031] A package as previously described is contemplated in any
embodiment, in which the
vessel is cosmetics container, optionally a mascara bottle or tube, optionally
an eye liner bottle
or tube, optionally a lip gloss bottle or tube.
[0032] A package as previously described is contemplated in any
embodiment, in which the
applicator is a makeup applicator, optionally an eyelash brush.
[0033] A package as previously described is contemplated in any
embodiment, in which the
fluid is a mascara composition.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
[0034] A package as previously described is contemplated in any
embodiment, in which the
fluid is a liquid or gel eye liner and the applicator is an eye liner brush.
[0035] A package as previously described is contemplated in any
embodiment, in which the
fluid is a lip gloss and the applicator is a lip gloss brush or pad.
[0036] A package as previously described is contemplated in any
embodiment, in which the
vessel is a contact lens container.
[0037] A package as previously described is contemplated in any
embodiment, in which the
fluid is a contact lens solution.
[0038] A package as previously described is contemplated in any
embodiment, in which the
vessel is a bottle and the fluid is a contact lens solution or a saline
solution.
[0039] A package as previously described is contemplated in any
embodiment, in which the
fluid is configured to be applied to a person's skin, and optionally wherein
the fluid is a cream,
ointment, or topical medication.
[0040] A package as previously described is contemplated in any
embodiment, in which the
fluid is an edible food product, optionally a spreadable food product,
optionally a spreadable
condiment.
[0041] A package as previously described is contemplated in any
embodiment, in which the
anti-microbial coating comprises zinc oxide, titanium dioxide, or silver
oxide, optionally wherein
the anti-microbial coating comprises zinc oxide, optionally wherein the anti-
microbial coating
comprises titanium dioxide, optionally wherein the anti-microbial coating
comprises silver oxide.
[0042] A package as previously described is contemplated in any
embodiment, in which the
anti-microbial coating is applied by PECVD, ALD, PEALD, sputtering,
evaporation, or sintering,
optionally wherein the anti-microbial coating is applied by PECVD, ALD, or
PEALD, optionally
wherein the anti-microbial coating is applied by PECVD, optionally wherein the
anti-microbial
coating is applied by ALD, optionally wherein the anti-microbial coating is
applied by PEALD.
[0043] A package as previously described is contemplated in any
embodiment, in which the
anti-microbial coating consists essentially of a plurality of atomic
monolayers, optionally wherein
the anti-microbial coating or layer is deposited by atomic layer deposition,
optionally by plasma-
assisted atomic layer deposition.
[0044] A package as previously described is contemplated in any
embodiment, in which the
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
anti-microbial coating has a thickness between about 1 nm and about 1000 nm,
optionally
between about 2 nm and about 1000 nm, optionally between about 5 nm and about
1000 nm,
optionally between about 10 nm and 1000 nm, optionally between about 1 nm and
about 500 nm,
optionally between 2 nm and about 500 nm, optionally between about 5 nm and
about 500 nm,
optionally between about 10 nm and 500 nm, optionally between about 1 nm and
about 250 nm,
optionally between about 2 nm and about 250 nm, optionally between about 5 nm
and about 250
nm, optionally between about 10 nm and 250 nm, optionally between about 1 nm
and about 100
nm, optionally between about 2 nm and about 100 nm, optionally between about 5
nm and about
100 nm, optionally between about 10 nm and 100 nm, optionally between about 1
nm and about
50 nm, optionally between about 2 nm and about 50 nm, optionally between about
5 nm and
about 50 nm, optionally between about 10 nm and about 50 nm.
[0045] A package as previously described is contemplated in any
embodiment, in which the
anti-microbial coating comprises zinc oxide (ZnO) applied by PECVD from a feed
gas comprising
zinc acetate, diethyl zinc, or a combination thereof, and an oxidant.
[0046] A package as previously described is contemplated in any
embodiment, in which the
anti-microbial coating comprises titanium dioxide (TiO2) applied by PECVD from
a feed gas
comprising titanium tetra chloride and an oxidant.
[0047] A package as previously described is contemplated in any
embodiment, in which the
anti-microbial coating comprises silver oxide (Ag2O) applied by PECVD from a
feed gas
comprising an organosilver compound and an oxidant, optionally wherein the
organosilver
compound has the composition:
Ag (Hfac)(P R3)
in which Hfac is 1,1,1,5,5,5-hexafluoroacetylacetonate, P is phosphine, and R
is methyl, ethyl,
or a combination thereof.
[0048] A package as previously described is contemplated in any
embodiment, in which the
anti-microbial coating comprises zinc oxide (ZnO) applied by ALD or PEALD
using feed gases
comprising zinc acetate, diethyl zinc, or a combination thereof, and an
oxidant.
[0049] A package as previously described is contemplated in any
embodiment, in which the
anti-microbial coating comprises titanium dioxide (TiO2) applied by ALD or
PEALD using feed
gases comprising titanium tetra chloride, titanium isopropoxide, or a
combination thereof, and an
oxidant.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
[0050] A package as previously described is contemplated in any
embodiment, in which the
anti-microbial coating comprises silver oxide (Ag20) applied by PECVD using
feed gases
comprising an organosilver compound and an oxidant, optionally wherein the
organosilver
compound has the composition:
Ag (Hfac)(P R3)
in which Hfac is 1,1,1,5,5,5-hexafluoroacetylacetonate, P is phosphine, and R
is methyl, ethyl,
or a combination thereof.
[0051] A package as previously described is contemplated in any
embodiment, in which the
oxidant is selected from 02, 03, H20, H202, N20, NO2, air, or a combination
thereof, optionally in
which the oxidant is 02.
[0052] A package as previously described is contemplated in any
embodiment, in which the
vessel wall further comprises a barrier coating, and optionally in which the
barrier coating may
be part of a coating set comprising a tie coating or layer, a barrier coating
or layer, and a pH
protective coating or layer.
[0053] The tie coating or layer can comprise SiOxCy or Si(NH)C. In
either formulation, x is
from about 0.5 to about 2.4 and y is from about 0.6 to about 3. The tie
coating or layer has an
interior surface facing the lumen and an outer surface facing the wall
interior surface.
[0054] The barrier coating or layer can comprise SiOx, wherein x is from
1.5 to 2.9. The
barrier layer can be from 2 to 1000 nm thick. It can have an interior surface
facing the lumen
and an outer surface facing the interior surface of the tie coating or layer.
The barrier coating
or layer optionally is effective to reduce the ingress of atmospheric gas into
the lumen compared
to an vessel without a barrier coating or layer.
[0055] The pH protective coating or layer can comprise SiOxCy or
Si(NH)C, where x is from
about 0.5 to about 2.4 and y is from about 0.6 to about 3. The pH protective
coating or layer
can have an interior surface facing the lumen and an outer surface facing the
interior surface
of the barrier coating or layer.
[0056] In an embodiment, in the presence of a fluid composition
contained in the lumen
and having a pH between 5 and 9, the calculated shelf life of the package can
be more than six
months at a storage temperature of 4 C.
[0057] A vessel as previously described is contemplated in any
embodiment, in which at
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
least a portion of the wall of the vessel comprises a thermoplastic polymer,
optionally in which
the vessel wall is made of a thermoplastic polymer.
[0058] A vessel as previously described is contemplated in any
embodiment, in which the
anti-microbial coating and/or the barrier coating or layer is from 4 nm to 500
nm thick.
[0059] A vessel as previously described is contemplated in any
embodiment, in which the pH
protective coating or layer comprises SiOxCy.
[0060] A vessel as previously described is contemplated in any
embodiment, in which the pH
protective coating or layer is applied by PECVD of a precursor feed comprising
an acyclic
siloxane, a nnonocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane,
a nnonocyclic
silazane, a polycyclic silazane, a polysilsesquiazane, a silatrane, a
silquasilatrane, a
silproatrane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a
combination of any
two or more of these precursors.
[0061] A vessel as previously described is contemplated in any
embodiment, in which the pH
protective coating or layer is applied by PECVD of a precursor feed comprising
octamethylcyclotetrasiloxane (OMCTS).
[0062] A vessel as previously described is contemplated in embodiment,
in which the pH
protective coating or layer as applied is between 10 and 1000 nm thick.
[0063] A vessel as previously described is contemplated in any
embodiment, in which
the rate of erosion of the pH protective coating or layer, if directly
contacted by a fluid composition
having a pH of 8, is less than 20% of the rate of erosion of the barrier
coating or layer, if directly
contacted by the same fluid composition under the same conditions.
[0064] A vessel as previously described is contemplated in any
embodiment, in which
the pH protective coating or layer is at least coextensive with the barrier
coating or layer.
[0065] A vessel as previously described is contemplated in any
embodiment, in which
the fluid composition removes the pH protective coating or layer at a rate of
1 nm or less of pH
protective coating or layer thickness per 44 hours of contact with the fluid
composition.
[0066] A vessel as previously described is contemplated in any
embodiment, in which
an FTIR absorbance spectrum of the pH protective coating or layer has a ratio
greater than
0.75 between:
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
- the maximum amplitude of the Si-0-Si symmetrical stretch peak between
about 1000 and 1040 cm-1, and
- the maximum amplitude of the Si-0-Si assymmetric stretch peak between
about 1060 and about 1100 cm-1.
[0067]
A vessel as previously described is contemplated in any embodiment,
in which
the silicon dissolution rate by a 50 mM potassium phosphate buffer diluted in
water for
injection, adjusted to pH 8 with concentrated nitric acid, and containing 0.2
wt. % polysorbate-80
surfactant from the vessel is less than 170 ppb/day.
[0068]
A vessel as previously described is contemplated in any embodiment,
in which
the total silicon content of the pH protective coating or layer and barrier
coating or layer, upon
dissolution into 0.1 N potassium hydroxide aqueous solution at 40 C from the
vessel, is less
than 66 ppm.
[0069]
A vessel as previously described is contemplated in any embodiment,
in which
the calculated shelf life (total Si / Si dissolution rate) is more than 2
years.
[0070]
A vessel as previously described is contemplated in any embodiment,
wherein the
pH protective coating or layer shows an 0-Parameter measured with attenuated
total
reflection (ATR) of less than 0.4, measured as:
0-Parameter = Intensity at 1253 cm-1
Maximum intensity in the range 1000 to 1100 cm-1.
[0071]
A vessel as previously described is contemplated in any embodiment,
wherein the
pH protective coating or layer shows an N-Parameter measured with attenuated
total
reflection (ATR) of less than 0.7, measured as:
N-Parameter = Intensity at 840 cm-1
Intensity at 799 cm-1
[0072]
A vessel as previously described is contemplated in any embodiment,
in which
the tie coating or layer is applied by PECVD of a precursor feed comprising
octamethylcyclotetrasiloxane (OMCTS), tetramethyldisiloxane
(TMDSO), or
hexamethyldisiloxane (HMDSO).
[0073]
A vessel as previously described is contemplated in any embodiment,
in which
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
the tie coating or layer is on average between 5 and 200 nm thick.
[0074] A vessel as previously described is contemplated in any
embodiment, in which
the tie coating or layer is at least coextensive with the barrier coating or
layer.
[0075] A vessel as previously described is contemplated in any
embodiment, in which
the barrier coating or layer is between 10 and 200 nm thick
[0076] Another aspect of the invention is a multi-dose, fragrance,
and/or cosmetic package
having a lumen defined at least in part by a wall, the wall having an interior
surface facing the
lumen, an outer surface, and a coating set on the interior surface that
comprises a barrier
coating and at least one additional coating layer.
[0077] The problem of permeability may be addressed by adding a barrier
coating or layer to
a plastic fragrance and/or cosmetic package where it contacts fluid contents
of the package. One
such barrier layer is a very thin coating of SiOx, as defined below, applied
by plasma enhanced
chemical vapor deposition. But SiOx barrier layers deposited on a package by
PECVD are etched
off by aqueous contents of the package having pH-values greater than 4,
particularly at higher
pH values. This reduces the pre-opening shelf life of the package as its
barrier efficacy is reduced.
[0078] Containers for cosmetic compositions also have a number of
challenges that must be
overcome as a result of the complexity of the cosmetic composition itself.
Cosmetic compositions
include a mascara composition, such as that of the type commonly used to
enhance lenghthening
and beautiful curvature on eyelashes, or a crème, such as a face or body crème
or a hair crème.
Such mascara compositions or crèmes may contain one or more waxes, a film-
forming polymer,
a silicone, a natural or synthetic latex or pseudolatex, and agents for
suspending the latex and
the silicone and/or a thickening agent, among other compositional materials or
admixtures. The
embodiments of the present invention provide a suitable solute block for the
underlying plastic to
avoid any detrimental effects or interactions with the compositions contained
within the container.
The embodiments of the present invention may also reduce the need for
additives in the
compositions, whether cosmetic or fragrance compositions, by providing an
inert environment.
[0079] The coating set may comprise a barrier coating or layer and any
one or more of a tie
coating or layer and a pH protective coating or layer.
[0080] The tie coating or layer may comprise or consist of SiOxCyHz or
SiNxCyHz in which x is
from about 0.5 to about 2.4 as measured by X-ray photoelectron spectroscopy
(XPS), y is from
about 0.6 to about 3 as measured by XPS, and z is from about 2 to about 9 as
measured by at
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
least one of Rutherford backscattering spectrometry (RBS) or hydrogen forward
scattering (HFS).
The tie coating or layer has an outer surface facing the wall surface and an
interior surface.
[0081] The barrier coating or layer may comprise or consist of SiOx, in
which x is from about
1.5 to about 2.9 as measured by XPS. The barrier coating or layer is
positioned between the
interior surface of the tie coating or layer and the lumen.
[0082] The pH protective coating or layer may comprise or consist of
SiOxCyHz, in which x is
from about 0.5 to about 2.4 as measured by XPS, y is from about 0.6 to about 3
as measured by
XPS, and z is from about 2 to about 9 as measured by at least one of RBS or
HFS. The pH
protective coating or layer is positioned between the barrier coating or layer
and the lumen.
[0083] The pH protective coating or layer and tie coating or layer
together may be effective to
keep the barrier coating or layer at least substantially undissolved as a
result of attack by a fluid
contained in the lumen having a pH greater than 5 for a period of at least six
months.
[0084] Another aspect of the invention is the use of such a vessel for
storing a multi-dose,
fragrance (e.g. perfume), and/or cosmetic fluid having a pH greater than 5.
[0085] Still another aspect of the invention is a process for making
such a vessel comprising
or consisting of the steps of: forming a tie coating or layer on the vessel
interior wall; forming a
barrier coating or layer over at least a portion of the tie coating or layer;
and forming a pH
protective coating or layer positioned between the barrier coating or layer
and the lumen.
[0086] In any embodiment of the invention, the tie coating or layer
optionally can be applied
by plasma enhanced chemical vapor deposition (PECVD). In any embodiment of the
invention,
the barrier coating or layer optionally can be applied by PECVD. In any
embodiment of the
invention, the pH protective coating or layer optionally can be applied by
PECVD.
[0087] In any embodiment of the invention, for the pH protective coating
or layer, x optionally
can be from about 1 to about 2 as measured by XPS, y optionally can be from
about 0.6 to about
1.5 as measured by XPS, and z optionally can be from about 2 to about 5 as
measured by RBS
or HFS.
[0088] In any embodiment of the invention, the pH protective coating or
layer may be applied
by PECVD of a precursor feed comprising an organosilicon precursor. In any
embodiment of the
invention, the organosilicon precursor comprises or consists of
hexamethyldisiloxane (HMDSO),
trimethylsilane (TriMS), tetramethylsilane (TetraMS), tetramethyldisiloxane
(TMDSO),
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
octamethylcyclotetrasiloxane (OMCTS) or a combination of two or more of them.
[0089] In any embodiment of the invention, the precursor feed for the
pH protective coating or
layer may comprise or consist of:
= from 0.5 to 10 standard volumes of the organosilicon precursor;
= from 0.1 to 10 standard volumes of oxygen; and
= from 1 to 100 standard volumes of a carrier gas.
[0090] In any embodiment of the invention, the pH protective coating or
layer optionally can
be from about 10 to about 1000 nm thick.
[0091] In any embodiment of the invention, the pH protective coating or
layer contacting the
fluid composition optionally can be from about 10 to about 1000 nm thick after
contact with a fluid
contained in the lumen having a pH greater than 5 for a period of two years.
[0092] In any embodiment of the invention, the rate of erosion of the
pH protective coating or
layer, if directly contacted by a fluid contained in the lumen having a pH
greater than 5, optionally
can be less than 20% of the rate of erosion of the barrier coating or layer,
if directly contacted by
the same fluid under the same conditions.
[0093] In any embodiment of the invention, the vessel may have a pre-
opening shelf life, while
directly contacted by a fluid contained in the lumen having a pH greater than
5, of at least two
years.
[0094] In any embodiment of the invention, the pre-opening shelf life
optionally can be based
on storage of the vessel containing the fluid at 20 C. In any embodiment of
the invention, the pre-
opening shelf life optionally can be based on storage of the vessel containing
the fluid at 40 C.
[0095] In any embodiment of the invention, a fluid contained in the
lumen having a pH greater
than 5 optionally can remove the pH protective coating or layer at a rate of 1
nm or less of pH
protective coating or layer thickness per 88 hours of contact with the fluid.
[0096] In any embodiment of the invention, an FTIR absorbance spectrum
of the pH protective
coating or layer may have a ratio greater than 0.75 between:
= the maximum amplitude of the Si-O-Si symmetrical stretch peak between
about
1000 and 1040 cm-1, and
= the maximum amplitude of the Si-O-Si asymmetric stretch peak between
about
1060 and about 1100 cm-1.
CA 03183219 2022- 12- 16
WO 2021/257728 PCT/US2021/037667
, [0097] In any embodiment of the invention, the silicon dissolution rate
by a 50 mM potassium
phosphate buffer diluted in water, adjusted to pH 8 with concentrated nitric
acid, and containing
0.2 wt. A) polysorbate-80 surfactant, from the vessel optionally can be less
than 170 ppb/day.
[0098] In any embodiment of the invention, the total silicon content of the
pH protective coating
or layer, barrier coating or layer, and tie coating or layer, as measured by
dissolution of the pH
protective coating or layer, barrier coating or layer, and tie coating or
layer into 0.1 N potassium
hydroxide aqueous solution at 40 C from the vessel, optionally can be less
than 66 ppm.
[0099] In any embodiment of the invention, the pre-opening calculated shelf
life optionally can
be more than 2 years.
[0100] In any embodiment of the invention, after formation of a groove by
focused ion beam
through the pH protective coating or layer, the barrier coating or layer, the
tie coating or layer,
and into the lumen wall, and exposure of the groove with 1N aqueous potassium
hydroxide (KOH)
solution maintained at 40 C in the lumen for 6.5 hours, the barrier coating or
layer optionally can
be detectable by XPS and optionally can have atomic percentages of oxygen and
silicon within
atomic percent of their values before treatment of the groove with the KOH
solution.
[0101] .. In any embodiment of the invention, the pH protective coating or
layer optionally can
show an 0-Parameter measured with attenuated total reflection (ATR) of less
than 0.4, measured
as:
0-Parameter = Intensity at 1253 cm-1
Maximum intensity in the range from 1000 to 1100 cm-1.
[0102] In any embodiment of the invention, the pH protective coating or
layer optionally can
show an N-Parameter measured with attenuated total reflection (ATR) of less
than 0.7, measured
as:
N-Parameter = Intensity at 840 cm -1
Intensity at 799 cm-1.
[0103] .. In any embodiment of the invention, the pH protective coating or
layer optionally can
be applied by PECVD at a power level per of more than 22,000 kJ/kg of mass of
polymerizing
gases in the PECVD reaction chamber. In any embodiment of the invention, the
pH protective
coating or layer optionally can be applied by PECVD at a power level per of
from 1 to 200 W. In
any embodiment of the invention, for formation of the pH protective coating or
layer the ratio of
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
the electrode power applied by PECVD to the plasma volume optionally can be
from 5 W/ml to
75 W/ml.
[0104] In any embodiment of the invention, for the tie coating or
layer, x optionally can be from
about 1 to about 2 as measured by X-ray photoelectron spectroscopy (XPS), y
optionally can be
from about 0.6 to about 1.5 as measured by XPS, and z optionally can be from
about 2 to about
as measured by Rutherford backscattering spectrometry (RBS) or hydrogen
forward scattering
(HFS).
[0105] In any embodiment of the invention, the tie coating or layer
optionally can be applied
by PECVD of a precursor feed comprising an organosilicon precursor. In any
embodiment of the
invention, the organosilicon precursor optionally can be tetramethylsilane
(TetraMS),
trimethylsilane (TriMS), hexamethyldisiloxane (HMDSO),
octamethylcyclotetrasiloxane
(OMCTS), tetramethyldisiloxane (TMDSO), or a combination of two or more of
these.
[0106] In any embodiment of the invention, the precursor feed for the
tie coating or layer
optionally comprises or consists of:
= from 0.5 to 10 standard volumes of the organosilicon precursor;
= from 0.1 to 10 standard volumes of oxygen; and
= from 1 to 120 standard volumes of a carrier gas.
[0107] In any embodiment of the invention, the tie coating or layer
optionally can be on
average from about 5 to about 200 nm thick.
[0108] Any embodiment of the invention optionally can further comprise
a lubricity coating or
layer applied between the pH protective coating or layer and the lumen.
[0109] In any embodiment of the invention, the vessel optionally can
contain a fragrance
and/or cosmetic composition having a pH greater than 5 in the lumen, and the
package may have
a pre-opening shelf life of at least six months.
[0110] In any embodiment of the invention, the vessel may contain a
liquid fragrance, a dry
powder cosmetic product, or a moist cosmetic product.
[0111] In any embodiment of the invention, the composition contained in
said vessels may be
a mascara composition, such as that of the type commonly used to enhance
lenghthening and
beautiful curvature on eyelashes, or a crème, such as a face or body crème or
a hair crème, or
a fragrance / perfume, among other cosmetic or fragrance compositions. Such
mascara
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
compositions or crèmes may contain one or more waxes, a film-forming polymer,
a silicone, a
natural or synthetic latex or pseudolatex, and agents for suspending the latex
and the silicone
and/or a thickening agent, among other compositional materials or admixtures.
Embodiments of
the present invention provide a suitable solute block for the underlying
plastic to avoid any
detrimental effects or interactions with the compositions contained within the
container.
Embodiments of the present invention also reduce the need for additives in the
compositions,
whether cosmetic or fragrance compositions, by providing an inert environment.
[0112] Many additional and alternative aspects and embodiments of the
invention are also
contemplated, and are described in the specification and claims that follow.
BRIEF DESCRIPTION OF THE DRAWINGS
[0113] FIG. 1 is a perspective view of a multi-dose eye drop bottle
according to an
embodiment of the invention.
[0114] FIG. 2 is a perspective view of a multi-dose eye drop bottle
according to an
embodiment of the invention.
[0115] FIG. 3 is a schematic sectional view of a multi-dose eye drop
bottle according to an
embodiment of the invention, including an enlarged detail view of a portion of
the vessel wall and
coating.
[0116] FIG. 4 is a schematic sectional view of a multi-dose eye drop
bottle according to an
embodiment of the invention, including an enlarged detail view of a portion of
the vessel wall and
coatings.
[0117] FIG. 5 is a perspective view of a nasal spray bottle according
to an embodiment of the
invention.
[0118] FIG. 6 is a perspective view of a nasal spray bottle according
to an embodiment of the
invention.
[0119] FIG. 7 is a schematic sectional view of a nasal spray bottle
according to an embodiment
of the invention, including an enlarged detail view of a portion of the vessel
wall and coating.
[0120] FIG. 8 is a schematic sectional view of a nasal spray bottle
according to an embodiment
of the invention, including an enlarged detail view of a portion of the vessel
wall and coatings.
[0121] FIG. 9 is a perspective view of a mascara bottle according to an
embodiment of the
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
invention.
[0122] FIG. 10 is a perspective view of a mascara bottle according to
an embodiment of the
invention.
[0123] FIG. 11 is a schematic sectional view of a mascara bottle
according to an embodiment
of the invention, including an enlarged detail view of a portion of the vessel
wall and coating.
[0124] FIG. 12 is a schematic sectional view of a mascara bottle
according to an embodiment
of the invention, including an enlarged detail view of a portion of the vessel
wall and coatings.
[0125] FIG. 13 is a perspective view of a small dose medicine bottle
package according to an
embodiment of the invention.
[0126] FIG. 14 is a perspective view of a small dose medicine bottle
package according to an
embodiment of the invention.
[0127] FIG. 15 is a schematic sectional view of a small dose medicine
bottle package
according to an embodiment of the invention, including enlarged detail views
of a portion of the
vessel wall and coating and a portion of the applicator wall and coating.
[0128] FIG. 16 is a schematic sectional view of a small dose medicine
bottle package
according to an embodiment of the invention, including enlarged detail views
of a portion of the
vessel wall and coatings and a portion of the applicator wall and coatings.
[0129] FIG. 17 is a perspective view of a pump bottle according to an
embodiment of the
invention.
[0130] FIG. 18 is a perspective view of a pump bottle according to an
embodiment of the
invention.
[0131] FIG. 19 is a schematic sectional view of a pump bottle according
to an embodiment of
the invention, including an enlarged detail view of a portion of the vessel
wall and coating.
[0132] FIG. 20 is a schematic sectional view of a pump bottle according
to an embodiment of
the invention, including an enlarged detail view of a portion of the vessel
wall and coatings.
[0133] FIG. 21 is a perspective view of a contact lens case according
to an embodiment of
the invention.
[0134] FIG. 22 is a schematic sectional view of a contact lens case
according to an
embodiment of the invention, including an enlarged detail view of a portion of
the vessel wall and
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
coating.
[0135] FIG. 23 is a schematic sectional view of a multi-dose inhaler
according to an
embodiment of the invention.
[0136] FIG. 24 is a schematic sectional view of a vessel according to
any embodiment of the
invention.
[0137] FIG. 25 is an enlarged detail view of a portion of the vessel
wall and coatings of FIG.
1.
[0138] FIG. 26 is a plot of silicon dissolution versus exposure time at
pH 6 for a glass
container versus a plastic container having a SiOx barrier layer coated in the
inside wall.
[0139] FIG. 27 is a plot of silicon dissolution versus exposure time at
pH 7 for a glass
container versus a plastic container having a SiOx barrier layer coated in the
inside wall.
[0140] FIG. 28 is a plot of silicon dissolution versus exposure time at
pH 8 for a glass
container versus a plastic container having a SiOx barrier layer coated in the
inside wall.
[0141] FIG. 29 is a plot of the SiOx coating thickness necessary
initially to leave a 30 nm
residual coating thickness when stored with solutions at different nominal pH
values from 3 to 9.
[0142] FIG. 30 shows the silicon dissolution rates at pH 8 and 40 C of
various PECVD
coatings.
[0143] FIG. 31 is a plot of the ratio of Si-O-Si symmetric/asymmetric
stretching mode versus
energy input per unit mass (W/FM or KJ/kg) of a PECVD coating using as the
reactive precursor
gases OMCTS and oxygen.
[0144] FIG. 32 is a plot of silicon shelf life (days) versus energy
input per unit mass (W/FM
or KJ/kg) of a PECVD coating using as the reactive precursor gases OMCTS and
oxygen.
[0145] FIG. 33 is a Fourier Transform Infrared Spectrophotometer (FTIR)
absorbance
spectrum of a PECVD coating.
[0146] FIG. 34 is a Fourier Transform Infrared Spectrophotometer (FTIR)
absorbance
spectrum of a PECVD coating.
[0147] FIG. 35 is a Fourier Transform Infrared Spectrophotometer (FTIR)
absorbance
spectrum of a PECVD coating.
[0148] FIG. 36 is a Fourier Transform Infrared Spectrophotometer (FTIR)
absorbance
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
spectrum of a PECVD coating.
[0149] FIG. 37 is a Fourier Transform Infrared Spectrophotometer (FTIR)
absorbance
spectrum of a PECVD coating, originally presented as FIG. 5 of U.S. Pat.
No.8,067,070,
annotated to show the calculation of the 0-Parameter referred to in that
patent.
[0150] FIG. 38 is a schematic view of a syringe with a trilayer coating
according to FIGS.
1, 2, and 3, showing a cylindrical region and specific points where data was
taken.
[0151] FIG. 39 is a Trimetric map of the overall trilayer coating
thickness versus position
in the cylindrical region of a syringe illustrated by FIGS. 18, 1, 2, and 3.
[0152] FIG. 40 is a photomicrograhic sectional view showing the
substrate and coatings
of the trilayer coating at position 2 shown in FIG. 18.
[0153] FIG. 41 is another Trimetric map of the overall trilayer coating
thickness versus
position in the cylindrical region of a syringe illustrated by FIGS. 18, 1, 2,
and 3.
[0154] FIG. 42 is a plot of coating thickness, representing the same
coating as FIG. 21, at
Positions 1, 2, 3, and 4 shown in FIG. 18.
[0155] FIG. 43 is a schematic illustration of a syringe, showing points
on its surface where
measurements were made in a working example.
[0156] FIG. 44 is a photograph showing the benefit of the present
trilayer coating in
preventing pinholes after attack by an alkaline reagent, as discussed in the
working examples.
[0157] FIG. 44A is an enlarged detail view of the indicated portion of
FIG. 24.
[0158] In the context of the present invention, the following
definitions and abbreviations are
used:
[0159] RF is radio frequency.
[0160] The term "at least" in the context of the present invention
means "equal or more"
than the integer following the term. The word "comprising" does not exclude
other elements or
steps, and the indefinite article "a" or "an" does not exclude a plurality
unless indicated
otherwise. Whenever a parameter range is indicated, it is intended to disclose
the parameter
values given as limits of the range and all values of the parameter falling
within said range.
[0161] "First" and "second" or similar references to, for example,
layers, processing stations
or processing devices refer to the minimum number of layers, processing
stations or devices
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
that are present, but do not necessarily represent the order or total number
of layers, processing
stations and devices or require additional layers, processing stations and
devices beyond the
stated number. These terms do not limit the number of processing stations or
the particular
processing carried out at the respective stations. For example, a "first"
layer in the context of
this specification can be either the only layer or any one of plural layers,
without limitation. In
other words, recitation of a "first" layer allows but does not require an
embodiment that also
has a second or further layer.
[0162] For purposes of the present invention, an "organosilicon
precursor" is a compound
having at least one of the linkages:
I I
¨0¨Si¨C¨H or ¨NH¨Si¨C¨H
I I
which is a tetravalent silicon atom connected to an oxygen or nitrogen atom
and an organic
carbon atom (an organic carbon atom being a carbon atom bonded to at least one
hydrogen
atom). A volatile organosilicon precursor, defined as such a precursor that
can be supplied as a
vapor in a PECVD apparatus, is an optional organosilicon precursor.
Optionally, the
organosilicon precursor is selected from the group consisting of a linear
siloxane, a monocyclic
siloxane, a polycyclic siloxane, a polysilsesquioxane, an alkyl
trimethoxysilane, a linear silazane,
a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, and a
combination of any
two or more of these precursors.
[0163] The feed amounts of PECVD precursors, gaseous reactant or
process gases, and
carrier gas are sometimes expressed in "standard volumes" in the specification
and claims.
The standard volume of a charge or other fixed amount of gas is the volume the
fixed amount of
the gas would occupy at a standard temperature and pressure (without regard to
the actual
temperature and pressure of delivery). Standard volumes can be measured using
different
units of volume, and still be within the scope of the present disclosure and
claims. For
example, the same fixed amount of gas could be expressed as the number of
standard cubic
centimeters, the number of standard cubic meters, or the number of standard
cubic feet.
Standard volumes can also be defined using different standard temperatures and
pressures,
and still be within the scope of the present disclosure and claims. For
example, the standard
temperature might be 0 C and the standard pressure might be 760 Torr (as is
conventional), or
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
the standard temperature might be 20 C and the standard pressure might be 1
Torr. But
whatever standard is used in a given case, when comparing relative amounts of
two or more
different gases without specifying particular parameters, the same units of
volume, standard
temperature, and standard pressure are to be used relative to each gas, unless
otherwise
indicated.
[0164] The corresponding feed rates of PECVD precursors, gaseous
reactant or process
gases, and carrier gas are expressed in standard volumes per unit of time in
the specification.
For example, in the working examples the flow rates are expressed as standard
cubic
centimeters per minute, abbreviated as sccm. As with the other parameters,
other units of time
can be used, such as seconds or hours, but consistent parameters are to be
used when
comparing the flow rates of two or more gases, unless otherwise indicated.
[0165] A "vessel" in the context of the present invention can be any
type of vessel with at least
one opening and a wall defining an inner or interior surface. The substrate
can be the wall of a
vessel having a lumen. The substrate surface can be part or all of the inner
or interior surface of
a vessel having at least one opening and an inner or interior surface. A
vessel can be of any
shape, with a vessel having a substantially cylindrical wall adjacent to at
least one of its open
ends being preferred.
[0166] In some embodiments, the package and vessel may be configured to
store multiple
doses of a fluid product. For instance, the vessel may be a multi-dose eye
dropper bottle or a
nasal spray bottle, configured for multiple applications/uses over a period of
time. Alternatively,
the vessel may be a cosmetic container, such as a mascara bottle or tube or a
liquid/gel eye liner
bottle or tube or a lip gloss bottle or tube. Alternatively, the vessel may be
a container configured
to store a cream that is applied to the skin, e.g. a can or canister of a
topical cream or ointment.
Alternatively, the vessel may be a container configured to store a fragrance,
e.g. a perfume.
[0167] In some embodiments, the package or vessel may comprise an
applicator for the fluid
product.
[0168] An "applicator" in the context of the present invention can be
any type of device that is
used to apply the fluid product to an intended location and can include
droppers, spray nozzles,
brushes, and the like. In some embodiments, for instance, the vessel may
comprise a dropper tip
or a spray tip. The dropper tip or spray tip is typically inserted into the
opening to the lumen,
thereby closing it off such that the fluid exits the lumen only through the
dropper tip or spray tip.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
In other embodiments, the applicator may be removed from the vessel during
use. For instance,
the applicator may include a makeup brush such as an eyelash brush, an eye
liner brush or pad,
or a lip gloss brush. Or the applicator may comprise a dropper cap that is
unscrewed from the
vessel for use and then re-attached to the vessel after use.
[0169] In other embodiments, rather than being part of the package of
the present disclosure,
the applicator may come from an external source. For instance, a topical cream
may be applied
by hand, with a user's hand thus serving as the applicator. Or a food product
may be applied by
a common kitchen utensil, such as a spoon, fork, or knife.
[0170] The terms "pre-opening shelf life" and "post-opening shelf life"
are used in the present
disclosure to refer to two different things. The pre-opening shelf life of a
package is the shelf life
of the package prior to a first opening of the package, i.e. during which the
product within the
lumen of the vessel remains sealed in the lumen by one or more closures and/or
seals. The post-
opening shelf life of a package is the shelf life of the package after the
package has been opened
(and typically the product dispensed for the first time) and subjected to
potential
microbial/bacterial contamination. The pre-opening shelf life of a product may
be extended by the
application of one or more coatings or layers that reduce gas ingress and/or
egress through the
vessel walls and/or that provide a solute block to avoid detrimental effects
or interactions between
the vessel wall and the composition contained within the container. The post-
opening shelf life of
a product, on the other hand, may be extended by the application of one or
more anti-microbial
coatings.
[0171] The term "at least" in the context of the present invention
means "equal or more"
than the integer following the term. Thus, a vessel in the context of the
present invention has
one or more openings. If the vessel has two openings, they can be of same or
different size.
If there is more than one opening, one opening can be used for the gas inlet
for a PECVD
coating method according to the present invention, while the other openings
are either capped
or open.
[0172] A "hydrophobic layer" in the context of the present invention
means that the coating or
layer lowers the wetting tension of a surface coated with the coating or
layer, compared to the
corresponding uncoated surface. Hydrophobicity is thus a function of both the
uncoated
substrate and the coating or layer. The same applies with appropriate
alterations for other
contexts wherein the term "hydrophobic" is used. The term "hydrophilic" means
the opposite,
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
i.e. that the wetting tension is increased compared to reference sample. The
present
hydrophobic layers are primarily defined by their hydrophobicity and the
process conditions
providing hydrophobicity. A coating or layer or treatment is defined as
"hydrophobic" if it lowers
the wetting tension of a surface, compared to the corresponding uncoated or
untreated surface.
Hydrophobicity is thus a function of both the untreated substrate and the
treatment.
[0173] "Wetting tension" is a specific measure for the hydrophobicity or
hydrophilicity of a
surface. An optional wetting tension measurement method in the context of the
present invention
is ASTM D 2578 or a modification of the method described in ASTM D 2578. This
method uses
standard wetting tension solutions (called dyne solutions) to determine the
solution that comes
nearest to wetting a plastic film surface for exactly two seconds. This is the
film's wetting tension.
The procedure utilized is varied herein from ASTM D 2578 in that the
substrates are not flat
plastic films, but are tubes made according to the Protocol for Forming PET
Tube and (except for
controls) coated according to the Protocol for coating Tube Interior with
Hydrophobic Coating or
Layer (see Example 9 of EP2251671 A2).
[0174] These values of w, x, y, and z are applicable to the empirical
composition SiwOxCyHz
throughout this specification. The values of w, x, y, and z used throughout
this specification
should be understood as ratios or an empirical formula (for example for a
coating or layer),
rather than as a limit on the number or type of atoms in a molecule. For
example,
octamethylcyclotetrasiloxane, which has the molecular composition Si404C8H24,
can be
described by the following empirical formula, arrived at by dividing each of
w, x, y, and z in the
molecular formula by 4, the largest common factor: Si10iC2H6. The values of w,
x, y, and z are
also not limited to integers. For example, (acyclic) octamethyltrisiloxane,
molecular composition
Si302C8H24,is reducible to Sii00.6702.67H8. Also, although SiOxCyHz is
described as equivalent
to SiOxCy, it is not necessary to show the presence of hydrogen in any
proportion to show
the presence of SiOxCy.
[0175] The atomic ratio can be determined by XPS. Taking into account
the H atoms,
which are not measured by XPS, the coating or layer may thus in one aspect
have the
formula SiwOxCyHz (or its equivalent SiOxCy), for example where w is 1, x is
from about 0.5 to
about 2.4, y is from about 0.6 to about 3, and z is from about 2 to about 9.
Typically, such
coating or layer would hence contain 36% to 41% carbon normalized to 100%
carbon plus
oxygen plus silicon.
[0176] The word "comprising" does not exclude other elements or steps.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
[0177] The indefinite article "a" or "an" does not exclude a plurality.
DETAILED DESCRIPTION
[0178] The present invention will now be described more fully, with
reference to the
accompanying drawings, in which several embodiments are shown. This invention
can,
however, be embodied in many different forms and should not be construed as
limited to the
embodiments set forth here. Rather, these embodiments are examples of the
invention,
which has the full scope indicated by the language of the claims. Like numbers
refer to like or
corresponding elements throughout. The following disclosure relates to all
embodiments
unless specifically limited to a certain embodiment.
Multi-Use Packages
[0179] A variety of products, and in particular fluid products, are sold
in multi-use or repeated-
use packages. Such products include drug or medical products, including for
example liquid
formulations configured for ocular administration and contained in multi-use
eye drop bottles,
liquid formulations configured for nasal administration and contained in nasal
spray bottles, liquid
formulations configured for a metered-dose inhaler and contained in a metered-
dose inhaler
canister, and drug formulations contained in bottles having small dosage
applicators, such as
medicines for infants, toddlers, or pets. Such products also include topical
medications, skin care
products, or cosmetic products, such as creams/cremes (which are considered
fluids in the
context of the present disclosure) and/or ointments. Such products also
include cosmetics such
as makeups, liquid/gel eye liners, lip glosses, and mascaras, which may
contain for instance one
or more pigments, one or more oils, and one or more waxes. Such products may
also include
contact lens solutions, which are packaged in multi-use bottles, and reusable
contact lens
containers/cases into which contact lens solutions are introduced. Such
products may also
include food products, including for example mayonnaise, mustard, and the
like, as well as solid
food products that are packed in a liquid such as pickles, olives, and the
like.
[0180] Such packages typically include a vessel having one or more walls
that enclose and at
least partially define a lumen, an opening to the lumen, and a closure, such
as a cap, sealing the
opening. A fluid product is stored in the lumen. Some of these packages
further include an
applicator for applying the fluid product. While the fluid product within the
lumen may be aseptic
or sterile when the package is sold, once the package is opened and the
product used,
contaminants may enter the fluid reservoir of the vessel, such as through the
applicator.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
[0181] For instance, multi-dose eye drop bottles typically include
dropper tip that seals and
communicates with the lumen. During use, however, the dropper tip may become
contaminated
with bacteria, e.g. if it is held too close to the eye. Nasal spray bottles
typically include a spray
cap, e.g. that may be operated by an integrated pump. During use, however, the
spray cap is
often inserted into the nose, whereby it can pick up bacteria that may be
introduced into the fluid
reservoir of the vessel. Small-dose medicines, such as those for infants,
toddlers, or pets may
have either a removable dropper cap or an independent dropper or plunger-
operated applicator.
Although these applicators are typically inserted into the mouth of the
recipient, they may not be
thoroughly washed between uses. Accordingly, bacteria from the mouth may be
introduced into
the fluid reservoir during a subsequent use. Metered-dose inhalers include an
actuator having a
mouthpiece applicator that is inserted into the mouth of a user, whereby it
can come into contact
with bacteria, which may subsequently be introduced into the fluid reservoir
of the canister.
Cosmetics such as makeups or mascaras may be provided in bottles, tubes,
canisters, or the
like, which may also contain a makeup applicator. In the case of mascaras, for
instance, the
package typically comprises a cap that includes an eyelash brush which is
inserted into the lumen
of the vessel to close the vessel opening. Similarly, liquid/gel eyeliners and
lip glosses are
typically provided in bottle or tube with a cap that includes an appropriately
configured applicator
brush which is inserted into the lumen of the vessel to close the vessel
opening. Should the
applicator brush collect bacteria, that bacteria will almost immediately be
introduced into the fluid
reservoir.
[0182] Although the packages for skin creams and ointments may not have
an applicator, they
are typically applied by hand. Accordingly, it is quite easy for bacteria or
other contaminants to
become introduced into the fluid reservoir. Similarly, though most food
packages do not include
a specific applicator, the contents may be removed from the container either
by a common kitchen
utensil, such as a knife, spoon, or fork, or by a user's hands (in the case of
solid food products
that are stored in a liquid). It is very easy for contaminants to enter the
fluid reservoirs of food
products in this manner.
[0183] The introduction of bacteria into the lumen of the vessel may
often lead to spoilage of
the product contained therein, which may prevent a user from being able to use
the entire
contents of the package.
[0184] Embodiments of the present disclosure are directed to methods of
inhibiting the growth
of microbes, including bacteria and fungi, in a fluid contained within a multi-
use package, such
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
, as any of the products and packages described above. Embodiments of the
present disclosure
are also directed to methods of inactivating or killing microbes, including
bacteria and fungi, in a
fluid contained within a multi-use package, such as any of the products and
packages described
above. Related to either of the above mechanisms (or both), embodiments of the
present
disclosure are also directed to methods of increasing the post-opening shelf
life of a multi-use
package, such as any of the products and packages described above. In some
embodiments, for
example, the post-opening shelf life of any of the above-described products
and packages may
be increased by at least one week, optionally at least two weeks, optionally
at least one month,
optionally at least two months, optionally at least three months, optionally
at least four months,
optionally at least five months, optionally at least six months, optionally at
least nine months,
optionally at least one year. By inhibiting and/or inactivating/killing
microbes that enter the vessel
lumen, embodiments of the present disclosure are also directed to methods of
reducing the
amount of preservatives and/or excipients used in a product contained in a
multi-use package.
Anti-Microbial Coatings
[0185] The anti-microbial coatings of the present disclosure may inhibit
the growth of
microbes, such as bacteria. In other words, the anti-microbial coatings may
reduce the amount
of bacteria present in the fluid product within the lumen at a defined period
of time after the
introduction of bacteria relative to the same vessel without the anti-
microbial coating. The period
of time selected for this determination may vary depending on how quickly the
bacteria grows
and may be on the order of hours, days, weeks, or months. In some embodiments,
the period of
time selected for a comparative analysis of the amount of bacteria present
within the lumen may
be, for instance, between one and seven days (e.g. one day after introduction,
two days after
introduction, three days after introduction, four days after introduction,
five days after introduction,
six days after introduction, or seven days after introduction) or between one
and four weeks (e.g.
one week after introduction, two weeks after introduction, three weeks after
introduction, or four
weeks after introduction).
[0186] In some embodiments, the comparative testing may be performed
after a period of use
or a replicated period of use that corresponds with a sample expiration date
of the product, e.g.
3 months, 6 months, 12 months, 18 months, 24 months, or 36 months. An example
of a specific
testing method may be found, for example, in Bashir et al., "Microbiological
study of used
cosmetic products: highlighting possible impact on consumer health," J. Appl.
Microbiol., vol.
128(2), pp. 598-605 (2020), the entirety of which is incorporated by reference
herein.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
[0187] Specific bacteria that may be reduced, and desirably eliminated
or substantially
eliminated, include Salmonella, Escherichia coil (E.coll), C.freundii,
Pseudomonas aeruginosa
(P.aeruginosa), Staphylococcus aureus (S.aureus), Staphylococcus epidermis,
Escherichia
hermannii, Bacillus cereus, Enterobacter species, and Candida species. In some
embodiments,
pathogenic bacteria such as E. Coli, C.freundli, P.aeruginosa, and/or S.aureus
may be
demonstrably reduced by anti-microbial coatings of the present disclosure. In
some
embodiments, the presence of S.aureus and P.aeruginosa, the two most common
pathogenic
contaminants of cosmetic products such as mascara, eyeliner, and lip gloss,
may be
demonstrably reduced by anti-microbial coatings of the present disclosure.
[0188] The anti-microbial coatings of the present disclosure may be
effective to inactivate or
kill microbes, such as bacteria, that are introduced into the lumen. For
example, silver ions have
been shown in other applications to react with certain enzymes to inactivate
them, leading to cell
death. Embodiments of the anti-microbial coatings of the present disclosure
may therefore be
used to destroy microbial contaminants that enter the fluid reservoir within
the lumen, such as
through contamination of an applicator, thereby reducing the amount of
bacteria (as opposed to
simply inhibiting its growth). As such, embodiments of the present disclosure
may be effective to
re-establish aseptic or sterile conditions within a fluid reservoir that has
been contaminated.
[0189] Regardless of the mechanism, anti-microbial coatings of the
present disclosure may
be effective to to increase the shelf-life of a multi-dose package after first
use of the product.
Because of the risk of contamination once opened, and particularly the risk of
contamination
caused by use of the product (e.g. through an applicator), many products have
limited shelf-lives
after opening. For instance, it is often recommended that a multi-dose eye
drop bottle be used
for no longer than, for example, four weeks after opening. In other words,
many multi-dose eye
drop bottles have a shelf-life after first use of about four weeks. By
inhibiting the growth of and/or
inactivating microbial contaminants, anti-microbial coatings of the present
disclosure may extend
that post-opening (i.e., post-first use) shelf-life for a commercially
significant amount of time. For
instance, embodiments of the anti-microbial coatings of the present disclosure
may increase the
shelf-life of the package after first use by at least one week, optionally at
least two weeks,
optionally at least one month, optionally at least two months, optionally at
least three months,
optionally at least four months, optionally at least five months, optionally
at least six months,
optionally at least nine months, optionally at least one year.
[0190] In some embodiments, the packages of the present disclosure may
enable a reduction
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
in the amount, or elimination, of anti-bacterial preservatives in the fluid
formulation. Again, using
eye drops as an example, the inclusion of excipients such as preservatives in
an ophthalmic
formulation is generally undesirable. Accordingly, the ability to reduce or
eliminate those
excipients would result in an improved ophthalmic fluid.
[0191] The anti-microbial coatings of the present disclosure may
comprise any of a variety of
metal oxides, including in particular zinc oxide, titanium dioxide, and silver
oxide. The anti-
microbial coatings may be applied by any of variety of processes, including
for example
sputtering, evaporation, or sintering. In some preferred embodiments, the anti-
microbial coatings
may be applied by plasma enhanced chemical vapor deposition (PECVD) or atomic
layer
deposition (ALD), including for instance plasma-enhanced atomic layer
deposition (PEALD).
[0192] Given that the vessels and packages of the present disclosure are
manufactured in
high quantites and, being disposable command relatively low prices, it is
desirable that the anti-
microbial coatings of the present disclosure be thin, e.g. on the nanometer
scale. It is also
desirable that the anti-microbial coating be applied consistently across at
least a portion of the
interior surface of the vessel that contacts the fluid, and preferably across
the entire interior
surface of the vessel. Finally, it is desirable that the anti-microbial
coatings can be applied to the
wall of the vessel without damage to the vessel itself, e.g. deformation or
melting of a
thermoplastic vessel wall. The application of an anti-microbial coating by
PECVD or ALD
(including PEALD) in accordance with the present disclosure provide for a thin
and consistent
coating across the desired surface and can be applied without damage to the
thermoplastic
vessel wall.
[0193] In some embodiments, for example, the anti-microbial coating
comprises zinc oxide
(ZnO) applied by PECVD from a feed gas comprising zinc acetate, diethyl zinc,
or a combination
thereof, and an oxidant. Alternatively, the anti-microbial coating may
comprise zinc oxide (ZnO)
applied by ALD or PEALD using feed gases comprising zinc acetate, diethyl
zinc, or a
combination thereof, and an oxidant.
[0194] In some embodiments, for example, the anti-microbial coating
comprises titanium
dioxide (TiO2) applied by PECVD from a feed gas comprising titanium tetra
chloride and an
oxidant. Alternatively, the anti-microbial coating may comprise titanium
dioxide (TiO2) applied by
ALD or PEALD using feed gases comprising titanium tetra chloride, titanium
isopropoxide, or a
combination thereof, and an oxidant.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
, [0195] In some embodiments, for example, the anti-microbial coating
comprises silver oxide
(Ag2O) applied by PECVD from a feed gas comprising an organosilver compound
and an oxidant,
optionally wherein the organosilver compound has the composition:
Ag(Hfac)(PR3), in which Hfac
is 1,1,1,5,5,5-hexafluoroacetylacetonate, P is phosphine, and R is methyl,
ethyl, or a combination
thereof. Alternatively, the anti-microbial coating may comprise silver oxide
(Ag2O) applied by
PECVD using feed gases comprising an organosilver compound and an oxidant,
optionally
wherein the organosilver compound has the composition: Ag(Hfac)(PR3), in which
Hfac is
1,1,1,5,5,5-hexafluoroacetylacetonate, P is phosphine, and R is methyl, ethyl,
or a combination
thereof.
[0196] In any of these embodiments, the oxidant may be selected from 02,
03, H20, H202,
N20, NO2, air, or a combination thereof.
[0197] In some embodiments, the anti-microbial coating may have a thickness
between about
1 nm and about 1000 nm, optionally between about 2 nm and about 1000 nm,
optionally between
about 5 nm and about 1000 nm, optionally between about 10 nm and 1000 nm,
optionally
between about 1 nm and about 500 nm, optionally between 2 nm and about 500 nm,
optionally
between about 5 nm and about 500 nm, optionally between about 10 nm and 500
nm, optionally
between about 1 nm and about 250 nm, optionally between about 2 nm and about
250 nm,
optionally between about 5 nm and about 250 nm, optionally between about 10 nm
and 250 nm,
optionally between about 1 nm and about 100 nm, optionally between about 2 nm
and about 100
nm, optionally between about 5 nm and about 100 nm, optionally between about
10 nm and 100
nm, optionally between about 1 nm and about 50 nm, optionally between about 2
nm and about
50 nm, optionally between about 5 nm and about 50 nm, optionally between about
10 nm and
about 50 nm.
[0198] In some embodiments, the anti-microbial coating may be applied as a
relatively
consistent layer across the interior surface of the vessel wall.
Exemplary Embodiments
[0199] Examples of a multi-use package according to an embodiment of the
present
disclosure, and in particular embodiments of a multi-dose eye drop bottle 300,
are shown in
Figures 1-4. The multi-dose eye drop bottle 300 comprises a vessel 210 having
a wall 214, and
more particularly one or more sidewalls 215 and a bottom wall 216, the wall
(e.g. the one or more
sidewalls and the bottom wall together) defining and at least partially
enclosing a lumen 212. The
sidewall 215 may comprise a main body portion 217 and a neck portion 218
having a reduced
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
diameter relative to the main body portion, with the main body portion and the
neck portion being
connected by a transition region 219. Opposite the bottom wall 216 is an
opening 220 through
which a fluid stored within the lumen 212 may be dispensed from the vessel
210.
[0200]
In the multi-dose eye drop bottle 300 shown in Figure 1, the vessel
comprises an
integral dropper tip 310 which compriess opening 311, with the opening being
sized and
configured to expel the fluid in small volume defined doses, e.g. droplets. In
the multi-dose eye
drop bottle 300 shown in Figure 2, on the other hand, the vessel 210 comprises
a relatively large
opening that is sealed by the insertion of a dropper tip element 310. The
dropper tip element 310
comprises an opening 311 that is sized and configured to expel the fluid from
the lumen of the
vessel in small volume defined doses, e.g. droplets. Typically each droplet
may be less than 0.3
mL, optionally less than 0.2 mL, optionally less than 0.1 mL. In some
embodiments, for instance,
each droplet may be abou 0.05 mL or less.
[0201]
The multi-dose eye drop bottle 300 may also comprise a cap 312, the
cap being
configured to seal the opening 311 in between uses (i.e., when the product is
not being
dispensed). The cap 312 may be secured to the vessel 210 in any of a variety
of manners. In the
illustrated embodiment, for example, the exterior surface of the neck portion
218 may comprise
a threaded portion 313 configured to mate with a threaded portion on the
interior surface of a cap
312 in order to secure the cap to the neck portion of the vessel 210.
[0202]
The multi-dose eye drop bottle 300 further comprises a fluid 350,
for example an
ophthalmic medical fluid, within the lumen 312. In some embodiments, the
ophthalmic medical
fluid 350 may be a drug-containing solution. In some embodiments, for example,
the ophthalmic
medical fluid 350 may comprise any one or more of the following: alcaftadine
ophthalmic, atropine
ophthalmic, azelastine ophthalmic, bepotastine ophthalmic, betaxolol
ophthalmic, bimatoprost
ophthalmic, brimonidine and timolol ophthalmic, brimonidine ophthalmic,
brinzolamide and
brimonidine ophthalmic, brinzolamide ophthalmic, bromfenac ophthalmic,
carteolol ophthalmic,
cenegermin ophthalmic, cetirizine ophthalmic, chloramphenicol ophthalmic,
cromolyn
ophthalmic, cyclopentolate and phenylephrine ophthalmic, cyclopentolate
ophthalmic,
cyclosporine ophthalmic, cysteamine ophthalmic, dexamethasone ophthalmic,
diclofenac
ophthalmic, difluprednate ophthalmic, dipivefrin ophthalmic, dorzolamide and
timolol ophthalmic,
dorzolamide ophthalmic, echothiophate iodide ophthalmic, emedastine
ophthalmic, epinastine
ophthalmic, fluocinolone ophthalmic, fluorometholone ophthalmic, flurbiprofen
ophthalmic,
ganciclovir ophthalmic, homatropine ophthalmic, hydrocortisone
ophthalmic,
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
hydroxyamphetamine and tropicamide Ophthalmic, ketorolac ophthalmic, ketotifen
ophthalmic,
latanoprost and netarsudil ophthalmic, latanoprost ophthalmic, latanoprostene
bunod ophthalmic,
levobunolol ophthalmic, levocabastine ophthalmic, lidocaine ophthalmic,
lifitegrast ophthalmic,
lodoxamide ophthalmic, loteprednol ophthalmic, metipranolol ophthalmic,
naphazoline and
antazoline ophthalmic, naphazoline and pheniramine ophthalmic, naphazoline and
zinc
ophthalmic, naphazoline ophthalmic, nedocromil ophthalmic, nepafenac
ophthalmic, netarsudil
ophthalmic, ocular lubricant, olopatadine ophthalmic, oxymetazoline
ophthalmic, pemirolast
ophthalmic, phenylephrine ophthalmic, physostigmine ophthalmic, pilocarpine
ophthalmic,
povidone and tetrahydrozoline ophthalmic, povidone-iodine ophthalmic,
prednisolone
ophthalmic, proparacaine ophthalmic, rimexolone ophthalmic, scopolamine
ophthalmic, sodium
chloride, hypertonic ophthalmic, tafluprost ophthalmic, tetracaine ophthalmic,
tetrahydrozoline
and zinc ophthalmic, tetrahydrozoline ophthalmic, timolol ophthalmic,
travoprost ophthalmic,
triamcinolone ophthalmic, trifluridine ophthalmic, tropicamide ophthalmic,
unoprostone
ophthalmic, vidarabine ophthalmic, or a combination thereof.
[0203] In some embodiments, the ophthalmic medical fluid 350 may
contain one or more
humectants (substances that help retain moisture), one or more lubricants, one
or more
electrolytes, such as potassium, or a combination thererof. In some
embodiments, the ophthalmic
medical fluid 350 may comprise one or more decongestants, one or more
antihistamines, one or
more mast cell stabilizers, or any combination thereof. In some embodiments,
the ophthalmic
medical fluid 350 may comprise one or more steroids. In some embodiments, the
ophthalmic
medical fluid 350 may have a viscosity similar to that of water while in other
embodiments, the
ophthalmic medical fluid may be a more viscous gel or ointment.
[0204] As shown in Figure 3, embodiments of the multi-dose eye drop
bottle 300 may
comprise an anti-microbial coating 100 on at least a portion of the interior
surface of the wall 214
(e.g. the interior surfaces of the sidewall 215 and the bottom wall 216), i.e.
the surfaces that are
in contact with the fluid 350 stored within the lumen 212. Note that Figure 3
is not intended to be
drawn to scale and that the anti-microbial coating 100 may be applied as a
very thin coating
relative to the thickness of the vessel wall 214.
[0205] As shown in Figure 4, embodiments of the multi-dose eye drop
bottle 300 may
comprise a coating set 285 that includes a barrier coating or layer 288 and
optionally one or more
of a tie coating or layer 289 and a pH protective coating or layer 286. Like
the anti-microbial
coating 100 described above, this coating set 285 may be applied to at least a
portion of the
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
interior surface of the vessel wall 214, e.g. the interior surfaces of the
sidewalls 215 and the
bottom wall 216 of the vessel. This coating set 285 may be provided in
addition to the anti-
microbial coating 100, e.g. as illustrated in Figure 4, or alone, i.e.
independent of an anti-microbial
coating (not illustrated). Generally, when applied in combination with an anti-
microbial coating
100, the anti-microbial coating is applied as the innermost layer, i.e. the
layer that is in contact
with the fluid 350 stored within the lumen 212. Note that Figure 4 is not
intended to be drawn to
scale and that the various coatings may be applied as very thin coatings
relative to the thickness
of the vessel wall 214.
[0206] In some embodiments of the multi-dose eye drop bottle 300, the
cap 312 may initially
seal the vessel 210 in a manner that prevents moisture and/or atmospheric gas
(e.g. oxygen)
and/or bacteria from entering into the lumen 212 (for example through the
incorporation of one
or more gaskets which may be compressed between the body of the cap and the
vessel). That
initial seal is then broken by the end user upon the first opening of the
multi-dose eye drop bottle
300, which typically corresponds with the first use of (i.e., dispensing of
product from) the bottle.
In other embodiments, the multi-dose eye drop bottle 300 may comprise a seal,
e.g. a film, foil,
or laminate, which extends over the opening of the vessel and which may
typically be sealed to
an upper surface or top flange of the neck portion 218 so as to prevent
moisture and/or
atmospheric gas (e.g. oxygen) and/or bacteria from entering into the lumen
212. That seal is
removed by the end user upon the first opening of the multi-dose eye drop
bottle 300, which
typically corresponds with the first use of (i.e., dispensing of product from)
the bottle. In some
embodiments, the multi-dose eye drop bottle 300 may comprise both initial
seals. Regardless,
however, where the multi-dose eye drop bottle 300 is in its initial sealed
state, moisture and/or
atmospheric gas (e.g. oxygen) may still enter into the lumen 212 of the vessel
through the vessel
walls 215, 216, which can result in deterioration of the fluid 350 contained
within the lumen before
the package is ever opened by the end user. Embodiments of the present
invention therefore
may comprise an oxygen barrier coating 288 that reduces the ingress of oxygen
into the lumen
212 compared to a vessel without the oxygen barrier coating. The resulting
increased oxygen
barrier properties may serve to increase the pre-opening shelf life of the
package.
[0207] In use, the multi-dose eye drop bottle 300 is typically inverted
and a particular number
of droplets of the ophthalmic medical fluid 350 is/are dispensed through the
opening 311 of the
dropper tip 310 into the user's eye. In doing so, the multi-dose eye drop
bottle 300 is typically
placed in close proximity to the eye and may come into contact with the user's
eye, eyelid,
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
, eyelashes, etc. As a result, the dropper tip 310 may come into contact with
bacteria, which can
then enter into the lumen 212 of the vessel 210 in which the remainder of the
ophthalmic medical
fluid is stored for future use, thereby contaminating the ophthalmic medical
fluid 350.
Embodiments of the present invention comprise an anti-microbial coating 100
that is effective to
inhibit the growth of microbes such as bacteria in the ophthalmic medical
fluid 350 contained
within the lumen 212 of the vessel 210 (e.g. as compared to a vessel without
the anti-microbial
coating) and/or to inactivate or kill bacteria introduced into the lumen of
the multi-dose eye drop
bottle 300, and/or to increase the shelf-life of the multi-dose eye drop
bottle package after first
use.
[0208] Another example of a multi-use package according to an embodiment
of the present
disclosure, and in particular a nasal spray bottle 400, is shown in Figures 5
to 8. The nasal spray
bottle 400 comprises a vessel 210 having a wall 214, and more particularly one
or more sidewalls
215 and a bottom wall 216, the wall (e.g. the one or more sidewalls and the
bottom wall together)
defining and at least partially enclosing a lumen 212. The sidewall 215 may
comprise a main
body portion 217 and a neck portion 218 having a reduced diameter relative to
the main body
portion, with the main body portion and the neck portion being connected by a
transition region
219. Opposite the bottom wall 216 is an opening through which a fluid stored
within the lumen
may be dispensed from the vessel.
[0209] The nasal spray bottle 400 may also comprise a cap 412, which is
securable to the
vessel 210, and in particular which may be securable to the neck portion 218
of the vessel. The
cap 412 may be secured to the vessel 210 in any of a variety of manners. In
the illustrated
embodiment, for example, the exterior surface of the neck portion 218 may
comprise a threaded
portion 413 configured to mate with a threaded portion on the interior surface
of a cap 412 in
order to secure the cap to the neck portion of the vessel.
[0210] The nasal spray bottle 400 may further comprise a spray
applicator 420. In some
embodiments, including that illustrated in Figures 5 and 6 for example, the
spray applicator 420
may form part of and/or be attached to (and/or a portion of the spray
applicator may be integral
with) the cap 412. The spray applicator 420 may comprise an outlet 421
configured to dispense
a small volume dose of a medical fluid. Typically the small volume dose may be
less than 0.5
mL, optionally less than 0.4 mL, optionally less than 0.3 mL, optionally less
than 0.2 mL, optionally
less than 0.1 mL. The spray applicator 420 may also comprise a dip tube 422
which extends into
the lumen of the vessel 212 and desirably into close proximity with the bottom
wall 216 of the
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
vessel, and through which the medical fluid stored in the lumen of the vessel
travels en route to
the outlet 421. The spray applicator 420 further comprises an actuating
element by which a user
may dispense a small volume dose of medical fluid. In some embodiments,
including that
illustrated in Figures 5-6 for example, the actuating element may be a piston
423 that is manually
operated by a user pushing down on a finger flange 424.
[0211]
In some embodiments, the nasal spray bottle 400 may comprise a cap,
also referred
to as a hood, that covers the outlet of the spray applicator 421 when the
bottle is not in use.
[0212]
The nasal spray bottle further comprises a fluid 450, for example a
medical fluid, within
the lumen 212. In some embodiments, the medical fluid 450 may be a drug-
containing solution.
In some embodiments, the nasal spray bottle 400 may be configured so that the
drug-containing
solution is delivered to the user's brain and/or into the user's bloodstream,
such as by intranasal
delivery. In other embodiments, the nasal spray bottle 400 may be configured
so that the drug-
containing solution is locally targeted at the nasal passage, e.g. delivered
as a topical
administration. In some embodiments, for example, the nasally-delivered
medical fluid 450 may
comprise any one or more of the following: Azelastine Nasal, Azelastine and
Fluticasone Nasal,
Beclomethasone Nasal, Budesonide Nasal, Butorphanol Nasal, Calcitonin Nasal,
Ciclesonide
Nasal, Corticosteroid Nasal, Cromolyn Nasal, Cyanocobalamin Nasal,
Desmopressin Nasal,
Epinephrine Nasal, Fentanyl Citrate Nasal, Flunisolide Nasal, Fluticasone
Nasal, Ipratropium
Nasal, Ketorolac Nasal, Levocabastine Nasal, Metoclopramide Nasal, Mometasone
Nasal,
Nafarelin Nasal, Naphazoline Nasal, Nicotine Nasal, Olopatadine Nasal,
Oxymetazoline Nasal,
Phenylephrine Nasal, Sodium Chloride Nasal, Testosterone Nasal,
Tetrahydrozoline Nasal,
Triamcinolone Nasal, Xylometazoline Nasal.
[0213]
In some embodiments, the medical solution 450 may contain one or
more
decongestants, such as pseudoephedrine, phenylephrine,
propylhexedrine,
phenylpropanolamine, levomethamphetamine, ephedrine, oxymetazoline,
anphazoline,
oxymetazoline, synephrine, tetryzoline, tramazoline, xylometazoline, and/or a
corticosteroid
(such as beclomethasone dipropionate, budesonide, ciclesonide, dexamethasone,
flunisolide,
fluticasone, fluticasone furoate, fluticasone propionate,
azelastine/fluticasone, mometasone
furoate, prednisolone, tixocortol, triamcinolone, and/or triamcinolone
acedtonide); one or more
antihistamines; one or more expectorants; saline; or a combination thereof. In
some
embodiments, the medical solution 450 may contain one or more migraine drugs.
In some
embodiments, the medical solution 450 may contain one or more antiasthma
drugs. In some
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
embdoiments, the medical solution 450 may contain one or more peptide drugs,
e.g. for hormone
treatment. In some embodiments, the medical solution 450 may contain one or
more steroids. In
some embodiments, the medical solution 450 may contain one or more anaesthetic
agents.
[0214] As shown in Figure 7, embodiments of the nasal spray bottle 400
comprise an anti-
microbial coating 100 on at least a portion of the interior surface of the
vessel wall 214 (e.g. on
the interior surfaces of the sidewall 215 and the bottom wall 215), i.e. the
surfaces that are in
contact with the fluid 450 stored within the lumen 212. Note that Figure 7 is
not intended to be
drawn to scale and that the anti-microbial coating 100 may be applied as a
very thin coating
relative to the thickness of the vessel wall 214.
[0215] As shown in Figure 8, embodiments of the nasal spray bottle 400
may also comprise
a coating set 285 including a barrier coating or layer 288 and optionally one
or more of a tie
coating or layer 289 and a pH protective coating or layer 286. Like the anti-
microbial coating 100
described above, this coating set 285 may be applied to at least a portion of
the interior surface
of the vessel wall 214, e.g. to the interior surfaces of the sidewall 215
and/or the bottom wall 216
of the vessel. This coating set 285 may be provided in addition to the anti-
microbial coating 100,
e.g. as illustrated in Figure 8, or alone, i.e. independent of an anti-
microbial coating (not
illustrated). Generally, when applied in combination with an anti-microbial
coating 100, the anti-
microbial coating is applied as the innermost layer, i.e. the layer that is in
contact with the fluid
450 stored within the lumen 212. Note that Figure 8 is not intended to be
drawn to scale and that
the various coatings may be applied as very thin coatings relative to the
thickness of the vessel
wall 214.
[0216] In some embodiments of the nasal spray bottle 400, the cap 412 or
a combination of
the cap and the hood may initially seal the opening of the vessel 210 in a
manner that prevents
moisture and/or atmospheric gas (e.g. oxygen) and/or bacteria from entering
into the lumen 212.
That initial seal is then broken by the end user upon the first opening of the
nasal spray bottle
400, which typically corresponds with the first use of (i.e., dispensing of
product from) the bottle.
In other embodiments, the nasal spray bottle 400 may comprise a seal, e.g. a
film, foil, or
laminate, which extends over the opening of the vessel 210 and which may
typically be sealed
to an upper surface or top flange of the neck portion 218 so as to prevent
moisture and/or
atmospheric gas (e.g. oxygen) and/or bacteria from entering into the lumen
212. That seal is
removed by the end user upon the first opening of the nasal spray bottle 400,
which typically
corresponds with the first use of (i.e., dispensing of product from) the
bottle. In those
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
embodiments, the seal may be covered by a separate cap and the cap comprising
the spray
applicator 420 may be detached from the vessel and/or provided separately.
Regardless,
however, where the nasal spray bottle 400 is in its initial sealed state,
moisture and/or
atmospheric gas (e.g. oxygen) may still enter into the lumen 212 of the vessel
210 through the
vessel wall 214, which can result in deterioration of the fluid 450 contained
within the lumen
before the package is ever opened by the end user. Embodiments of the present
invention
therefore may comprise an oxygen barrier coating 288 that reduces the ingress
of oxygen into
the lumen compared to a vessel without the oxygen barrier coating. The
resulting increased
oxygen barrier properties may serve to increase the pre-opening shelf life of
the package.
[0217] In use, the nasal spray bottle 400 is typically held near a user
or patient's nose with at
least the tip of the spray applicator 420 being placed into the user or
patient's nostril, and the
actuator is actuated one or more times in order to dispense the medical fluid
into the nostril. In
use therefore the spray applicator 420 may come into contact with the inside
of the user or
patient's nasal passage and with bacteria present therein, which can then
enter into the lumen
212 of the vessel 210 in which the remainder of the medical fluid is stored
for future use, thereby
contaminating the medical fluid 450. Embodiments of the present invention
comprise an anti-
microbial coating 100 that is effective to inhibit the growth of microbes such
as bacteria in the
medical fluid 450 contained within the lumen 212 of the vessel (e.g. as
compared to a vessel
without the anti-microbial coating) and/or to inactivate or kill bacteria
introduced into the lumen of
the nasal spray bottle 400, and/or to increase the shelf-life of the nasal
spray bottle package after
first use.
[0218] Another example of a multi-use package according to an
embodiment of the present
disclosure, and in particular an embodiment of a mascara bottle 500, also
referred to as a
mascara tube, is shown in Figures 9-12. The mascara bottle 500 comprises a
vessel 210 having
a wall 214, and more particularly one or more sidewalls 215 and a bottom wall
216, the wall (e.g.
the one or more sidewalls and the bottom wall together) defining and at least
partially enclosing
a lumen 212. The sidewall 215 may comprise a main body portion 217 and a neck
portion 218
having a reduced diameter relative to the main body portion, with the main
body portion and the
neck portion being connected by a transition region 219. Opposite the bottom
wall 216 is an
opening through which a fluid stored within the lumen, e.g. a mascara
composition, may be
dispensed from the vessel.
[0219] The mascara bottle 500 may also comprise a cap 512, the cap
being configured to seal
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
the opening in between uses (i.e., when the product is not being dispensed).
The cap 512 may
be secured to the vessel 210 in any of a variety of manners. In the
illustrated embodiment, for
example, the exterior surface of the neck portion 218 of the vessel may
comprise a threaded
portion 513 configured to mate with a threaded portion on the interior surface
of a cap 512 in
order to secure the cap to the neck portion of the vessel.
[0220] The mascara bottle 500 may also comprise an eyelash brush 520,
also referred to as
a wand, which is used to apply the mascara composition. In the mascara bottle
500 shown in
Figures 9-10, the eyelash brush 520 is attached to cap 512. In other
embodiments, however, the
eyelash brush 520 may be separate from the cap 512. The eyelash brush 520 is
sized and
configured to be inserted through the opening of the vessel and into the lumen
212 of the vessel.
When attached to the cap 512, the eyelash brush 520 may be inserted into the
lumen 212 of the
vessel 210 so as to take up am amount of the mascara composition contained
therein and then
the eyelash brush may be removed from the lumen of the vessel and used to
apply the amount
of mascara composition to the user's eyelashes. That process may be repeated a
number of
times until a desired amount of mascara has been applied. When the desired
amount has been
applied, the eyelash brush 520 may be inserted into the lumen 212 of the
vessel and then the
cap 512 may be rotated in order to secure the cap to the vessel 210.
[0221] The mascara bottle 500 further comprises a fluid 550, for example
mascara
composition, within the lumen 212. In some embodiments, the mascara
composition 550 may
include one or more pigments, one or more waxes and/or oils, and one or more
film-forming
polymers. In some embodiments, for example, the mascara composition 550 may
include a
carbon black, iron oxide, titanium dioxide, and/or ultramarine blue pigment to
darken lashes; one
or more polymers such as polyvinylpyrrolidone (PVP), ceresin, gum tragacanth,
methyl
ceullulose, etc., to form a film that coats lashes; one or more thickening
waxes or oils such as
lanolin, mineral oil, linseed oil, eucalyptus oil, sesame oil, oil of
turpentine, paraffin, petrolatum,
castor oil, carnauba wax, beeswax, palm wax, and candelilla wax. In some
embodiments, the
mascara composition 550 may comprise a base of wax selected from beeswax,
paraffin,
carnauba wax, palm wax, and a combination thereof, a pigment that includes
carbon black and/or
iron oxide, one or more film-forming polymers. Some embodiments of mascara
compositions 550
may also contain nylon and/or rayon microfibers to provide the eyelashes with
more length. Some
embodiments of mascara compositions 550 may also contain a moisturizer and/or
vitamins to
condition eyelashes.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
[0222] Some mascara compositions 550 may be free or substantially free
of water, thereby
providing what is considered a waterproof and hydrophobic mascara, while other
mascara
compositions may comprise an emulsion of water and oil(s), and be considered
hydrophilic. An
example waterproof mascara composition may contain petroleum distillate,
polyethylene,
carnauba wax, pentaerythrityl hydrogenated rosinate, and tall oil glycerides.
An example
hydrophilic mascara may contain, for example, water, glyceryl stearate,
ammonium acrylates
copolymer, polyvinyl alcohol, and alcohol.
[0223] In some embodiments, the mascara bottle 500 may be configured
such that the lumen
212 of the vessel contains between about 3 mL and about 15 mL of fluid,
alternatively between
about 5 mL and about 12 mL of fluid, alternatively between about 7 mL and
about 12 mL of fluid,
alternatively between about 4 mL and about 12 mL, alternatively between about
4 mL and about
mL of fluid, alternatively about 4 mL of fluid, alternatively about 10 mL of
fluid.
[0224] As shown in Figure 11, embodiments of the mascara bottle 500
comprise an anti-
microbial coating 100 on at least a portion of the interior surface of the
vessel wall 214 (on the
interior surfaces of the sidewalls 215 and/or bottom wall 216), i.e. the
surfaces that are in contact
with the fluid 550 stored within the lumen 212. Note that Figure 11 is not
intended to be drawn to
scale and that the anti-microbial coating 100 may be applied as a very thin
coating relative to the
thickness of the vessel wall 214.
[0225] As shown in Figure 12, embodiments of the mascara bottle 500 may
comprise a
coating set 285 that includes a barrier coating or layer 288 and optionally
one or more of a tie
coating or layer 289 and a pH protective coating or layer 286. Like the anti-
microbial coating 100
described above, this coating set 285 may be applied to at least a portion of
the interior surface
of the vessel wall 214, e.g. the interior surfaces of the sidewall 215 and/or
bottom wall 216 of the
vessel. This coating set 285 may be provided in addition to the anti-microbial
coating 100, e.g.
as illustrated in Figure 12, or alone, i.e. independent of an anti-microbial
coating (not illustrated).
Generally, when applied in combination with an anti-microbial coating 100, the
anti-microbial
coating is applied as the innermost layer, i.e. the layer that is in contact
with the fluid 550 stored
within the lumen. Note that Figure 12 is not intended to be drawn to scale and
that the various
coatings may be applied as very thin coatings relative to the thickness of the
vessel wall 214.
[0226] In some embodiments of the mascara bottle 500, the cap 512 may
initially seal the
opening of the vessel 210 in a manner that prevents moisture and/or
atmospheric gas (e.g.
oxygen) and/or bacteria from entering into the lumen 212 (for example through
the incorporation
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
of one or more gaskets which may be compressed between the body of the cap and
the vessel).
That initial seal is then broken by the end user upon the first opening of the
mascara bottle 500,
which typically corresponds with the first use of (i.e., dispensing of product
from) the bottle. In
other embodiments, the mascara bottle 500 may comprise a seal, e.g. a film,
foil, or laminate,
which extends over the opening of the vessel and which may typically be sealed
to an upper
surface or top flange of the neck portion 218 so as to prevent moisture and/or
atmospheric gas
(e.g. oxygen) and/or bacteria from entering into the lumen 212. That seal is
removed by the end
user upon the first opening of the mascara bottle 500, which typically
corresponds with the first
use of (i.e., dispensing of product from) the bottle. In some embodiments, the
mascara bottle 500
may comprise both initial seals. However, where the mascara bottle 500 is in
its initial sealed
state, moisture and/or atmospheric gas (e.g. oxygen) may still enter into the
lumen 212 of the
vessel 210 through the vessel wall 214, which can result in deterioration of
the fluid 450 contained
within the lumen 212 before the package is ever opened by the end user.
Embodiments of the
present invention therefore may comprise an oxygen barrier coating 288 that
reduces the ingress
of oxygen into the lumen 212 compared to a vessel without the oxygen barrier
coating. The
resulting increased oxygen barrier properties may serve to increase the pre-
opening shelf life of
the package.
[0227] During use, the eyelash brush 520 is typically placed into
contact with the user's
eyelashes and in close proximity to the user's face. As a result, the eyelash
brush 520 may come
into contact with bacteria, which can then enter into the lumen 212 of the
vessel 210 in which the
remainder of the mascara composition is stored for future use, thereby
contaminating the
mascara composition 550. Embodiments of the present invention comprise an anti-
microbial
coating 100 that is effective to inhibit the growth of microbes such as
bacteria in the mascara
composition 550 contained within the lumen 212 of the vessel 210 (e.g. as
compared to a vessel
without the anti-microbial coating) and/or to inactivate or kill bacteria
introduced into the lumen of
the mascara bottle 500, and/or to increase the shelf-life of the mascara
bottle package after first
use.
[0228] Another, non-illustrated example of a multi-use package
according to an embodiment
of the present disclosure is a liquid or gel eyeliner package (e.g., as
opposed to a pencil eyeliner).
Liquid or gel eyeliner is provided in a package that is similar to the mascara
bottle/tube shown
and described above. The primary difference ¨ apart from the composition of
the fluid itself ¨ is
the configuration of the applicator. Rather than an eyelash brush such as that
shown in Figures
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
9-12, the applicator may comprise an eyeliner brush or pad. Like the eyelash
brush shown in
Figures 9-12, the eyeliner brush or pad typically extends from the underside
of the cap and is
inserted into and stored within the lumen of the vessel when the cap is
secured to the vessel.
The primary difference is in the configuration of the brush itself, as an
eyeliner brush will typically
have a fine, sharp-tipped brush that extends from the end of the applicator
and which creates a
fine, precise line on the skin around the eye as opposed to an eyelash brush
which extends
around the periphery/circumference of at least a portion of the applicator and
is used to apply
mascara to the eyelashes. The eyeliner fluid stored in the lumen of the vessel
may include one
or more film formers, one or more thickeners (e.g. waxes such as Japan wax,
natural gums,
clays), and/or one or more pigments (e.g. iron oxides, ultramarine, chromium
oxide, titanium
dioxide). One or more of the antimicrobial coating or layer 100 and/or the
coating set 285 may be
provided on the interior surface(s) of the eyeliner vessel in the same manner
as described above
with respect to mascara bottles/tubes and will function in the same manner.
[0229] Another, non-illustrated example of a multi-use package according
to an embodiment
of the present disclosure is a lip gloss package. Lip gloss may be provided in
a package that is
similar to the mascara bottle/tube shown and described above and the eyeliner
bottle/tube
described above. Once again, the primary difference ¨ apart from the
composition of the fluid
itself ¨ is the configuration of the applicator. Rather than an eyelash brush
such as that shown in
Figures 9-12, or an eyeliner brush, the applicator may comprise a lip brush,
sometimes called a
wand. Like the eyelash brush shown in Figures 9-12 and the eyeliner brush
described above, the
lip brush typically extends from the underside of the cap and is inserted into
and stored within the
lumen of the vessel when the cap is secured to the vessel. The primary
difference is in the
configuration of the brush itself, as a lip brush will typically have a spongy
material at the tip of
the applicator, which is used to brush the lip gloss onto a user's lips. The
spongy tip (sometimes
referred to as a "doe foot") may be provided in any of a variety of shapes,
including curved,
spatula, flame, and drop configurations. The lip gloss fluid stored in the
lumen of the vessel may
include one or more waxes (e.g. lanolin), one or more oils, and/or one or more
pigments. One or
more of the antimicrobial coating or layer 100 and/or the coating set 285 may
be provided on the
interior surface(s) of the lip gloss vessel in the same manner as described
above with respect to
mascara bottles/tubes and will function in the same manner.
[0230] Another example of a multi-use package according to an embodiment
of the present
disclosure, and in particular an embodiment of a small-dose medicine package
600, is shown in
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
, Figures 13-16. The small-dose medicine package 600 comprises a vessel 210
having a wall 214,
and more particularly one or more sidewalls 215 and a bottom wall 216, the
wall (e.g. the one or
more sidewalls and the bottom wall together) defining and at least partially
enclosing a lumen
212. The sidewall 215 may comprise a main body portion 217 and a neck portion
218 having a
reduced diameter relative to the main body portion, with the main body portion
and the neck
portion being connected by a transition region 219. Opposite the bottom wall
216 is an opening
through which a fluid stored within the lumen, e.g. the small-dose medical
fluid, may be dispensed
from the vessel 210.
[0231] The small-dose medicine bottle 600 may also comprise a cap 612,
the cap being
configured to seal the opening in between uses (i.e., when the product is not
being dispensed).
The cap 612 may be secured to the vessel 210 in any of a variety of manners.
In the illustrated
embodiment, for example, the exterior surface of the neck portion 218 of the
vessel may comprise
a threaded portion 613 configured to mate with a threaded portion on the
interior surface of a cap
612 in order to secure the cap to the neck portion of the vessel.
[0232] Small-dose medicine packages 600, such as those for infants,
toddlers, or pets often
include an applicator 620, such as a dropper (which can be integrated into a
cap and provided
as a dropper cap or which can be an independent component) or a plunger-
operated applicator,
as is illustrated in Figures 13-16.
[0233] A plunger-operated applicator 620 may comprise a plastic barrel
621 having a main
body 622 portion, a narrowed dispensing tip 623 at a first end, and an opening
624 at the opposite
end. A plastic plunger 625 is inserted into the barrel 621 through the opening
624 and is slidable
within the barrel. In some embodiments, the barrel 621 may contain a series of
ridges and/or
markings that correspond with various dosage measurements, whereas in other
embodiments
the applicator 620 may be configured for only a single dosage size. During
use, the dispensing
tip 623 of the applicator 620 is inserted into the lumen 212 of the vessel 210
and a desired dosage
of medical fluid 650 is pulled into the barrel 6210f the applicator by suction
produced by
movement of the plunger 625 rearward away from the dispensing tip 623. The
properly measured
dosage of medical fluid is then dispensed through the dispensing tip 623 of
the applicator 620
directly to its intended location, typically the mouth of an infant, toddler,
or pet.
[0234] A dropper-type applicator is used in substantially the same
manner, with a desired
dosage of the fluid being pulled from the lumen 212 of the vessel 210 into the
dropper through
suction caused by a user slowly releasing pressure on a rubber bulb that is
attached to an
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
opening at the non-dispensing end of the dropper and the dosage of fluid then
being dispensed
through the dispensing end of the dropper by application of pressure to the
rubber bulb. Although
these applicators 620 are typically inserted into the mouth of the recipient,
they may not be
thoroughly washed between uses. Accordingly, bacteria from the mouth may be
introduced into
the medical fluid contained within the lumen 212 of the vessel 210 either
immediately after use
(e.g. if the applicator 620 is stored in the vessel lumen) or during a
subsequent use (when the
applicator is re-introduced into the lumen).
[0235] The small-dose medicine package 600 further comprises a fluid
650, for example a
medicinal formulation within the lumen 212 of the vessel 210. In some
embodiments, the fluid
650 may comprise an analgesic drug such as acetaminophen or ibuprofen. In some
embodiments, the fluid 650 may comprise a prescription drug.
[0236] In some embodiments, the applicator 620 may be configured to hold
and dispense up
to about 10 mL of fluid, alternatively up to about 7 mL of fluid,
alternatively up to about 5 mL of
fluid, alternatively up to about 2 mL of fluid.
[0237] As shown in Figure 15, embodiments of the vessel 210 of the small-
dose medicine
package 600 comprise an anti-microbial coating 100 on at least a portion of
the interior surface
of the vessel wall 214 (e.g. on the interior surfaces of the sidewall 215
and/or the bottom wall
216), i.e. the surfaces that are in contact with the fluid 650 stored within
the lumen 212. Note that
Figure 15 is not intended to be drawn to scale and that the anti-microbial
coating 100 may be
applied as a very thin coating relative to the thickness of the vessel wall
214.
[0238] As shown in Figure 16, embodiments of the vessel 210 of the small-
dose medicine
package 600 may comprise a coating set 285 comprising a barrier coating or
layer 288 and
optionally one or more of a tie coating or layer 289 and a pH protective
coating or layer 286. Like
the anti-microbial coating 100 described above, this coating set 285 may be
applied to at least a
portion of the interior surface 214 of the vessel, e.g. the interior surfaces
of the sidewall 215
and/or the bottom wall 216 of the vessel. This coating set 285 may be provided
in addition to the
anti-microbial coating 100, e.g. as illustrated in Figure 16, or alone, i.e.
independent of an anti-
microbial coating (not illustrated). Generally, when applied in combination
with an anti-microbial
coating 100, the anti-microbial coating is applied as the innermost layer,
i.e. the layer that is in
contact with the fluid 650 stored within the lumen 212. Note that Figure 16 is
not intended to be
drawn to scale and that the various coatings may be applied as very thin
coatings relative to the
thickness of the vessel wall 214.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
[0239] In some embodiments, one or more surfaces of the applicator 620
may also comprise
an anti-microbial coating 100. For example, where the small-dose medicine
package 600
comprises a plunger-operated applicator 620, the interior surface of at least
a portion of the barrel
wall 621 and/or the exterior surface of at least a portion of the barrel wall
may be provided with
an anti-microbial coating 100 as described herein. In some embodiments, and as
illustrated in
Figure 15, the interior surface of at least a portion of the barrel wall 621
may be provided with an
anti-microbial coating 100 as described herein. In some embodiments, the
exterior surface of at
least a portion of the barrel wall 621 may be provided with an anti-microbial
coating 100 as
described herein. In some embodiments, both the interior surface of at least a
portion of the barrel
wall 621 and the exterior surface of at least a portion of the barrel wall may
be provided with an
anti-microbial coating 100 as described herein.
[0240] In some embodiments of the small-dose medicine package 600, the
cap 612 may
initially seal the opening of the vessel 210 in a manner that prevents
moisture and/or atmospheric
gas (e.g. oxygen) and/or bacteria from entering into the lumen 212 (for
example through the
incorporation of one or more gaskets which may be compressed between the body
of the cap
and the vessel). That initial seal is then broken by the end user upon the
first opening of the
small-dose medicine package 600, which typically corresponds with the first
use of (i.e.,
dispensing of product from) the bottle. In other embodiments, the small-dose
medicine package
600 may comprise a seal, e.g. a film, foil, or laminate, which extends over
the opening of the
vessel and which may typically be sealed to an upper surface or top flange of
the neck portion
218 so as to prevent moisture and/or atmospheric gas (e.g. oxygen) and/or
bacteria from entering
into the lumen 212. That seal is removed by the end user upon the first
opening of the small-dose
medicine package 600, which typically corresponds with the first use of (i.e.,
dispensing of
product from) the bottle. In some embodiments, the small-dose medicine package
600 may
comprise both initial seals. Regardless, however, where the small-dose
medicine package 600
is in its initial sealed state, moisture and/or atmospheric gas (e.g. oxygen)
may still enter into the
lumen 212 of the vessel 210 through the vessel wall 214, which can result in
deterioration of the
fluid 650 contained within the lumen before the package is ever opened by the
end user.
Embodiments of the present invention therefore may comprise an oxygen barrier
coating 288
that reduces the ingress of oxygen into the lumen 212 compared to a vessel
without the oxygen
barrier coating. The resulting increased oxygen barrier properties may serve
to increase the pre-
opening shelf life of the package.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
[0241] During use, the applicator 620, and more particularly the
dispensing tip 623 of the
applicator (and often a portion of the main body 622 adjacent the dispensing
tip), is placed into
the recipient's mouth and the medical fluid dispensed directly into the
recipient's mouth. As a
result, the applicator 620 may come into contact with bacteria, which can then
enter into the
lumen 212 of the vessel 210 in which the remainder of the medical fluid is
stored for future use,
thereby contaminating the medical fluid 650 contained within the lumen.
Embodiments of the
present invention comprise an anti-microbial coating 100 that is effective to
inhibit the growth of
microbes such as bacteria in the medical fluid 650 contained within the lumen
212 of the vessel
210 (e.g. as compared to a vessel without the anti-microbial coating) and/or
to inactivate or kill
bacteria introduced into the lumen of the small-dose medicine package 600,
and/or to increase
the shelf-life of the small-dose medicine package after first use.
[0242] Another example of a multi-use package according to an
embodiment of the present
disclosure, and in particular a pump bottle 700, is shown in Figures 17-20.
The pump bottle 700
comprises a vessel 210 having a wall 214, and more particularly one or more
sidewalls 215 and
a bottom wall 216, the wall (e.g. the one or more sidewalls and the bottom
wall together) defining
and at least partially enclosing a lumen 212. The sidewall 215 may comprise a
main body portion
217 and a neck portion 218 having a reduced diameter relative to the main body
portion, with the
main body portion and the neck portion being connected by a transition region
219. Opposite the
bottom wall 216 is an opening through which a fluid stored within the lumen
may be dispensed
from the vessel.
[0243] The pump bottle 700 may also comprise a pump cap 712, which is
securable to the
vessel 210, and in particular which may be securable to the neck portion 218
of the vessel. The
pump cap 712 may be secured to the vessel 210 in any of a variety of manners.
In some
embodiments, for example, the exterior surface of the neck portion 218 may
comprise a threaded
portion configured to mate with a threaded portion on the interior surface of
the pump cap 712 in
order to secure the pump cap to the neck portion of the vessel 210.
[0244] The pump bottle 700 may further comprise a pump applicator 720.
The pump applicator
720 may form part of and/or be attached to the pump cap 712. The pump
applicator 720
comprises an outlet 721 configured to dispense an amount of a fluid contained
within the lumen
212 of the vessel 210, typically into a user's hand. The pump applicator 720
may also comprise
a dip tube 722 which extends into the lumen 212 of the vessel 210 and
desirably into close
proximity with the bottom wall 216 of the vessel, and through which the fluid
stored in the lumen
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
of the vessel travels en route to the outlet 721. The pump applicator 720
further comprises an
actuating element 723 by which a user may dispense an amount of fluid from the
outlet 721. In
some embodiments, including that illustrated in Figures 1 7-1 8 for example,
the actuating element
723 may be a piston that is manually operated by a user pushing down on an
upper surface 724
of the pump applicator 720.
[0245] The pump bottle 700 may also comprise a cap 725, also referred to
as a hood, that
covers the outlet 721 of the pump applicator 720 when the bottle is not in
use.
[0246] The pump bottle 700 further comprises a fluid 750, for example a
cosmetic fluid, within
the lumen 212. In some embodiments, the cosmetic fluid 750 may be a cream or
lotion such as
a moisturing and/or conditioning cream or lotion (including e.g. a baby cream
or lotion), a skin
care cream or lotion, an anti-aging cream or lotion, a pore cleansing cream or
lotion, a shaving
cream or lotion, or the like. In some embodiments, the fluid 750 may be a
medical fluid, such as
an ointment, salve, or medical cream. In some embodiments, the fluid 750 may
be a fragrance
composition, such as a perfume or cologne.
[0247] As shown in Figure 19, embodiments of the pump bottle 700
comprise an anti-microbial
coating 100 on at least a portion of the interior surface of the vessel wall
214 (e.g. on the interior
surfaces of the sidewall 215 and/or bottom wall 216), i.e. the surfaces that
are in contact with the
fluid stored within the lumen 212. Note that Figure 19 is not intended to be
drawn to scale and
that the anti-microbial coating 100 may be applied as a very thin coating
relative to the thickness
of the vessel wall 214.
[0248] As shown in Figure 20, embodiments of the pump bottle 700 may
also comprise a
coating set 285 that includes a barrier coating or layer 288 and optionally
one or more of a tie
coating or layer 289 and a pH protective coating or layer 286. Like the anti-
microbial coating 100
described above, this coating set 285 may be applied to at least a portion of
the interior surface
of the vessel wall 214, e.g. the interior surfaces of the sidewall(s) 15 and
the bottom wall 16 of
the vessel. This coating set 285 may be provided in addition to the anti-
microbial coating 100,
e.g. as illustrated in Figure 20, or alone, i.e. independent of an anti-
microbial coating (not
illustrated). Generally, when applied in combination with an anti-microbial
coating 100, the anti-
microbial coating is applied as the innermost layer, i.e. the layer that is in
contact with the fluid
750 stored within the lumen 212. Note that Figure 20 is not intended to be
drawn to scale and
that the various coatings may be applied as very thin coatings relative to the
thickness of the
vessel wall 214.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
[0249] In some embodiments of the pump bottle 700, the cap 712 or a
combination of the cap
and the hood 725 may initially seal the vessel 210 in a manner that prevents
moisture and/or
atmospheric gas (e.g. oxygen) and/or bacteria from entering the lumen 212 (for
example through
the incorporation of one or more gaskets which may be compressed between the
body of the cap
and the vessel). That initial seal is then broken by the end user upon the
first opening of the pump
bottle package 700, which typically corresponds with the first use of (i.e.,
dispensing of product
from) the bottle. In other embodiments, the pump bottle 700 may comprise a
seal, e.g. a film, foil,
or laminate, which extends over the opening of the vessel 210 and which may
typically be sealed
to an upper surface or top flange of the neck portion 218 so as to prevent
moisture and/or
atmospheric gas (e.g. oxygen) and/or bacteria from entering into the lumen
212. That seal is
removed by the end user upon the first opening of the pump bottle package 700,
which typically
corresponds with the first use of (i.e., dispensing of product from) the
bottle. In those
embodiments, the seal may be covered by a separate cap and the pump cap 712
may be
detached from the vessel 210 and/or provided separately such that a user
attaches the pump
cap to the vessel once he/she has removed the seal. Regardless, however, where
the pump
bottle 700 is in its initial sealed state, moisture and/or atmospheric gas
(e.g. oxygen) may still
enter into the lumen 212 of the vessel 210 through the vessel wall(s) 214,
which can result in
deterioration of the fluid 750 within the lumen before the package is ever
opened by the end user.
Embodiments of the present invention therefore may comprise an oxygen barrier
coating 288
that reduces the ingress of oxygen into the lumen 212 compared to a vessel
without the oxygen
barrier coating. The resulting increased oxygen barrier properties may serve
to increase the pre-
opening shelf life of the package.
[0250] In use, a user typically places his/her hand in close proximity
to the outlet 721 of the
pump applicator 720 and operates the actuator 723, e.g. pushes down on the
upper surface 724
of the pump applicator, to dispense a desired amount of fluid 750 from the
lumen of the vessel
210. Often the user's hand will come into contact with the outlet 721 of the
pump applicator 720,
particularly because operation of the actuator 723 may cause the outlet to
move downward
toward the user's hand. In use therefore the pump applicator 720 may come into
contact with
bacteria present on the user's hand, which can then enter into the lumen 212
of the vessel 210
in which the remainder of the fluid is stored for future use, thereby
contaminating the fluid 750.
Embodiments of the present invention therefore comprise an anti-microbial
coating 100 that is
effective to inhibit the growth of microbes such as bacteria in the fluid 750
contained within the
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
lumen 212 of the vessel 210 (e.g. as compared to a vessel without the anti-
microbial coating)
and/or to inactivate or kill bacteria introduced into the lumen of the pump
bottle 700, and/or to
increase the shelf-life of the pump bottle package after first use.
[0251] Another, non-illustrated example of a multi-use package according
to an embodiment
of the present disclosure, is a cosmetic jar. A cosmetic jar comprises a
vessel having one or more
sidewalls 215 and a bottom wall 216, the one or more sidewalls and the bottom
wall together
defining and at least partially enclosing a lumen 212. Opposite the bottom
wall 216 is an opening
sized and configured so that a user may dip his/her fingers (which thereby
serve as an applicator)
or an applicator into the lumen 212 in order to take up an amount of the
cosmetic product, e.g. a
cream or the like, contained therein. The cosmetic jar may further comprise a
cap that is
removable and resealable on the vessel.
[0252] The cosmetic jar further comprises a fluid, e.g. a cosmetic cream
or lotion, contained
within the vessel lumen.
[0253] Embodiments of the cosmetic jar comprise an anti-microbial
coating 100 on at least a
portion of the interior surface of the vessel wall 214 (e.g. the interior
surfaces of the one or more
sidewalls 215 and the bottom wall 216), i.e. the surfaces that are in contact
with the fluid stored
within the lumen 212. Embodiments of the cosmetic jar may also comprise a
coating set 285 that
includes a barrier coating or layer 288 and optionally one or more of a tie
coating or layer 289
and a pH protective coating or layer 286. Like the anti-microbial coating 100
described above,
this coating set 285 may be applied to at least a portion of the interior
surface of the vessel wall
214, e.g. the interior surfaces of the sidewalls 215 and/or the bottom wall
216 of the vessel. This
coating set 285 may be provided in addition to the anti-microbial coating 100
or alone, i.e.
independent of an anti-microbial coating. Generally, when applied in
combination with an anti-
microbial coating 100, the anti-microbial coating is applied as the innermost
layer, i.e. the layer
that is in contact with the fluid stored within the lumen 212.
[0254] In some embodiments of the cosmetic jar, the cap may initially
seal the opening of the
vessel 210 in a manner that prevents moisture and/or atmospheric gas (e.g.
oxygen) and/or
bacteria from entering into the lumen 212 (for example through the
incorporation of one or more
gaskets which may be compressed between the body of the cap and the vessel).
That initial seal
is then broken by the end user upon the first opening of the cosmetic jar
which typically
corresponds with the first use of (i.e., dispensing of product from) the jar.
In other embodiments,
the cosmetic jar may comprise a seal, e.g. a film, foil, or laminate, which
extends over the opening
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
, of the vessel 210 and which may typically be sealed to an upper surface or
top flange of the
vessel sidewall(s) so as to prevent moisture and/or atmospheric gas (e.g.
oxygen) and/or bacteria
from entering into the lumen. That seal is removed by the end user upon the
first opening of the
cosmetic jar, which typically corresponds with the first use of (i.e.,
dispensing of product from)
the jar. In some embodiments, the cosmetic jar may comprise both initial
seals. However, where
the cosmetic jar is in its initial sealed state, moisture and/or atmospheric
gas (e.g. oxygen) may
still enter into the lumen 212 of the vessel 2100 through the vessel wall 214,
which can result in
deterioration of the fluid contained within the lumen before the jar is ever
opened by the end user.
Embodiments of the present invention therefore may comprise an oxygen barrier
coating 288
that reduces the ingress of oxygen into the lumen compared to a vessel without
the oxygen barrier
coating. The resulting increased oxygen barrier properties may serve to
increase the pre-opening
shelf life of the package.
[0255] In use, a user typically places his/her hand into the lumen 212
of the vessel 210 in
order to extract the cosmetic product, e.g. cream or lotion, contained
therein. At each use,
therefore, bacteria present on the user's hand can easily enter into the lumen
212 of the vessel
210 in which the remainder of the product is stored for future use, thereby
contaminating the
product. Embodiments of the present invention therefore comprise an anti-
microbial coating that
is effective to inhibit the growth of microbes such as bacteria in the fluid
contained within the
lumen of the vessel (e.g. as compared to a vessel without the anti-microbial
coating) and/or to
inactivate or kill bacteria introduced into the lumen of the cosmetic jar,
and/or to increase the
shelf-life of the cosmetic jar product after first use.
[0256] Another example of a multi-use package according to an
embodiment of the present
disclosure, and in particular an embodiment of a contact lens case 800, is
shown in Figures 21-
22. The contact lens case comprises a vessel 810 having a first reservoir 811
and a second
reservoir 812. Each of the first and second reservoirs 811, 812 is defined by
a side wall 815 and
a bottom wall 816, the side wall and the bottom wall together defining the
reservoir. Opposite the
bottom wall 816 of each reservoir 811, 812 is an opening through which a
contact lens may be
placed into the reservoir. The first and second reservoirs 811, 812 are
typically connected
together by a connecting portion 813.
[0257] The contact lens case 800 may also comprise a first cap 821 and
a second cap 822,
each of the first and second caps 821, 822 being configured to close the
opening of one of the
first and second reservoirs 811, 812. The caps 821, 822 may be secured to the
vessel 810 in any
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
, of a variety of manners. In the illustrated embodiment, for example, the
exterior surface of the
sidewall 815 of each reservoir 811, 812 may comprise a threaded portion 817
configured to mate
with a threaded portion 823 on the interior surface of a cap 821, 822 in order
to secure the cap
to the vessel.
[0258] The contact lens case 800 differs from the other embodiments
described herein in that
the contact lens case is not a product package in which the lumen of a vessel
is filled with a multi-
use, cosmetic, and/or fragrance product, when purchased, but rather acts as a
reusable storage
container for contact lenses which is typically purchased with the reservoirs
being empty. As
such, the contact lense case 800 does not have a pre-opening shelf life and
thus there is no need
for an oxygen barrier coating of the sort described herein. However, at least
a portion of the walls
that define each of the first and second reservoirs 811, 812 and/or at least a
portion of the interior
surface, e.g. underside, of each of the first and second caps 821, 822 may be
coated with an
anti-microbial coating 100 of the sort described herein.
[0259] In use, each of the first and second reservoirs 811, 812 is
typically partially filled with
a contact lens solution, which may be configured to clean, rinse, and/or
disinfect contact lenses,
a contact lens is placed ¨ with a user's fingers ¨ into each reservoir for
storage, and the first and
second caps 821, 822 are secured onto the first and second reservoirs. Then,
after a period of
storage time, the user removes each of the first and second caps 821, 822 and
extracts the
contact lenses from the reservoirs 811, 812, again using his/her fingers. As a
result, each of the
first and second reservoirs 811, 812 may come into contact with bacteria from
the user's hand
both during insertion and removal of the contact lenses. Similarly, when a
user removes each of
the first and second caps 821, 822, the interior surface of the cap may come
into contact with the
user's hand and/or any of a variety of surfaces on which they may be placed,
any of which may
contain bacteria. Contact lens solution and/or contact lenses may thus be
enclosed in a
contaminated environment for storage.
[0260] Embodiments of the present invention comprise an anti-microbial
coating 100 that is
effective to inhibit the growth of microbes such as bacteria in the reservoirs
811, 812 of a contact
lens case 800 (e.g. as compared to a contact lens case without the anti-
microbial coating) and/or
to inactivate or kill bacteria introduced into the reservoirs of the contact
lens case, and/or to
increase the shelf-life of the contact lens case after first use.
[0261] As shown in Figure 22, embodiments of the contact lens case 800
may comprise an
anti-microbial coating 100 on at least a portion of the interior surface of
the wall 214, e.g. the
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
interior surfaces of the sidewall 215 and/or the bottom wall 216 of each
reservoir 211, 212.
Similarly, embodiments of the contact lens case 800 may comprise an anti-
microbial coating 100
on the interior surface, e.g. underside, of each of the first and second caps
821, 822. Note that
Figure 22 is not intended to be drawn to scale and that the anti-microbial
coating 100 may be
applied as a very thin coating relative to the thickness of the vessel and cap
walls 214.
[0262] Another example of a multi-use package according to an embodiment
of the present
disclosure, and in particular a multi-dose inhaler or metered-dose inhaler
(MDI) 900 is shown in
Figure 23. The multi-dose inhaler 900 comprises a vessel 210, e.g. a
cannister, having a side
wall 215 and a bottom wall 216, the side wall and the bottom wall together
defining and at least
partially enclosing a lumen 212. The sidewall 215 may comprise a main body
portion 217 and a
neck portion 218 having a reduced diameter relative to the main body portion,
with the main body
portion and the neck portion being connected by a transition region 219.
Opposite the bottom
wall 216 is an opening through which a fluid stored within the lumen 212 may
be dispensed from
the vessel 210. The canister 210 may further comprise a metering valve 920
which may comprise
a metering chamber 921 and a metering valve stem 922 that extends from the top
of the canister.
The metering valve 920 may serve as the opening of the canister through which
fluid stored within
the lumen may be dispensed from the vessel.
[0263] The canister 210 may also comprise a cap, which is securable to
the vessel, and in
particular which may be secured to the neck portion 218 of the vessel, and
cover the meter valve
stem 922, prior to first use.
[0264] The multi-dose inhaler 900 may further comprise an actuator 930.
The actuator 930
may comprise a plastic body having a mouthpiece 931 at a first end and an
opening 932 sized
and configured to receive the canister 210 at the opposite end. The actuator
930 may further
comprise a seat 933 configured to receive the metering valve stem 922 of the
canister 210 and
a nozzle 934 configured to spray the fluid contents out of the mouthpiece 931.
The actuator 930
may also comprise a cap configured to cover the mouthpiece 931 when not in
use.
[0265] The multi-dose inhaler 900 further comprises a fluid 950, for
example a medical fluid,
within the lumen 212 of the canister. In some embodiments, the medical fluid
950 may be a drug-
containing solution that is formulated for administration into the lungs of a
patient. In some
embodiments, the drug-containing solution may comprise a respiratory drug,
such as one
configured to treat asthma, chronic obstructive pulmonary disease (COPD), or
other respiratory
diseases. In some embodiments, for example, the medical fluid 950 may comprise
one or more
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
bronchodilators, one or more corticosteroids, or a combination thereof. In
some embodiments,
the medical fluid 950 may comprise one or more mast cell stabilizers, such as
cromoglicate or
nedocromil, or one or more phospholipids. The fluid 950 may further comprise
one or more
propellants. In some embodiments, for instance, the fluid 950 may comprise a
hydrofluorocarbon,
e.g. hydrofluoroalkane, propellant.
[0266] In use, a canister 210 is inserted into the actuator 930 and the
metering valve stem
922 of the canister placed into operably engagement with the seat 933 of the
actuator. The
mouthpiece 931 is placed into the mouth of the user and the actuator is
operated by pressing
down on the bottom wall 216 of the canister 210, which causes a metered dose
of fluid to be
discharged from the canister through the metering valve 920 and out of the
actuator nozzle 934.
The drug may be dissolved or suspended in the propellant. Discharge through
the nozzle breaks
up the volatile propellant into droplets, which are then rapidly evaporated,
resulting in an aerosol
of micrometer-sized medication particles that are then inhaled into the user's
lungs.
[0267] Embodiments of the multi-dose inhaler 900 may comprise an anti-
microbial coating
100 on the at least a portion of the interior surface of the vessel wall 214
(e.g. the interior surfaces
of the sidewall 215 and/or the bottom wall 216 of the canister), i.e. the
surfaces that are in contact
with the fluid 950 stored within the lumen 212.
[0268] Embodiments of the multi-dose inhaler 900 may comprise an anti-
microbial coating
100 on at least a portion of the interior surfaces of the actuator 930,
including for instance the
interior surfaces of the mouthpiece 931 and/or the interior surfaces of the
actuator body that are
positioned between the nozzle 934 and the mouthpiece 931.
[0269] In use, the mouthpiece 931 of the multi-dose inhaler 900 is
placed into the user or
patient's mouth, and the actuator 930 is actuated one or more times in order
to dispense the
medical fluid into the user or patient's lungs. In use therefore the actuator
930, and in particular
the mouthpiece 931, may come into contact with the inside of the user or
patient's with bacteria,
which can then enter into the interior of the actuator 930 and/or the lumen
212 of the vessel 210
in which the remainder of the medical fluid 950 is stored for future use,
thereby contaminating the
actuator and/or the medical fluid. Embodiments of the present invention
comprise an anti-
microbial coating 100 that is effective to inhibit the growth of microbes such
as bacteria in the
medical fluid 950 contained within the lumen 212 of the vessel 210 (e.g. as
compared to a vessel
without the anti-microbial coating) and/or to inactivate or kill bacteria
introduced into the lumen of
the canister, and/or to increase the shelf-life of the canister after first
use. Further, embodiments
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
of the present invention may comprise an anti-microbial coating 100 that is
effective to inhibit the
growth of microbes such as bacteria in the actuator 930 (e.g. as compared to
an actuator without
the anti-microbial coating) and/or to inactivate or kill bacteria introduced
into the interior of the
actuator, and/or to extend the life of the actuator after first use.
[0270] Embodiments of the multi-dose inhaler 900 may also comprise a
canister 210 having
a coating set 285 that includes a barrier coating or layer 288 and optionally
one or more of a tie
coating or layer 289 and a pH protective coating or layer 286. Like the anti-
microbial coating 100
described above, this coating set 285 may be applied to at least a portion of
the interior surface
of the vessel wall 214, e.g. the interior surfaces of the sidewall 215 and/or
the bottom wall 216 of
the vessel. This coating set 285 may be provided in addition to the anti-
microbial coating 100 or
alone, i.e. independent of an anti-microbial coating. Generally, when applied
in combination with
an anti-microbial coating 100, the anti-microbial coating is applied as the
innermost layer, i.e. the
layer that is in contact with the fluid stored within the lumen 212.
Gas Barrier Coatings
[0271] As described above, embodiments of the present disclosure may
include a gas barrier
coating, such as an oxygen barrier coating. In some embodiments, the gas
barrier coating may
comprise an oxygen gas barrier and/or be part of a coating set, such as the
"trilayer" coating set
described below.
Vessels and Coating Sets
[0272] An aspect of the invention, illustrated most broadly by Fig. 24
and the detail view of
Fig. 25, is a vessel 210 including a wall 214 enclosing a lumen 212 and a
vessel coating or layer
set 285 on at least a portion of the wall 214 facing the lumen 212. The vessel
may be any of the
multi-dose vessels described above or any other vessel configured to contain
and/or
containings a cosmetic or fragrance composition.
[0273] An embodiment of the vessel coating or layer set 285 is at least
one tie coating or
layer 289, at least one barrier coating or layer 288, and at least one pH
protective coating or
layer 286, illustrated in Figs. 24-25. This embodiment of the vessel coating
or layer set is
sometimes known as a "trilayer coating" in which the barrier coating or layer
288 of SiO, is
protected against contents having a pH otherwise high enough to remove it by
being sandwiched
between the pH protective coating or layer 286 and the tie coating or layer
289, each an organic
layer of SiO,Cy as defined in this specification. A specific example of this
trilayer coating is
provided in this specification. The preferred contemplated thicknesses of the
respective layers
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
in nm (preferred ranges in parentheses) are given in the Trilayer Thickness
Table.
Trilayer Thickness Table
Adhesion Barrier Protection
5-100 (5-20) 20-200 (20-30) 10-500 (100-200)
if by PECVD if by PECVD
1-20 (2-15) 1-20 (2-15)
if by ALD if by ALD
[0274] The trilayer coating set 285 includes as a first layer an
adhesion or tie coating or layer
289 that improves adhesion of the barrier coating or layer to the substrate,
i.e. vessel wall. The
adhesion or tie coating or layer 289 is also believed to relieve stress on the
barrier coating or
layer 288, making the barrier layer less subject to damage from thermal
expansion or
contraction or mechanical shock. The adhesion or tie coating or layer 289 is
also believed to
decouple defects between the barrier coating or layer 288 and the substrate.
This is believed
to occur because any pinholes or other defects that may be formed when the
adhesion or
tie coating or layer 289 is applied tend not to be continued when the barrier
coating or layer
288 is applied, so the pinholes or other defects in one coating do not line up
with defects in the
other. The adhesion or tie coating or layer 289 has some efficacy as a barrier
layer, so even a
defect providing a leakage path extending through the barrier coating or layer
289 is blocked by
the adhesion or tie coating or layer 289.
[0275] The trilayer coating set 285 includes as a second layer a barrier
coating or layer 288
that provides a barrier to oxygen that has permeated the vessel wall. The
barrier coating or
layer 288 also is a barrier to extraction of the composition of the barrel
wall 214 by the contents
of the lumen 214.
[0276] The trilayer coating set 285 includes as a third layer a pH
protective coating or layer
286 that provides protection of the underlying barrier coating or layer 288
against contents of
the vessel having a pH from 4 to 8. For a vessel wall that is in contact with
the contents of
the vessel from the time the package is manufactured to the time it is used,
the pH protective
coating or layer 286 prevents or inhibits attack of the barrier coating or
layer 288 sufficiently to
maintain an effective oxygen barrier over the intended pre-use shelf life of
the package.
Tie Coating or Layer
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
[0277] The tie coating or layer 289 has at least two functions. One
function of the tie
coating or layer 289 is to improve adhesion of a barrier coating or layer 288
to a substrate, in
particular a thermoplastic substrate, although a tie layer can be used to
improve adhesion to a
glass substrate or to another coating or layer. For example, a tie coating or
layer, also referred
to as an adhesion layer or coating can be applied to the substrate and the
barrier layer can
be applied to the adhesion layer to improve adhesion of the barrier layer or
coating to the
substrate.
[0278] Another function of the tie coating or layer 289 has been
discovered: a tie coating or
layer 289 applied under a barrier coating or layer 288 can improve the
function of a pH
protective coating or layer 286 applied over the barrier coating or layer 288.
[0279] The tie coating or layer 289 can be composed of, comprise, or
consist essentially of
SiOxCy, in which x is between 0.5 and 2.4 and y is between 0.6 and 3.
Alternatively, the atomic
ratio can be expressed as the formula SiwOxCy, The atomic ratios of Si, 0, and
C in the tie
coating or layer 289 are, as several options:
Si 100: 0 50-150 : C 90-200 (i.e. w = 1, x = 0.5 to 1.5, y = 0.9 to 2);
Si 100: 0 70-130 : C 90-200 (i.e. w = 1, x = 0.7 to 1.3, y = 0.9 to 2)
Si 100 : 0 80-120 : C 90-150 (i.e. w = 1, x = 0.8 to 1.2, y = 0.9 to 1.5)
Si 100 : 0 90-120 : C 90-140 (i.e. w = 1, x = 0.9 to 1.2, y = 0.9 to 1.4), or
Si 100 : 0 92-107 : C 116-133 (i.e. w = 1, x = 0.92 to 1.07, y = 1.16 to 1.33)
[0280] The atomic ratio can be determined by XPS. Taking into account
the H atoms,
which are not measured by XPS, the tie coating or layer 289 may thus in one
aspect have the
formula SiwOxCyH, (or its equivalent SiOxCy), for example where w is 1, x is
from about 0.5 to
about 2.4, y is from about 0.6 to about 3, and z is from about 2 to about 9.
Typically, tie
coating or layer 289 would hence contain 36% to 41% carbon normalized to 100%
carbon
plus oxygen plus silicon.
[0281] Optionally, the tie coating or layer can be similar or identical
in composition with the pH
protective coating or layer 286 described elsewhere in this specification,
although this is not a
requirement.
[0282] The tie coating or layer 289 is contemplated in any embodiment
generally to be
from 5 nm to 100 nm thick, preferably from 5 to 20 nm thick, particularly if
applied by
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
chemical vapor deposition. These thicknesses are not critical. Commonly but
not necessarily,
the tie coating or layer 289 will be relatively thin, since its function is to
change the surface
properties of the substrate.
Barrier Layer
[0283] A barrier coating or layer 288 optionally can be deposited by
plasma enhanced
chemical vapor deposition (PECVD) or other chemical vapor deposition processes
on the
vessel wall, in particular a thermoplastic vessel wall, to prevent oxygen,
carbon dioxide, or other
gases from entering the vessel and/or to prevent leaching of the content of
the vessel into or
through the package wall.
[0284] The barrier coating or layer for any embodiment defined in this
specification (unless
otherwise specified in a particular instance) is a coating or layer,
optionally applied by
PECVD as indicated in U.S. Pat. No. 7,985,188. The barrier layer optionally is
characterized as
an "SiOx" coating, and contains silicon, oxygen, and optionally other
elements, in which x, the
ratio of oxygen to silicon atoms, is from about 1.5 to about 2.9, or 1.5 to
about 2.6, or about
2. These alternative definitions of x apply to any use of the term SiOx in
this specification.
[0285] The barrier coating 288 comprises or consists essentially of
SiOx, wherein x is from
1.5 to 2.9, from 2 to 1000 nm thick, the barrier coating 288 of SiOx having an
interior surface 220
facing the lumen 212 and an outer surface 222 facing the wall 214 article
surface 254, the barrier
coating 288 being effective to reduce the ingress of atmospheric gas into the
lumen 212
compared to an uncoated vessel 250. One suitable barrier composition is one
where x is 2.3, for
example.
[0286] For example, the barrier coating or layer such as 288 of any
embodiment can be
applied at a thickness of at least 2 nm, or at least 4 nm, or at least 7 nm,
or at least 10 nm, or at
least 20 nm, or at least 30 nm, or at least 40 nm, or at least 50 nm, or at
least 100 nm, or at least
150 nm, or at least 200 nm, or at least 300 nm, or at least 400 nm, or at
least 500 nm, or at least
600 nm, or at least 700 nm, or at least 800 nm, or at least 900 nm. The
barrier coating or layer
can be up to 1000 nm, or at most 900 nm, or at most 800 nm, or at most 700 nm,
or at most 600
nm, or at most 500 nm, or at most 400 nm, or at most 300 nm, or at most 200
nm, or at most 100
nm, or at most 90 nm, or at most 80 nm, or at most 70 nm, or at most 60 nm, or
at most 50 nm,
or at most 40 nm, or at most 30 nm, or at most 20 nm, or at most 10 nm, or at
most 5 nm thick.
Ranges of 20-200 nm, optionally 20-30 nm, are contemplated. Specific thickness
ranges
composed of any one of the minimum thicknesses expressed above, plus any equal
or
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
, greater one of the maximum thicknesses expressed above, are expressly
contemplated.
[0287] The thickness of the SiOx or other barrier coating or layer can
be measured, for
example, by transmission electron microscopy (TEM), and its composition can be
measured by
X-ray photoelectron spectroscopy (XPS).
[0288] A barrier coating or layer 286 of SiOx, in which x is between 1.5
and 2.9, is applied by
plasma enhanced chemical vapor deposition (PECVD) directly or indirectly to
the thermoplastic
wall 214 (for example a tie coating or layer 289 can be interposed between
them) so that in
the filled vessel 210 the barrier coating or layer 286 is located between the
inner or interior
surface 220 of the thermoplastic wall 214 and the fluid 218.
[0289] The barrier coating or layer 286 of SiOx is supported by the
thermoplastic wall 214.
The barrier coating or layer 286 as described elsewhere in this specification,
or in U.S. Patent No.
7,985,188, can be used in any embodiment.
[0290] Certain barrier coatings or layers 286 such as SiOx as defined
here have been
found to have the characteristic of being subject to being measurably
diminished in barrier
improvement factor in less than six months as a result of attack by certain
relatively high pH
contents of the coated vessel as described elsewhere in this specification,
particularly where the
barrier coating or layer directly contacts the contents. This issue can be
addressed using a pH
protective coating or layer as discussed in this specification.
[0291] The barrier coating or layer 286 of SiOx also can function as a
primer coating or
layer 283, as discussed elsewhere in this specification.
pH Protective Coating or Layer
[0292] Barrier layers or coatings of SiOx are eroded or dissolved by
some fluids, for
example aqueous compositions having a pH above about 5. Since coatings applied
by
chemical vapor deposition can be very thin ¨ tens to hundreds of nanometers
thick ¨ even a
relatively slow rate of erosion can remove or reduce the effectiveness of the
barrier layer in less
time than the desired pre-use shelf life of a product package. This is
particularly a problem for
multi-use, cosmetic, and/or fragrance compositions having a pH of roughly 7,
or more broadly
in the range of 5 to 9. The higher the pH of the composition, the more quickly
it erodes or
dissolves the SiOx coating. Optionally, this problem can be addressed by
protecting the barrier
coating or layer 288, or other pH sensitive material, with a pH protective
coating or layer 286.
[0293] Optionally, the pH protective coating or layer 286 can be
composed of, comprise, or
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
consist essentially of SiwOxCyHz (or its equivalent SiOxCy) or SiwNxCyH, or
its equivalent
Si(NH)C), each as defined previously. The atomic ratio of Si : 0 : C or Si : N
: C can be
determined by XPS (X-ray photoelectron spectroscopy). Taking into account the
H atoms, the pH
protective coating or layer may thus in one aspect have the formula SiwOxCyHz,
or its
equivalent SiOxCy, for example where w is 1, x is from about 0.5 to about 2.4,
y is from about to
about 3, and z is from about 2 to about 9.
[0294] Typically, expressed as the formula SiwOxCy, the atomic ratios of
Si, 0, and C are, as
several options:
= Si 100: 0 50-150 : C 90-200 (i.e. w = 1, x = 0.5 to 1.5, y = 0.9 to 2);
= Si 100: 0 70-130 : C 90-200 (i.e. w = 1, x = 0.7 to 1.3, y = 0.9 to 2);
= Si 100: 0 80-120 : C 90-150 (i.e. w 1, x = 0.8 to 1.2, y = 0.9 to 1.5);
= Si 100: 0 90-120 : C 90-140 (i.e. w 1, x = 0.9 to 1.2, y = 0.9 to 1.4);
= Si 100 : 0 92-107 : C 116-133 (i.e. w = 1, x = 0.92 to 1.07, y = 1.16 to
1.33);
= Si 100: 0 80-130: C 90-150.
[0295] Alternatively, the pH protective coating or layer can have atomic
concentrations
normalized to 100% carbon, oxygen, and silicon, as determined by X-ray
photoelectron
spectroscopy (XPS) of less than 50% carbon and more than 25% silicon.
Alternatively, the
atomic concentrations are from 25 to 45% carbon, 25 to 65% silicon, and 10 to
35% oxygen.
Alternatively, the atomic concentrations are from 30 to 40% carbon, 32 to 52%
silicon, and 20 to
27% oxygen. Alternatively, the atomic concentrations are from 33 to 37%
carbon, 37 to 47%
silicon, and 22 to 26% oxygen.
[0296] The thickness of the pH protective coating or layer can be, for
example:
= from 10 nm to 1000 nm;
= alternatively from 10 nm to 1000 nm;
= alternatively from 10 nm to 900 nm;
= alternatively from 10 nm to 800 nm;
= alternatively from 10 nm to 700 nm;
- alternatively from 10 nm to 600 nm;
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
= alternatively from 10 nm to 500 nm;
= alternatively from 10 nm to 400 nm;
= alternatively from 10 nm to 300 nm;
= alternatively from 10 nm to 200 nm;
= alternatively from 10 nm to 100 nm;
= alternatively from 10 nm to 50 nm;
= alternatively from 20 nm to 1000 nm;
= alternatively from 50 nm to 1000 nm;
= alternatively from 10 nm to 1000 nm;
= alternatively from 50 nm to 800 nm;
= alternatively from 100 nm to 700 nm;
= alternatively from 300 to 600 nm.
[0297] Optionally, the atomic concentration of carbon in the protective
layer, normalized to
100% of carbon, oxygen, and silicon, as determined by X-ray photoelectron
spectroscopy
(XPS), can be greater than the atomic concentration of carbon in the atomic
formula for the
organosilicon precursor. For example, embodiments are contemplated in which
the atomic
concentration of carbon increases by from 1 to 80 atomic percent,
alternatively from 10 to 70
atomic percent, alternatively from 20 to 60 atomic percent, alternatively from
30 to 50 atomic
percent, alternatively from 35 to 45 atomic percent, alternatively from 37 to
41 atomic
percent.
[0298] Optionally, the atomic ratio of carbon to oxygen in the pH
protective coating or
layer can be increased in comparison to the organosilicon precursor, and/or
the atomic ratio of
oxygen to silicon can be decreased in comparison to the organosilicon
precursor.
[0299] Optionally, the pH protective coating or layer can have an atomic
concentration of
silicon, normalized to 100% of carbon, oxygen, and silicon, as determined by X-
ray
photoelectron spectroscopy (XPS), less than the atomic concentration of
silicon in the atomic
formula for the feed gas. For example, embodiments are contemplated in which
the atomic
concentration of silicon decreases by from 1 to 80 atomic percent,
alternatively by from 10 to 70
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
atomic percent, alternatively by from 20 to 60 atomic percent, alternatively
by from 30 to 55
atomic percent, alternatively by from 40 to 50 atomic percent, alternatively
by from 42 to 46
atomic percent.
[0300] As another option, a pH protective coating or layer is
contemplated in any
embodiment that can be characterized by a sum formula wherein the atomic ratio
C : 0 can be
increased and/or the atomic ratio Si : 0 can be decreased in comparison to the
sum formula
of the organosilicon precursor.
[0301] The pH protective coating or layer 286 commonly is located
between the barrier
coating or layer 288 and the fluid 218 in the finished article. The pH
protective coating or
layer 286 is supported by the thermoplastic wall 214.
[0302] The pH protective coating or layer 286 optionally is effective to
keep the barrier
coating or layer 288 at least substantially undissolved as a result of attack
by the fluid 218 for a
period of at least six months.
[0303] The pH protective coating or layer can have a density between
1.25 and 1.65
g/cm3, alternatively between 1.35 and 1.55 g/cm3, alternatively between 1.4
and 1.5 g/cm3,
alternatively between 1.4 and 1.5 g/cm3, alternatively between 1.44 and 1.48
g/cm3, as
determined by X-ray reflectivity (XRR).
[0304] The pH protective coating or layer optionally can prevent or
reduce the precipitation of
a compound or component of a composition in contact with the pH protective
coating or layer
in comparison to the uncoated surface.
[0305] The pH protective coating or layer optionally can have an RMS
surface roughness
value (measured by AFM) of from about 5 to about 9, optionally from about 6 to
about 8,
optionally from about 6.4 to about 7.8. The Ra surface roughness value of the
pH protective
coating or layer, measured by AFM, can be from about 4 to about 6, optionally
from about 4.6 to
about 5.8. The Rmax surface roughness value of the pH protective coating or
layer, measured
by AFM, can be from about 70 to about 160, optionally from about 84 to about
142, optionally
from about 90 to about 130.
[0306] The interior surface of the pH protective optionally can have a
contact angle (with
distilled water) of from 90 to 1100, optionally from 80 to 1200, optionally
from 70 to 1300, as
measured by Goniometer Angle measurement of a water droplet on the pH
protective surface,
per ASTM D7334 08 "Standard Practice for Surface Wettabty of Coatings,
Substrates and
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
Pigments by Advancing Contact Angle Measurement."
[0307] The passivation layer or pH protective coating or layer 286
optionally shows an 0-
Parameter measured with attenuated total reflection (ATR) of less than 0.4,
measured as:
0-Parameter = Intensity at 1253 cm-1
Maximum intensity in the range 1000 to 1100 cm-1
[0308] The 0-Parameter is defined in U.S. Patent No. 8,067,070, which
claims an 0-
parameter value of most broadly from 0.4 to 0.9. It can be measured from
physical analysis of
an FTIR amplitude versus wave number plot to find the numerator and
denominator of the above
expression, as shown in FIG. 6, which is the same as FIG. 5 of U.S. Patent No.
8,067,070,
except annotated to show interpolation of the wave number and absorbance
scales to arrive
at an absorbance at 1253 cm-1 of .0424 and a maximum absorbance at 1000 to
1100 cm-1 of
0.08, resulting in a calculated 0-parameter of 0.53. The 0-Parameter can also
be measured
from digital wave number versus absorbance data.
[0309] U.S. Patent No. 8,067,070 asserts that the claimed 0-parameter
range provides a
superior pH protective coating or layer, relying on experiments only with
HMDSO and HMDSN,
which are both non-cyclic siloxanes. Surprisingly, it has been found that if
the PECVD precursor
is a cyclic siloxane, for example OMCTS, 0-parameters outside the ranges
claimed in U.S.
Patent No. 8,067,070 provide even better results than are obtained in U.S.
Patent No. 8,067,070
with HMDSO.
[0310] Alternatively in some embodiments, the 0-parameter has a value of
from 0.1 to 0.39,
or from 0.15 to 0.37, or from 0.17 to 0.35.
[0311] The passivation layer or pH protective coating or layer 286
optionally shows an N-
Parameter measured with attenuated total reflection (ATR) of less than 0.7,
measured as:
N-Parameter = Intensity at 840 cm-1
Intensity at 799 cm-1.
[0312] The N-Parameter is also described in U.S. Patent No. 8,067,070,
and is measured
analogously to the 0-Parameter except that intensities at two specific wave
numbers are
used ¨ neither of these wave numbers is a range. U.S. Patent No. 8,067,070
claims a
passivation layer with an N-Parameter of 0.7 to 1.6. Again, it has been
determined that one may
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
produce better coatings employing a pH protective coating or layer 286 having
an N-Parameter
lower than 0.7, as described above. Alternatively, the N-parameter has a value
of at least 0.3,
or from 0.4 to 0.6, or at least 0.53.
[0313] The rate of erosion, dissolution, or leaching (different names
for related concepts) of
the pH protective coating or layer 286, if directly contacted by the fluid
218, is less than the rate
of erosion of the barrier coating or layer 288, if directly contacted by the
fluid 218.
[0314] The thickness of the pH protective coating or layer is
contemplated in any
embodiment to be from 50-500 nm, with a preferred range of 100-200 nm.
[0315] The pH protective coating or layer 286 is effective to isolate
the fluid 218 from the
barrier coating or layer 288, at least for sufficient time to allow the
barrier coating to act as a
barrier during the pre-opening shelf life of the vessel 210.
[0316] It has also been found that certain pH protective coatings or
layers of SiOxCy or
Si(NH)xCy formed from polysiloxane precursors, which pH protective coatings or
layers have a
substantial organic component, do not erode quickly when exposed to fluids,
and in fact erode
or dissolve more slowly when the fluids have higher pHs within the range of 5
to 9. For example,
at pH 8, the dissolution rate of a pH protective coating or layer made from
the precursor
octamethylcyclotetrasiloxane, or OMCTS, is quite slow. These pH protective
coatings or
layers of SiOxCy or Si(NH)xCy can therefore be used to cover a barrier layer
of SiOx, retaining
the benefits of the barrier layer by protecting it from the fluid in the multi-
use, cosmetic, and/or
fragrance product package. The protective layer is applied over at least a
portion of the SiOx
layer to protect the SiOx layer from contents stored in a vessel, where the
contents otherwise
would be in contact with the SiOx layer.
[0317] Although the present invention does not depend upon the accuracy
of the following
theory, it is further believed that effective pH protective coatings or layers
for avoiding erosion can
be made from siloxanes and silazanes as described in this disclosure. SiOxCy
or Si(NH)xCy
coatings deposited from cyclic siloxane or linear silazane precursors, for
example
octamethylcyclotetrasiloxane (OMCTS), are believed to include intact cyclic
siloxane rings
and longer series of repeating units of the precursor structure. These
coatings are believed to
be nanoporous but structured and hydrophobic, and these properties are
believed to
contribute to their success as pH protective coatings or layers, and also
protective coatings or
layers. This is shown, for example, in U.S. Pat. No. 7,901,783.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
[0318] SiO,Cy or Si(NH),Cy coatings also can be deposited from linear
siloxane or linear
silazane precursors, for example hexamethyldisiloxane (HMDSO) or
tetramethyldisiloxane
(TMDSO).
[0319] Optionally an FTIR absorbance spectrum of the pH protective
coating or layer 286 of
any embodiment has a ratio greater than 0.75 between the maximum amplitude of
the Si- 0-Si
symmetrical stretch peak normally located between about 1000 and 1040 cm-1,
and the
maximum amplitude of the Si-O-Si assynnnnetric stretch peak normally located
between about
1060 and about 1100 cm-1. Alternatively, in any embodiment, this ratio can be
at least 0.8, or at
least 0.9, or at least 1.0, or at least 1.1, or at least 1.2. Alternatively,
in any embodiment, this
ratio can be at most 1.7, or at most 1.6, or at most 1.5, or at most 1.4, or
at most 1.3. Any
minimum ratio stated here can be combined with any maximum ratio stated here.
[0320] Optionally, in any embodiment the pH protective coating or layer
286, in the
absence of the medicament, has a non-oily appearance. This appearance has been
observed
in some instances to distinguish an effective pH protective coating or layer
from a lubricity layer,
which in some instances has been observed to have an oily (i.e. shiny)
appearance.
[0321] Optionally, for the pH protective coating or layer 286 in any
embodiment, the silicon
dissolution rate by a 50 mM potassium phosphate buffer diluted in water for
injection,
adjusted to pH 8 with concentrated nitric acid, and containing 0.2 wt. %
polysorbate-80
surfactant, (measured in the absence of the medicament, to avoid changing the
dissolution
reagent), at 40 C, is less than 170 ppb/day. (Polysorbate-80 is a common
ingredient of
pharmaceutical preparations, available for example as Tween0-80 from Uniqema
Americas
LLC, Wilmington Delaware.)
[0322] Optionally, for the pH protective coating or layer 286 in any
embodiment, the silicon
dissolution rate is less than 160 ppb/day, or less than 140 ppb/day, or less
than 120 ppb/day, or
less than 100 ppb/day, or less than 90 ppb/day, or less than 80 ppb/day.
Optionally, in any
embodiment of Figures 24-26 the silicon dissolution rate is more than 10
ppb/day, or more
than 20 ppb/day, or more than 30 ppb/day, or more than 40 ppb/day, or more
than 50
ppb/day, or more than 60 ppb/day. Any minimum rate stated here can be combined
with any
maximum rate stated here for the pH protective coating or layer 286 in any
embodiment.
[0323] Optionally, for the pH protective coating or layer 286 in any
embodiment the total
silicon content of the pH protective coating or layer and barrier coating,
upon dissolution into a
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
test composition with a pH of 8 from the vessel, is less than 66 ppm, or less
than 60 ppm, or
less than 50 ppm, or less than 40 ppm, or less than 30 ppm, or less than 20
ppm.
[0324] The protective coating or layer of SiwOxCy or its equivalent
SiOxCy also can have utility
as a hydrophobic layer, independent of whether it also functions as a pH
protective coating
or layer. Suitable hydrophobic coatings or layers and their application,
properties, and use
are described in U.S. Patent No. 7,985,188. Dual functional protective /
hydrophobic coatings
or layers having the properties of both types of coatings or layers can be
provided for in any
embodiment of the present invention.
[0325] An embodiment can be carried out under conditions effective to
form a hydrophobic pH
protective coating or layer on the substrate. Optionally, the hydrophobic
characteristics of the pH
protective coating or layer can be set by setting the ratio of the 02 to the
organosilicon precursor
in the gaseous reactant, and/or by setting the electric power used for
generating the plasma.
Optionally, the pH protective coating or layer can have a lower wetting
tension than the uncoated
surface, optionally a wetting tension of from 20 to 72 dyne/cm, optionally
from 30 to 60
dynes/cm, optionally from 30 to 40 dynes/cm, optionally 34 dyne/cm.
Optionally, the pH
protective coating or layer can be more hydrophobic than the uncoated surface.
Atomic Layer Deposition Coating of Vessels
[0326] One or more of the layers described herein may be applied by
atomic layer deposition
coating. Coatings applied by atomic layer deposition are structurally (though
not necessarily
chemically) distinct from those applied by CVD or PECVD. In contrast to
coatings applied by CVD
or PECVD, coatings applied by atomic layer deposition consist of a plurality
of monolayers of the
deposited compound. Because each step deposit only a single monolayer, defects
of the sort
that can develop due to non-uniform growth during CVD or PECVD are avoided.
The result is a
coating having significantly higher density than that of a coating (of
generally the same chemical
composition) applied by CVD or PECVD. Because the coating consists of a
plurality of
monolayers of the deposited compound, the coating may also have a higher
degree of
compositional purity and consistency than coatings applied by PECVD.
[0327] In an atomic layer deposition process, sources, i.e., precursors,
may be sequentially
introduced in non-overlapping timeframes to deposit one material at a time.
Once each possible
adsorption site is occupied in a particular precursor flow, the precursor may
be halted and a purge
process may be completed before the next source material is introduced, with
one timeframe for
each precursor comprising one cycle. As the chamber is typically under a 1-20
mbar vacuum, the
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
remaining precursor may be evacuated upon stopping flow. In this manner, the
deposition
process continues in a self-limited way in that there are only a finite number
of sites on which the
reactant can adsorb, so once they are filled, the growth stops until the next
precursor is
introduced, where the total material thickness is controlled by the number of
cycles. This process
may continue for each precursor, resulting in a coating or layer being
deposited one atomic layer
at a time. Accordingly, ALD is capable of growing very thin conformal films
with excellent
thickness uniformity and control, as well as increased density compared to
other deposition
techniques. Furthermore, precise composition control is enabled by the ALD
process.
[0328]
A plasma may be optionally utilized to enhance the material
deposition, i.e., plasma
enhanced atomic layer deposition (PEALD), also sometimes referred to as plasma-
assisted
atomic layer deposition, where the precursor dissociation may be increased
using a plasma,
enabling a lower growth temperature, which may be useful when applying
coatings to certain
thermoplastics.
[0329]
ALD is useful for depositing high-density layers with low defect
density. In an example,
a thin SiOx film may be deposited by thermal and/or plasma enhanced ALD. The
deposition
temperature may be in the range of 30 C to 120 C. For instance, where thermal
ALD is used, the
deposition temperature may desirably be in the range of 80-120 C. Where PEALD
is used, the
temperature may be at least 30 C, e.g. between 30 C and 80 C or between 30
C and 60 C.
[0330]
Precursors for the deposition of a SiOx film by ALD or PEALD
include one or more
silicon-containng precursor and one or more oxygen precusors. The silicon
precursors may
include, for example, aminosilanes; alkyl-aminosilanes, such as tetradimethyl-
aminosilicon; 1,2-
bis(diisopropylamino)disilane (for low temperature deposition, e.g. 50-60 C);
diisopropylaminosilane; tris(dimethylamino)silane;
bis(ethyl-methyl-amino)silane; and
combinations thereof. Ozone may be used as an oxygen precursor in thermal ALD
and 02 plasma
may be utilized with PEALD. Further, the silicon precursor (or precursors) may
be pulsed to
control the growth rate.
[0331]
In another example, ALD and/or PEALD may be utilized to deposit
other barrier
layer materials such as silicon nitrides, silicon carbides, and aluminum
oxides, or other such
materials which may improve the gas barrier and/or material dissociation
capabilities. Due to the
slow and controlled growth rate of ALD, which may result in increased material
adhesion, tie
layers may not be needed.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
.
,
EXAMPLES
[0332] Although the examples provided below predominantly involve the
coating of
thermoplastic syringes and vials, which are not the subject of the present
application, it is
believed that a person of ordinary skill in the art can use the teaching of
this specification to
adjust the coating parameters as necessary in order to provide desired coating
sets for the multi-
use, cosmetic, and/or fragrance packages described herein.
Examples 1-4 ¨ Conditions for Production of pH Protective Layer
[0333] Some conditions used for production of pH Protective Layers are
shown in Table 1.
CA 03183219 2022- 12- 16
n
>
o
u,
,
65810W001 (S10-0171PC)
to
.
,
TABLE 1: OMCTS-BASED PLASMA pH PROTECTIVE COATING OR LAYER
MADE WITH CARRIER GAS
o
N
0
N
Example pH PH pH protective
Carrier pH .
-.-J
!A
protectiv protective protectiv OMCTS
Gas protectiv -1
-.1
e coating Monomer e coating Flow Rate protective
(Ar) e coating N
DO
or layer or layer (sccm) 02
Flow Flow or layer
Type Time
Rate Rate Power
(sec)
(sccm) (sccm) (Watts)
1 Uncoated n/a n/a n/a n/a
n/a n/a
(Control) COC
2 Silicon oil n/a n/a n/a n/a
n/a n/a
(Industry on COC
Standard)
3 L3 lubricity OMCTS 10 sec 3 0
65 6
(without coating or
Oxygen) layer over
SiOx on
COC
4 L2 pH OMCTS 10 sec 3 1
65 6
(with protective
Oxygen) coating or
layer over
SiOx on
COC
1-0
n
Cl)
N
0
tsJ
0
C=4
-4
0 \
0 \
--1
WO 2021/257728
PCT/US2021/037667
Examples 5-8
[0334] Syringe samples were produced as follows. A COC 8007 extended
barrel syringe
was produced according to the Protocol for Forming COC Syringe Barrel. An SiOx
barrier
coating or layer was applied to the syringe barrels according to the Protocol
for Coating COC
Syringe Barrel Interior with SiOx. A pH protective coating or layer was
applied to the SiOx coated
syringes according to the Protocol for Coating COC Syringe Barrel Interior
with OMCTS,
modified as follows. Argon carrier gas and oxygen were used where noted in
Table 2. The
process conditions were set to the following, or as indicated in Table 2:
= OMCTS ¨3 sccm (when used)
= Argon gas ¨7.8 sccm (when used)
= Oxygen 0.38 sccm (when used)
= Power ¨ 3 watts
= Power on time ¨ 10 seconds
Syringes of Examples 5, 6, and 7 were tested to determine total extractable
silicon levels
(representing extraction of the organosilicon-based PECVD pH protective
coating or layer)
using the Protocol for Measuring Dissolved Silicon in a Vessel, modified and
supplemented as
shown in this example.
[0335] The silicon was extracted using saline water digestion. The tip
of each syringe
plunger was covered with PTFE tape to prevent extracting material from the
elastomeric tip
material, then inserted into the syringe barrel base. The syringe barrel was
filled with two
milliliters of 0.9% aqueous saline solution via a hypodermic needle inserted
through the Luer
tip of the syringe. This is an appropriate test for extractables because many
prefilled syringes
are used to contain and deliver saline solution. The Luer tip was plugged with
a piece of
PTFE beading of appropriate diameter. The syringe was set into a PTFE test
stand with the
Luer tip facing up and placed in an oven at 50 C for 72 hours.
[0336] Then, either a static or a dynamic mode was used to remove the
saline solution
from the syringe barrel. According to the static mode indicated in Table 2,
the syringe plunger
was removed from the test stand, and the fluid in the syringe was decanted
into a vessel.
According to the dynamic mode indicated in Table 2, the Luer tip seal was
removed and the
plunger was depressed to push fluid through the syringe barrel and expel the
contents into a
vessel. In either case, the fluid obtained from each syringe barrel was
brought to a volume of
50m1 using 18.2M0-cm deionized water and further diluted 2x to minimize sodium
background
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
during analysis. The CVH barrels contained two milliliters and the commercial
barrels contained
2.32 milliliters.
[0337] Next, the fluid recovered from each syringe was tested for
extractable silicon using
the Protocol for Measuring Dissolved Silicon in a Vessel. The instrument used
was a Perkin
Elmer Elan DRC il equipped with a Cetac ASX-520 autosampler. The following ICP-
MS
conditions were employed:
- Nebulizer: Quartz Meinhardt
- Spray Chamber: Cyclonic
- RE (radio frequency) power: 1550 Watts
- Argon (Ar) Flow: 15.0 L/min
- Auxiliary Ar Flow: 1.2 L/min
= Nebulizer Gas Flow: 0.88 L/min
= Integration time: 80 sec
= Scanning mode: Peak hopping
= RPq (The RPq is a rejection parameter) for Cerium as Ce0 (m/z 156: <2 %)
[0338] Aliquots from aqueous dilutions obtained from Syringes E, F, and
G were injected
and analyzed for Si in concentration units of micrograms per liter. The
results of this test are
shown in Table 2. While the results are not quantitative, they do indicate
that extractables from
the pH protective coating or layer are not clearly higher than the
extractables for the SiOx barrier
layer only. Also, the static mode produced far less extractables than the
dynamic mode, which
was expected.
TABLE 2: OMCTS PH PROTECTIVE COATING OR LAYER (E and F)
OMCTS 02 Ar
Example (sccm) (sccm) (sccm)
3.0 0.38 7.8
6 3.0 0.38 7.8
7 n/a n/a n/a
(SiOxonly)
8 n/a n/a n/a
(silicon oil)
Examples 9-11
[0339] Syringe Examples 9, 10, and 11, employing three different pH
protective coatings
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
or layers, were produced in the same manner as for Examples 5-8 except as
follows or as
indicated in Table 3:
= OMCTS ¨2.5 sccm
- Argon gas ¨7.6 sccm (when used)
= Oxygen 0.38 sccm (when used)
= Power ¨ 3 watts
- Power on time ¨ 10 seconds
[0340] Syringe Example 9 had a three-component pH protective coating or
layer employing
OMCTS, oxygen, and carrier gas. Syringe Example 10 had a two component pH
protective
coating or layer employing OMCTS and oxygen, but no carrier gas. Syringe
Example 11 had a
one-component pH protective coating or layer (OMCTS only). Syringes of
Examples 9-11 were
then tested for lubricity as described for Examples 5-8.
[0341] The pH protective coatings or layers produced according to these
working examples
are also contemplated to function as protective coatings or layers to increase
the shelf life of the
vessels, compared to similar vessels provided with a barrier coating or layer
but no pH protective
coating or layer.
TABLE 3: OMCTS pH protective coating or layer
- OMCTS ¨2.5 sccm
- Argon gas ¨7.6 sccm (when used)
- Oxygen 0.38 sccm (when used)
= Power ¨ 3 watts
= Power on time ¨ 10 seconds
Examples 12-14
[0342] Examples 9-11 using an OMCTS precursor gas were repeated in
Examples 12-14,
except that HMDSO was used as the precursor in Examples 12-14. The results are
shown in
Table 4. The coatings produced according to these working examples are
contemplated to
function as pH protective coatings or layers, and also as protective coatings
or layers to
increase the shelf life of the vessels, compared to similar vessels provided
with a barrier coating
or layer but no pH protective coating or layer.
TABLE 4: HMDSO pH protective coating or layer
CA 03183219 2022- 12- 16
WO 2021/257728 PCT/US2021/037667
Example HMDS0(sccm) 02 (sccm) Ar (sccm)
12 2.5 0.38 7.6
13 2.5 0.38
14 2.5 -
[0343] The pH protective coatings or layers produced according to these
working examples
are also contemplated to function as protective coatings or layers to increase
the shelf life of the
vessels, compared to similar vessels provided with a barrier coating or layer
but no pH protective
coating or layer.
TABLE 5
OMCTS Ar/02 Power Dep. Time AFM RMS
Example (sccm) (sccm) (Watts) (sec)
(nanometers)
16 2.0 10/0.38 3.5 10
17 19.6,
9.9, 9.4
(Average=13.0)
21
22 2.0 10/0.38 4.5 10 FIG. 7
12.5, 8.4, 6.1
23
(Average=6.3)
24
2.0 10/0 3.4 10
1.9, 2.6, 3.0
(Average=2.3)
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
TABLE 6
Dep.
Siloxane Power
Time
SiOx/Lub Coater Mode Feed Ar/02 (W) (Sec.)
HMDSO
52.5 in,
Example 18 133.4 0 sccm Ar,
SiOx/Baseline SiOx: Auto-Tube Auto cm. 90 sccm 02
37 7
OMCTS Lub
OMCTS, 10 sccm Ar
Lubricity: Auto-S Same 2.0 sccm 0.38 sccm 02 3,4
10
Example 19 SiOx: Same same Same
Same 37 7
SiOx/High Pwr
OMCTS Lub Lubricity: Same Same Same
Same 4,5 10
0 sccm Ar,
Example 20 SiOx: Auto-Tube Same Same 90 sccm 02
37 7
SiOx/No 02
OMCTS Lub 10 sccm Ar
Lubricity: Auto-S Same Same
0 sccm 02 3,4 10
Summary of Lubricity and/or Protective Measurements
[0344] Table 8 shows a summary of the above OMCTS coatings or layers
TABLE 8: Summary Table of OMCTS PH PROTECTIVE COATING OR LAYER
fromTables 1, 2, 3 and 5
Example OMCTS(sccm) 02 (sccm) Ar (sccm) Power (Watt) Dep Time (sec)
3 3.0 0.00 65 6 10
4 3.0 1.00 65 6 10
3.0 0.38 7.8 6 10
6 3.0 0.38 7.8 6 10
9 2.5 0.38 7.6 6 10
2.5 0.38 0.0 6 10
11 2.5 0.00 0.0 6 10
2.0 0.38 10 3.5 10
16 2.0 0.38 10 4.5 10
16A 2.0 0.00 10 3.4
10
18 2.0 0.38 10 3.4 10
19 2.0 0.38 10 4.5 10
2.0 0.00 10 3.4 10
Comparative Example 26: Dissolution of SiOx Coating Versus pH
[0345] The Protocol for Measuring Dissolved Silicon in a Vessel is
followed, except as
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
modified here. Test solutions ¨50 mM buffer solutions at pH 3, 6, 7, 8, 9, and
12 are prepared.
Buffers are selected having appropriate pKa values to provide the pH values
being studied. A
potassium phosphate buffer is selected for pH 3, 7, 8 and 12, a sodium citrate
buffer is
utilized for pH 6 and tris buffer is selected for pH 9. 3 ml of each test
solution is placed in
borosilicate glass 5 ml pharmaceutical vials and SiOx coated 5 ml
thermoplastic pharmaceutical
vials. The vials are all closed with standard coated stoppers and crimped. The
vials are
placed in storage at 20 - 25 C and pulled at various time points for
inductively coupled
plasma spectrometer (ICP) analysis of Si content in the solutions contained in
the vials, in
parts per billion (ppb) by weight, for different storage times.
[0346] The Protocol for Determining Average Dissolution Rate Si content
is used to monitor
the rate of glass dissolution, except as modified here. The data is plotted to
determine an
average rate of dissolution of borosilicate glass or SiOx coating at each pH
condition.
Representative plots at pH 6 through 8 are FIGS 26-28.
[0347] The rate of Si dissolution in ppb is converted to a predicted
thickness (nm) rate of
Si dissolution by determining the total weight of Si removed, then using a
surface area calculation
of the amount of vial surface (11.65 cm2) exposed to the solution and a
density of SiOx of 2.2
g/cm3. FIG. 29 shows the predicted initial thickness of the SiOx coating
required, based on the
conditions and assumptions of this example (assuming a residual SiOx coating
of at least 30 nm
at the end of the desired shelf life of two years, and assuming storage at 20
to 25 C). As FIG.
29 shows, the predicted initial thickness of the coating is about 36 nm at pH
5, about 80 nm at
pH 6, about 230 nm at pH 7, about 400 nm at pH 7.5, about 750 nm at pH 8, and
about 2600 nm
at pH 9.
[0348] The coating thicknesses in FIG. 29 represent atypically harsh
case scenarios for
pharma and biotech products. Most biotech products and many pharnna products
are stored
at refrigerated conditions and none are typically recommended for storage
above room
temperature. As a general rule of thumb, storage at a lower temperature
reduces the thickness
required, all other conditions being equivalent.
[0349] The following conclusions are reached, based on this test. First,
the amount of
dissolved Si in the SiOx coating or glass increases exponentially with
increasing pH. Second,
the SiOx coating dissolves more slowly than borosilicate glass at a pH lower
than 8. The SiOx
coating shows a linear, monophasic dissolution over time, whereas borosilicate
glass tends to
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
show a more rapid dissolution in the early hours of exposure to solutions,
followed by a slower
linear dissolution. This may be due to surface accumulation of some salts and
elements on
borosilicate during the forming process relative to the uniform composition of
the SiOx coating.
This result incidentally suggests the utility of a SiOx coating on the wall of
a borosilicate glass vial
to reduce dissolution of the glass at a pH lower than 8. Third, PECVD applied
barrier coatings
for vials in which pharmaceutical preparations are stored will need to be
adapted to the specific
pharmaceutical preparation and proposed storage conditions (or vice versa), at
least in some
instances in which the pharmaceutical preparation interacts with the barrier
coating significantly.
Example 27
[0350] An experiment is conducted with vessels coated with siox coating
+ OMCTS pH
protective coating or layer, to test the pH protective coating or layer for
its functionality as a
protective coating or layer. The vessels are 5 mL vials (the vials are
normally filled with product
to 5 mL; their capacity without headspace, when capped, is about 7.5 mL)
composed of cyclic
olefin co-polymer (COC, Tapas 6013M-07).
[0351] Sixty vessels are coated on their interior surfaces with an SiOx
coating produced in a
plasma enhanced chemical vapor deposition (PECVD) process using a HMDSO
precursor gas
according to the Protocol for Coating Tube Interior with SiOx set forth above,
except that
equipment suitable for coating a vial is used. The following conditions are
used.
= HMDSO flow rate: 0.47 sccm
= Oxygen flow rate: 7.5 sccm
= RF power: 70 Watts
= Coating time: 12 seconds (includes a 2-sec RF power ramp-up time)
[0352] Next the SiOx coated vials are coated over the SiOx with an
SiOxCy coating produced
in a PECVD process using an OMCTS precursor gas according to the Protocol for
Coating COC
Syringe Barrel Interior with OMCTS Lubricity Coating set forth above, except
that the same
coating equipment is used as for the SiOx coating. Thus, the special
adaptations in the protocol
for coating a syringe are not used. The following conditions are used.
= OMCTS flow rate: 2.5 sccm
= Argon flow rate: 10 sccm
= Oxygen flow rate: 0.7 sccm
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
- RF power: 3.4 Watts
- Coating time: 5 seconds
[0353] Eight vials are selected and the total deposited quantity of
PECVD coating (SiO. +
SiO,Cy) is determined with a Perkin Elmer Optima Model 7300DV ICP-OES
instrument, using
the Protocol for Total Silicon Measurement set forth above. This measurement
determines
the total amount of silicon in both coatings, and does not distinguish between
the respective
SiO, and SiO,Cy coatings. The results are shown below.
Vial Total Silicon ug/L
1 13844
2 14878
3 14387
4 13731
15260
6 15017
7 15118
8 12736
Mean 14371
Std Dev 877
Quantity of SiOx + Lubricity layer
on Vials
[0354] In the following work, except as indicated otherwise in this
example, the Protocol
for Determining Average Dissolution Rate is followed. Two buffered pH test
solutions are used
in the remainder of the experiment, respectively at pH 4 and pH 8 to test the
effect of pH on
dissolution rate. Both test solutions are 50 nnM buffers using potassium
phosphate as the buffer,
diluted in water for injection (WEI) (0.1 um sterilized, filtered). The pH is
adjusted to pH 4 or 8,
respectively, with concentrated nitric acid.
[0355] 25 vials are filled with 7.5 ml per vial of pH 4 buffered test
solution and 25 other
vials are filled with 7.5 ml per vial of pH 4 buffered test solution (note the
fill level is to the top
of the vial ¨ no head space). The vials are closed using prewashed butyl
stoppers and aluminum
crimps. The vials at each pH are split into two groups. One group at each pH
containing 12
vials is stored at 4 C and the second group of 13 vials is stored at 23 C
[0356] The vials are sampled at Days 1, 3, 6, and 8. The Protocol for
Measuring Dissolved
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
Silicon in a Vessel is used, except as otherwise indicated in this example.The
analytical result is
reported on the basis of parts per billion of silicon in the buffered test
solutions of each vial. A
dissolution rate is calculated in terms of parts per billion per day as
described above in the
Protocol for Determining Average Dissolution Rate. The results at the
respective storage
temperatures follow:
Shelf Life Conditions 23g C
Vial SiO, + Lubricity Vial SiO, +
Lubricity
Coating at pH4 Coating at
pH8
Si Dissolution Rate(PPB/day) 31 7
Shelf Life Conditions 42 C
Vial SiO, + Lubricity Vial SiO, +
Lubricity
Coating at pH4 Coating at
pH8
Si Dissolution Rate (PPB/day) 7 11
[0357] The observations of Si dissolution versus time for the OMCTS-
based coating at pH 8
and pH 4 indicate the pH 4 rates are higher at ambient conditions. Thus, the
pH 4 rates are used
to determine how much material would need to be initially applied to leave a
coating of adequate
thickness at the end of the shelf life, taking account of the amount of the
initial coating that would
be dissolved. The results of this calculation are:
Vial SiO, + Lubricity
Coatingat pH4
Si Dissolution Rate (PPB/day) 31
Mass of Coating Tested (Total Si) 14,371
Shelf Life (days) at 232 C 464
Shelf Life (years) at 23Q C 1.3
Required Mass of Coating (Total Si) ¨ 2 years 22,630
Required Mass of Coating (Total Si) ¨ 3 years 33,945
Shelf Life Calculation
[0358] Based on this calculation, the OMCTS protective layer needs to be
about 2.5 times
thicker ¨ resulting in dissolution of 33945 ppb versus the 14,371 ppb
representing the entire mass
of coating tested ¨ to achieve a 3-year calculated shelf life.
Example 28
[0359] The results of Comparative Example 26 and Example 27 above can be
compared
as follows, where the "pH protective coating or layer" is the coating of
SiOxCy referred to in
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
Example BB.
Shelf Life Conditions - - pH8 and 232 C
Vial SiOx Vial SiOx + Lubricity
Coating
Si Dissolution Rate (PPB/day) 1,250 7
[0360] This data shows that the silicon dissolution rate of SiOx alone
is reduced by more
than 2 orders of magnitude at pH 8 in vials also coated with SiOxCy coatings.
Example 29
[0361] Another comparison is shown by the following data from several
different
experiments carried out under similar accelerated dissolution conditions, of
which the 1- day data
is also presented in FIG. 30.
Silicon Dissolution with pH 8 at 40 C (ug/L)
Vial Coating Description 1day 2days 3days 4 days 7 days 10days
15 days
A. SiOx made with HMDSO
Plasma + SiwOxCy or its
165 211 226 252 435 850 1,364
equivalent SiOxCy made with
OMCTS Plasma
B. SiwOxCy or its equivalent
SiOxCy made with OMCTS 109 107 76 69 74 158
198
Plasma
C. SiOx made with HMDSO
2,504 4,228 5,226 5,650 9,292 10,177 9,551
Plasma
D. SiOx made with HMDSO
Plasma + SiwOxCy or its
1,607 1,341 3,927 10,182 18,148 20,446 21,889
equivalent SiOxCy made with
HMDSO Plasma
E. SiwOxCy or its equivalent
SiOxCy made with HMDSO 1,515 1,731 1,813 1,743 2,890 3,241
3,812
Plasma
[0362] FIG. 30 and Row A (SiO, with OMCTS coating) versus C (SiO,
without OMCTS
coating) show that the OMCTS pH protective coating or layer is also an
effective protective
coating or layer to the SiOx coating at pH 8. The OMCTS coating reduced the
one-day
dissolution rate from 2504 ug/L ("u" or or the Greek letter "mu" as used
herein are identical,
and are abbreviations for "micro") to 165 ug/L. This data also shows that an
HMDSO-based
SiwOxCy (or its equivalent SiOxCy) overcoat (Row D) provided a far higher
dissolution rate than
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
an OMCTS-based SiwOxCy (or its equivalent SiOxCy) overcoat (Row A). This data
shows that a
substantial benefit can be obtained by using a cyclic precursor versus a
linear one.
Example 30
[0363] Samples 1-6 as listed in Table 9 were prepared as described in
Example AA, with
further details as follows.
[0364] A cyclic olefin copolymer (COC) resin was injection molded to
form a batch of 5m1 vials.
Silicon chips were adhered with double-sided adhesive tape to the internal
walls of the vials.
The vials and chips were coated with a two-layer coating by plasma enhanced
chemical vapor
deposition (PECVD). The first layer was composed of SiOx with barrier
properties as defined in
the present disclosure, and the second layer was an SiOxCy pH protective
coating or layer.
[0365] A precursor gas mixture comprising OMCTS, argon, and oxygen was
introduced
inside each vial. The gas inside the vial was excited between capacitively
coupled electrodes
by a radio-frequency (13.56 MHz) power source. The monomer flow rate (Fm) in
units of scorn,
oxygen flow rate (Fo) in units of sccnn, argon flowrate in sccm, and power (W)
in units of watts
are shown in Table 9.
[0366] A composite parameter, W/FM in units of kJ/kg, was calculated
from process
parameters W, Fm, Fo and the molecular weight, M in g/mol, of the individual
gas species.
W/FM is defined as the energy input per unit mass of polymerizing gases.
Polymerizing
gases are defined as those species that are incorporated into the growing
coating such as, but
not limited to, the monomer and oxygen. Non-polymerizing gases, by contrast,
are those species
that are not incorporated into the growing coating, such as but not limited to
argon, helium and
neon.
[0367] In this test, PECVD processing at high W/FM is believed to have
resulted in higher
monomer fragmentation, producing organosiloxane coatings with higher cross-
link density.
PECVD processing at low W/FM, by comparison, is believed to have resulted in
lower
monomer fragmentation producing organosiloxane coatings with a relatively
lower cross-link
density.
[0368] The relative cross-link density of samples 5, 6, 2, and 3 was
compared between
different coatings by measuring FTIR absorbance spectra. The spectra of
samples 5, 6, 2, and 3
are provided in FIGS. 33 to 36. In each spectrum, the ratio of the peak
absorbance at the
symmetric stretching mode (1000-1040 cm-1) versus the peak absorbance at the
asymmetric
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
stretching mode (1060-1100 cm-1) of the Si-O-Si bond was measured, and the
ratio of these two
measurements was calculated, all as shown in Table 9. The respective ratios
were found to have
a linear correlation to the composite parameter W/FM as shown in FIG. 31.
[0369] A qualitative relation ¨ whether the coating appeared oily
(shiny, often with
irridescence) or non-oily (non-shiny) when applied on the silicon chips ¨ was
also found to
correlate with the W/FM values in Table 9. Oily appearing coatings deposited
at lower W/FM
values, as confirmed by Table 9, are believed to have a lower crosslink
density, as determined
by their lower sym/asym ratio, relative to the non-oily coatings that were
deposited at higher
W/FM and a higher cross-link density. The only exception to this general rule
of thumb was
sample 2 in Table 9. It is believed that the coating of sample 2 exhibited a
non-oily appearance
because it was was too thin to see. Thus, an oilyness observation was not
reported in
Table 9 for sample 2. The chips were analyzed by FTIR in transmission mode,
with the
infrared spectrum transmitted through the chip and sample coating, and the
transmission
through an uncoated null chip subtracted.
[0370] Non-oily organosiloxane layers produced at higher W/FM values,
which protect the
underlying SiOx coating from aqueous solutions at elevated pH and temperature,
were preferred
because they provided lower Si dissolution and a longer shelf life, as
confirmed by Table 9.
For example, the calculated silicon dissolution by contents of the vial at a
pH of 8 and 40 C was
reduced for the non-oily coatings, and the resulting shelf life was 1381 days
in one case and 1147
days in another, as opposed to the much shorter shelf lives and higher rates
of dissolution for
oily coatings. Calculated shelf life was determined as shown for Example AA.
The calculated
shelf life also correlated linearly to the ratio of symmetric to asymmetric
stretching modes of the
Si-0- Si bond in organosiloxane pH protective coatings or layers.
[0371] Sample 6 can be particularly compared to Sample 5. An
organosiloxane, pH protective
coating or layer was deposited according to the process conditions of sample 6
in Table 9. The
coating was deposited at a high W/FM. This resulted in a non-oily coating with
a high Si-O-Si
sym/asym ratio of 0.958, which resulted in a low rate of dissolution of 84.1
ppb/day (measured
by the Protocol for Determining Average Dissolution Rate) and long shelf life
01 1147 days
(measured by the Protocol for Determining Calculated Shelf Life). The FTIR
spectra of this
coating is shown in Figure 35, which exhibits a relatively similar asymmetric
Si-O-Si peak
absorbance compared to the symmetric Si-O-Si peak absorbance. This is an
indication of a
higher cross-link density coating, which is a preferred characteristic for pH
protection and long
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
shelf life.
[0372] An organosiloxane pH protective coating or layer was deposited
according to the
process conditions of sample 5 in Table 9. The coating was deposited at a
moderate W/FM. This
resulted in an oily coating with a low Si-0-Si sym/asym ratio of 0.673, which
resulted in a high
rate of dissolution of 236.7 ppb/day (following the Protocol for Determining
Average Dissolution
Rate) and shorter shelf life of 271 days (following the Protocol for
Determining Calculated Shelf
Life). The FTIR spectrum of this coating is shown in FIG. 13, which exhibits a
relatively high
asymmetric Si-0-Si peak absorbance compared to the symmetric Si-0-Si peak
absorbance. This
is an indication of a lower cross-link density coating, which is contemplated
in any embodiment
to be an unfavorable characteristic for pH protection and long shelf life.
[0373] Sample 2 can be particularly compared to Sample 3. A pH
protective coating or layer
was deposited according to the process conditions of sample 2 in Table 9. The
coating was
deposited at a low W/FM. This resulted in a coating that exhibited a low Si- 0-
Si sym/asym ratio
of 0.582, which resulted in a high rate of dissolution of 174 ppb/day and
short shelf life of 107
days. The FTIR spectrum of this coating is shown in Figure 36, which exhibits
a relatively high
asymmetric Si-0-Si peak absorbance compared to the symmetric Si-0-Si peak
absorbance.
This is an indication of a lower cross-link density coating, which is an
unfavorable characteristic
for pH protection and long shelf life.
[0374] An organosiloxane, pH pH protective coating or layer was
deposited according to
the process conditions of sample 3 in Table 9. The coating was deposited at a
high W/FM. This
resulted in a non-oily coating with a high Si-0-Si sym/asym ratio of 0.947,
which resulted in a
low rate of Si dissolution of 79.5 ppb/day (following the Protocol for
Determining Average
Dissolution Rate) and long shelf life of 1381 days (following the Protocol for
Determining
Calculated Shelf Life). The FTIR spectrum of this coating is shown in Figure
37, which exhibits
a relatively similar asymmetric Si-0-Si peak absorbance compared to the
symmetric Si-0-Si
peak absorbance. This is an indication of a higher cross-link density coating,
which is a
preferred characteristic for pH protection and long shelf life.
CA 03183219 2022- 12- 16
n
>
o
u J
,
r'qj
to .
N J
o
N J
N J
, .
N J
Ci)
0
l,4
0
TABLE 9
l,4
I¨,
l-µ4
!A
-4
Process Parameters Si
Dissolution @ pH8/40 C FT I R Absorbance ,1
l,4
DO
Si-O-Si
Si-O-Si sym asym
Flow Rate
of stretch stretch Ratio Si-0-
Rate 02 Flow Power W/FM
Total Si Shelf life Dissolution (1000-1040 (1060- Si
Samples OMCTS Ar Rate (W) (kJ/kg) (ppb)
(days) (ppb/day) cm-1) 1100 cm-1) (sym/asym) Oilyness
1
3 10 0.5 14 21613 43464 385 293.18 0.153 0.219 0.700 YES
2 3 20 0.5 2 3088 7180 107 174.08
0.011 0.020 0.582 NA
3 1 20 0.5 14 62533 42252.17 1381 79.53
0.093 0.098 0.947 NO
4 2 15 0.5 8 18356 27398 380 187.63 0.106 0.141 0.748 YES
3 20 0.5 14 21613 24699 271 236.73 0.135 0.201 0.673 YES
6
1 10 0.5 14 62533 37094 1147 84.1 0.134 0.140 0.958 NO
ro
n
-1-.,
Cl)
l,4
0
ts4
I¨,
0
Co)
-4
0
0
-4
WO 2021/257728
PCT/US2021/037667
.
'
Example 31
[0375] An experiment similar to Example 27 was carried out, modified
as indicated in this
example and in Table 10 (where the results are tabulated). 100 5 mL COP vials
were
made and coated with an SiOx barrier layer and an OMCTS-based pH protective
coating
or layer as described previously, except that for Sample PC194 only the pH
protective
coating or layer was applied. The coating quantity was again measured in parts
per
billion extracted from the surfaces of the vials to remove the entire pH
protective
coating or layer, as reported in Table 10.
[0376] In this example, several different coating dissolution conditions were
employed. The test solutions used for dissolution contained either 0.02 or 0.2
wt.%
polysorbate-80 surfactant, as well as a buffer to maintain a pH of 8.
Dissolution tests were
carried out at either 23 C or 40 C. Multiple syringes were filled with each
test solution,
stored at the indicated temperature, and analyzed at several intervals to
determine the
extraction profile and the amount of silicon extracted. An average dissolution
rate for
protracted storage times was then calculated by extrapolating the data
obtained according
to the Protocol for Determining Average Dissolution Rate. The results were
calculated
as described previously and are shown in Table 10. Of particular note, as
shown on Table
10, were the very long calculated shelf lives of the filled packages provided
with a PC
194 pH protective coating or layer:
= 21045 days (over 57 years) based on storage at a pH of 8, 0.02 wt.%
polysorbate-80 surfactant, at 23 C;
= 38768 days (over 100 years) based on storage at a pH of 8, 0.2 wt.%
polysorbate-80 surfactant, at 23 C;
= 8184 days (over 22 years) based on storage at a pH of 8, 0.02 wt.%
polysorbate-
80 surfactant, at 40 C; and
= 14732 days (over 40 years) based on storage at a pH of 8, 0.2 wt.%
polysorbate-
80 surfactant, at 40 C.
[0377] Referring to Table 10, the longest calculated shelf lives
corresponded with the use
of an RE power level of 150 Watts and a corresponding high W/FM value. It is
believed
that the use of a higher power level causes higher cross-link density of the
pH protective
coating or layer.
CA 03183219 2022- 12- 16
n
>
o
u ,
,
0
u ,
tol
r . ,
rr. J3
, .
r . ,
Ci)
TABLE 10
o
N
0
N
b."
OM CTS Argon 02
Total Si Average !A
Plasma
Calculated --.1
Sample Flow Flow Flow Power Duration
W/FRA (PPb) Shelf-life Rate of -4
N
PP
Rate Rate Rate (W)
(kJ/kg) (OMCTS) Dissolution
(sec)
(days)
(sccm) (sccm) (sccm)
layer) (ppb/day)
Process Parameters Si
Dissolution @ pH8/23'C/0.02 /0 Tweene-80
PC194 0.5 20 0.5 150 20 1223335
73660 21045 3.5
018 1.0 20 0.5 18 15 77157
42982 1330 32.3
Process Parameters Si
Dissolution @ pH8/23PC/0.2 /0Tweene-80
PC194 0.5 20 0.5 150 20 1223335
73660 38768 1.9
018 1.0 20 0.5 18 15 77157
42982 665 64.6
048 4 80 2 35 20 37507
56520 1074 52.62
Process Parameters Si
Dissolution @ pH8/40 C/0.02 /0 Tweene-80
PC194
0.5 20 0.5 150 20 1223335 73660 8184 9
018
it
1.0 20 0.5 18 15 77157 42982 511 84
n
.t.!
Cl)
Process Parameters Si
Dissolution @ pH8/40 C/0.2 /oTweene-80 N
0
ts.)
PC194 0.5 20 0.5 150 20 1223335
73660 14732 5 O-I--
c.4
--4
cA
018 1.0 20 0.5 18 15 77157
42982 255 168 c,
--.1
WO 2021/257728
PCT/US2021/037667
Example 32
[0378] Another series of experiments similar to those of Example 31
are run, showing
the effect of progressively increasing the RF power level on the FTIR
absorbance
spectrum of the pH protective coating or layer. The results are tabulated in
Table 11, which
in each instance shows a symmetric / assymmetric ratio greater than between
the
maximum amplitude of the Si-0-Si symmetrical stretch peak normally located
between
about 1000 and 1040 cm-1, and the maximum amplitude of the Si-0-Si assymmetric
stretch
peak normally located between about 1060 and about 1100 cm-1. Thus, the
symmetric /
assymmetric ratio is 0.79 at a power level of 20 W, 1.21 or 1.22 at power
levels of 40, 60,
or BOW, and 1.26 at 100 Watts under otherwise comparable conditions.
[0379] The 150 Watt data in Table 11 is taken under somewhat
different conditions
than the other data, so it is not directly comparable with the 20 ¨ 100 Watt
data
discussed above. The FTIR data of samples 6 and 8 of Table 11 was taken from
the
upper portion of the vial and the FTIR data of samples 7 and 9 of Table 11 was
taken
from the lower portion of the vial. Also, the amount of OMCTS was cut in half
for
samples 8 and 9 of Table 11, compared to samples 6 and 7. Reducing the oxygen
level
while maintaining a power level of 150 W raised the symmetric / asymmetric
ratio still
further, as shown by comparing samples 6 and 7 to samples 8 and 9 in Table 11.
[0380] It is believed that, other conditions being equal, increasing
the symmetric /
asymmetric ratio increases the shelf life of a vessel filled with a material
having a pH
exceeding 5.
[0381] Table 12 shows the calculated 0-Parameters and N-Parameters
(as defined in
U.S. Pat. No. 8,067,070) for the experiments summarized in Table 11. As Table
12 shows,
the 0-Parameters ranged from 0.134 to 0.343, and the N-Parameters ranged from
0.408
to 0.623 ¨ all outside the ranges claimed in U.S. Pat. No. 8,067,070.
CA 03183219 2022- 12- 16
9
.
. 65810W001 (S10-
0171 PC)
,
,
.
,
,
.
0
N
0
N
TABLE 11
.
-.-J
!A
--1
,1
N
DO
02 Plasm
Symmetri Assymetr
OMCT Argon Flow a c Stretch icStretch
Symmetric /
Sample S Flow Flow
Rate Pme Durati W/FM Peak at Peak at Assymetric
s ID Rate Rate r (W) (kJ/kg)
(scc on 1000- 1060- Ratio
(sccm) (sccm)
m) (sec) 1040
cm-1 1100 cm-1
Process Parameters
FTIR Results
1 1 20 0.5 20 20 85,730
0.0793 0.1007 0.79
2 1 20 0.5 40 20 171,460
0.0619 0.0507 1.22
3 1 20 0.5 60 20 257,190
0.1092 0.0904 1.21
4 1 20 0.5 80 20 342,919
0.1358 0.1116 1.22
1 20 0.5 100 20 428,649 0.209 0.1658 1.26
6 1 20 0.5 150 20 642,973
0.2312 0.1905 1.21
7 1 20 0.5 150 20 642,973
0.2324 0.1897 1.23
8 0.5 20 0.5 150 20 1,223,335
0.1713 0.1353 1.27 1-0
n
9 0.5 20 0.5 150 20 1,223,335
0.1475 0.1151 1.28
cp
N
0
tsJ
I-,
0
C=4
-4
0 \
0 \
--1
n
1;
, 65810W001 (S10-
0171 PC)
.-
,
,
TABLE 12
o
N
0
N
I¨,
l-=J
!A
--1
,1
N
DO
OMCTS Argon 02 Flow Plasma
Samples Flow Rate Flow Rate Rate Power Duration -- W/FM
ID (sccm) (sccm) (sccm) (W) (sec)
(kJ/kg) 0-Parameter N-Parameter
Process Parameters
1 1 20 0.5 20 20
85,730 0.343 0.436
2 1 20 0.5 40 20
171,460 0.267 0.408
3 1 20 0.5 60 20
257,190 0.311 0.457
4 1 20 0.5 80 20
342,919 0.270 0.421
1 20 0.5 100 20 428,649 0.177 0.406
6 1 20 0.5 150 20
642,973 0.151 0.453
7 1 20 0.5 150 20
642,973 0.151 0.448
8 0.5 20 0.5 150 20
1,223,335 0.134 0.623
9 0.5 20 0.5 150 20
1,223,335 0.167 0.609 1-0
n
Cl)
N
0
tsJ
I¨,
0
C=4
-4
0 \
0 \
--1
WO 2021/257728
PCT/US2021/037667
Example 33
[0382] The purpose of this example was to evaluate the recoverability
or drainage of a
slightly viscous aqueous solution from glass, COP and coated vials.
[0383] This study evaluated the recovery of a 30 cps (centipoise)
carbohydrate
solution in water-for-injection from (A) an uncoated COP vial, (B) an SiOx +
pH protective
layer coated COP vial prepared according to the above Protocol for Coating
Syringe Barrel
Interior with SiOx, followed by the Protocol for Coating Syringe Barrel
Interior with OMCTS
PH protective Coating or Layer, and (C) a glass vial.
[0384] 2.0 ml of the carbohydrate solution was pipetted into 30 vials
each of glass,
COP and pH protective coated vials. The solution was aspirated from the vials
with a 10
ml syringe, through a 23 gauge, 1.5" needle. The vials were tipped to one side
as the
solution was aspirated to maximize the amount recovered. The same technique
and
similar withdrawal time was used for all vials. The vials were weighed empty,
after placing
2.0 ml of the solution to the vial and at the conclusion of aspirating the
solution from the
vial. The amount delivered to the vial (A) was determined by subtracting the
weight of
the empty vial from the weight of the vial with the 2.0 ml of solution. The
weight of
solution not recovered (B) was determined by subtracting the weight of the
empty vial
from the weight of the vials after aspirating the solution from the vial. The
percent
unrecovered was determined by dividing B by A and multiplying by 100.
[0385] It was observed during the aspiration of drug product that the
glass vials
remained wetted with the solution. The COP vial repelled the liquid and as the
solution was
aspirated from the vials. This helped with recovery but droplets were observed
to bead on
the sidewalls of the vials during the aspiration. The pH protective coated
vials also repelled
the liquid during aspiration but no beading of solution on the sidewalls was
observed.
[0386] The conclusion was that pH protective coated vials do not wet
with aqueous
solutions as do glass vials, leading to superior recovery of drug product
relative to glass. pH
protective coated vials were not observed to cause beading of solution on
sidewall during
aspiration of aqueous products therefore coated vials performed better than
uncoated COP
vials in product recovery experiments.
[0387] The hydrophobic characteristics of the pH protective coating
or layer may have
significant benefit/use in the multi-use, cosmetic, and/or fragrance packages
of the present
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
disclosure, regardless of whether or not the pH protective coating or layer is
applied over a
barrier coating or layer and/or intended to protect any such barrier coating
or layer from
dissolution. For instance, a hydrophobic coating or layer may help ensure that
more of a
water-based fluid contained within the lumen of a vessel is available for
extraction, e.g. by
the applicator, because it does not stick to the walls of the vessel.
Example 34
[0388] Syringe samples were produced as follows. A COC 8007 extended
barrel
syringe was produced according to the Protocol for Forming COC Syringe Barrel.
An SiOx
coating or layer was applied to some of the syringes according to the Protocol
for coating
COC Syringe Barrel Interior with SiOx. A pH protective coating or layer was
applied to
the SiOx coated syringes according to the Protocol for Coating COC Syringe
Barrel Interior
with OMCTS Lubricity Coating, modified as follows. The OMCTS was supplied from
a
vaporizer, due to its low volatility. Argon carrier gas was used. The process
conditions
were set to the following:
= OMCTS ¨ 3 sccm
= Argon gas ¨ 65 sccm
- Power ¨ 6 watts
= Time ¨ 10 seconds
[0389] The coater was later determined to have a small leak while
producing the
samples identified in the Table, which resulted in an estimated oxygen flow of
1.0 sccm. The
samples were produced without introducing oxygen.
[0390] The coatings produced according to these working examples are
contemplated
to function as primer coatings or layers, and also as protective coatings or
layers to increase
the shelf life of the vessels, compared to similar vessels provided with a
barrier coating or
layer but no pH protective coating or layer.
PECVD Process for Trilayer Coating
[0391] The PECVD trilayer coating described in this specification can
be applied, for
example, as follows for a 1 to 5 mL vessel. Two specific examples are 1 mL
thermoplastic
resin syringe and a 5 mL thermoplastic resin drug vial. Though the present
application
is not specifically directed to these syringes and vials, larger or smaller
vessels for
various multi-use, cosmetic, and/or fragrance packages, will call for
adjustments in
parameters that a person of ordinary skill can carry out in view of the
teaching of this
CA 03183219 2022- 12- 16
WO 2021/257728 PCT/US2021/037667
specification.
[0392] The apparatus used is the PECVD apparatus with rotating
quadrupole magnets
as described generally in this specification.
[0393] The general coating parameter ranges, with preferred ranges in
parentheses, for
a trilayer coating for a 1 mL syringe barrel are shown in the PECVD Trilayer
Process General
Parameters Tables (1 mL syringe and 5 mL vial).
PECVD Trilayer Process General Parameters Table (1 mL syringe)
Parameter Units Tie Barrier pH Protective
Power W 40-90 (60-80) 140 40-90 (60-
80)
TMDSO Flow sccm 1-10 (3-5) None 1-10 (3-
5)
HMDSO Flow sccm None 1.56 None
02 Flow sccm 0.5-5 (1.5-2.5) 20 0.5-5 (1.5-
2.5)
Argon Flow sccm 40-120 (70-90) 0 40-120 (70-90)
Ramp Time seconds None None None
Deposition Time seconds 0.1-10 (1-3) 20 0.1-40 (15-25)
Tube Pressure Torr 0.01-10 (0.1-1.5)
0.59 0.01-10 (0.1-1.5)
PECVD Trilayer Process General Parameters Table (5 mL vial)
Parameter Units Adhesion Barrier Protection
Power W 40-90 (60-80) 140 40-90 (60-
80)
TMDSO Flow sccm 1-10 (3-5) None 1-10 (3-
5)
HMDSO Flow sccm None 1.56 None
02 Flow sccm 0.5-5 (1.5-2.5) 20 0.5-5 (1.5-
2.5)
Argon Flow sccm 40-120 (70-90) 0 40-120 (70-90)
Ramp Time seconds None None None
Deposition Time seconds 0.1-10 (1-3) 20 0.1-40 (15-25)
Tube Pressure Torr 0.01-10 (0.1-1.5)
0.59 0.01-10 (0.1-1.5)
CA 03183219 2022- 12- 16
WO 2021/257728 PCT/US2021/037667
Example 35
[0394] Examples of specific coating parameters that have been used
for a 1 mL
syringe and 5 mL vial are shown in the PECVD Trilayer Process Specific
Parameters
Tables (1 mL syringe and 5 mL vial):
PECVD Trilayer Process Specific Parameters Table (1 mL syringe)
Parameter Units Tie Barrier pH Protective
Power W 70 140 70
TMDSO Flow sccm 4 None 4
HMDSO Flow sccm None 1.56 None
02 Flow sccm 2 20 2
Argon Flow sccm 80 0 80
Ramp Time seconds None None None
Deposition Time seconds 2.5 20 10
Tube Pressure Torr 1 0.59 1
PECVD Trilayer Process Specific Parameters Table (5 mL vial)
Parameter Units Adhesion Barrier Protection
Power W 20 40 20
TMDSO Flow sccm 2 0 2
HMDSO Flow sccm 0 3 0
02 Flow sccm 1 50 1
Argon Flow sccm 20 0 20
Ramp Time seconds 0 2 2
Deposition Time seconds 2.5 10 10
Tube Pressure Torr 0.85 1.29 0.85
[0395] The 0-parameter and N-parameter values for the pH protective
coating or
layer applied to the 1 mL syringe as described above are 0.34 and 0.55,
respectively.
[0396] The 0-parameter and N-parameter values for the pH protective
coating or
layer applied to the 5 mL vial are 0.24 and 0.63, respectively.
Example 36
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
[0397] Referring to Fig. 38 and Table, Example 36, the thickness
uniformity at four
different points along the length of a 1 mL syringe with a staked needle
(present during
PECVD deposition) and the indicated trilayer coating (avg. thicknesses: 38 nm
adhesion or
tie coating or layer; 55 nm barrier coating or layer, 273 nm pH protective
coating or layer) is
shown. The table shows individual layer thicknesses at the four marked points,
showing
adequate thickness of each layer at each point along the high profile syringe
barrel.
TABLE, Example 36
Syringe Location Adhesion Barrier Protection
1 46 75 343
2 38 55 273
3 86 47 493
4 42 25 287
[0398] Referring to FIG. 39, the plot maps the coating thickness over
the portion of the
cylindrical inner surface of the barrel shown in FIG. 38, as though unrolled
to form a
rectangle. The overall range of thickness of the trilayer coating is 572 plus
or minus 89 nm.
[0399] FIG. 40 is a photomicrograph showing a cross-section of the
trilayer coating on
a COP syringe substrate at the point 2 shown in FIG. 38.
[0400] A syringe having a coating similar to the trilayer coating of
FIGS. 38-40 is
tested for shelf life, using the silicon dissolution and extrapolation method
described in this
specification, compared to syringes having a bilayer coating (similar to the
trilayer coating
except lacking the tie coating or layer) and a monolayer coating which is just
the pH
protective coating or layer directly applied to the thermoplastic barrel of
the syringe, with no
barrier layer. The test solution was a 0.2% Tween, pH 8 phosphate buffer. The
extrapolated
shelf lives of the monolayer and trilayer coatings were similar and very long
¨ on the
order of 14 years. The shelf life of the syringes having a bilayer coating
were much lower
¨ less than two years. In other words, the presence of a barrier layer under
the pH protective
layer shortened the shelf life of the coating substantially, but the shelf
life was restored by
providing a tie coating or layer under the barrier layer, sandwiching the
barrier coating
or layer with respective SiO,Cy layers. The barrier layer is necessary to
establish a gas
barrier, so the monolayer coating would not be expected to provide adequate
gas barrier
properties by itself. Thus, only the trilayer coating had the combination of
gas barrier
properties and a long shelf life, even while in contact with a solution that
would attack an
exposed barrier coating or layer.
CA 03183219 2022- 12- 16
WO 2021/257728 PCT/US2021/037667
Example 37
[0401] FIGS. 41 and 42 show a trilayer coating distribution for the 5
mL vial, which is
much shorter in relation to its inner diameter and thus easier to coat
uniformly, showing
very little variation in coating thickness, with the great majority of the
surface coated
between 150 and 250 nm thickness of the trilayer, with only a small proportion
of the
container coated with between 50 and 250 nm of the trilayer.
Example 38
[0402] Figure 43 shows the breakdown of coating thickness (nm) by
vial location.
The Vial Coating Distribution Table shows the uniformity of coating.
Vial Coating Distribution Table
Vial Location Adhesion Barrier Protection Total
Trilayer,nm
1 13 29 77 119
2 14 21 58 93
3 25 37 115 177
4 35 49 158 242
39 49 161 249
6 33 45 148 226
7 31 29 153 213
8 48 16 218 282
9 33 53 155 241
31 29 150 210
Average 30 36 139 205
Example 39
[0403] Fig. 44 is a visual test result showing the integrity of the
trilayer vial coating
described above. The three 5 mL cyclic olefin polymer (COC) vials of FIGS. 44
and 44A
were respectively:
= uncoated (left vial),
= coated with the bilayer coating described in this specification (a
barrier coating or
layer plus a pH protective coating or layer ¨ the second and third components
of
the trilayer coating) (center vial); and
= coated with the trilayer coating as described above (right vial).
[0404] The three vials were each exposed to 1 N potassium hydroxide
for four hours,
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
then exposed for 24 hours to a ruthenium oxide (Ru04) stain that darkens any
exposed part
of the thermoplastic vial unprotected by the coatings. The high pH potassium
hydroxide
exposure erodes any exposed part of the barrier coating or layer at a
substantial rate, greatly
reduced, however by an intact pH protective coating or layer. In particular,
the high pH
exposure opens up any pinholes in the coating system. As FIG. 44 shows, the
uncoated
vial is completely black, showing the absence of any effective coating. The
bilayer coating
was mostly intact under the treatment conditions, but on microscopic
inspection has many
pinholes (illustrated by FIG. 44A) where the ruthenium stain reached the
thermoplastic
substrate through the coating. The overall appearance of the bilayer coating
clearly shows
visible "soiled" areas where the stain penetrated. The trilayer coating,
however, protected
the entire vial against penetration of the stain, and the illustrated vial
remains clear after
treatment. This is believed to be the result of sandwiching the barrier
coating or layer
between two layers of SiOxCy, which both protects the barrier layer against
direct etching
and against undercutting and removal of flakes of the barrier layer.
Protocol for Total Silicon Measurement
[0405] This protocol is used to determine the total amount of silicon
coatings present on
the entire vessel wall. A supply of 0.1 N potassium hydroxide (KOH) aqueous
solution
is prepared, taking care to avoid contact between the solution or ingredients
and glass.
The water used is purified water, 18 MI) quality. A Perkin Elmer Optima Model
7300DV
ICP-OES instrument is used for the measurement except as otherwise indicated.
[0406] Each device (vial, syringe, tube, or the like) to be tested
and its cap and crimp (in
the case of a vial) or other closure are weighed empty to 0.001 g, then filled
completely with the KOH solution (with no headspace), capped, crimped, and
reweighed
to 0.001g. In a digestion step, each vial is placed in an autoclave oven
(liquid cycle) at
121(C for 1 hour. The digestion step is carried out to quantitatively remove
the silicon
coatings from the vessel wall into the KOH solution. After this digestion
step, the vials
are removed from the autoclave oven and allowed to cool to room temperature.
The
contents of the vials are transferred into ICP tubes. The total Si
concentration is run on each
solution by ICP/OES following the operating procedure for the ICP/OES.
[0407] The total Si concentration is reported as parts per billion of
Si in the KOH
solution. This concentration represents the total amount of silicon coatings
that were on the
vessel wall before the digestion step was used to remove it.
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
[0408] The total Si concentration can also be determined for fewer
than all the silicon
layers on the vessel, as when an SiOx barrier layer is applied, an SiOxCy
second layer (for
example, a lubricity layer or a primer coating or layer) is then applied, and
it is desired
to know the total silicon concentration of just the SiOxCy layer. This
determination is
made by preparing two sets of vessels, one set to which only the SiOx layer is
applied and
the other set to which the same SiOx layer is applied, followed by the SiOxCy
layer or
other layers of interest. The total Si concentration for each set of vessels
is determined in
the same manner as described above. The difference between the two Si
concentrations is
the total Si concentration of the SiOxCy second layer.
Protocol for Measuring Dissolved Silicon in a Vessel
[0409] In some of the working examples, the amount of silicon
dissolved from the wall of
the vessel by a test solution is determined, in parts per billion (ppb), for
example to evaluate
the dissolution rate of the test solution. This determination of dissolved
silicon is made by
storing the test solution in a vessel provided with an SiOx and/or SiOxCy
coating or layer
under test conditions, then removing a sample of the solution from the vessel
and testing
the Si concentration of the sample. The test is done in the same manner as the
Protocol for
Total Silicon Measurement, except that the digestion step of that protocol is
replaced by
storage of the test solution in the vessel as described in this protocol. The
total Si
concentration is reported as parts per billion of Si in the test solution
Protocol for Determining Average Dissolution Rate
[0410] The average dissolution rates reported in the working examples
are determined
as follows. A series of test vessels having a known total total silicon
measurement are filled
with the desired test solution analogous to the manner of filling the vials
with the KOH
solution in the Protocol for Total Silicon Measurement. (The test solution can
be a
physiologically inactive test solution as employed in the present working
examples or a
physiologically active pharmaceutical preparation intended to be stored in the
vessels to
form a pharmaceutical package). The test solution is stored in respective
vessels for several
different amounts of time, then analyzed for the Si concentration in parts per
billion in the
test solution for each storage time. The respective storage times and Si
concentrations are
then plotted. The plots are studied to find a series of substantially linear
points having the
steepest slope.
[0411] The plot of dissolution amount (ppb Si) versus days decreases
in slope with time,
CA 03183219 2022- 12- 16
WO 2021/257728
PCT/US2021/037667
even though it does not appear thatthe Si layer has been fully digested by the
test solution.
[0412] For the PC194 test data in Table 10 below, linear plots of
dissolution versus
time data are prepared by using a least squares linear regression program to
find a
linear plot corresponding to the first five data points of each of the
experimental plots. The
slope of each linear plot is then determined and reported as representing the
average
dissolution rate applicable to the test, measured in parts per billion of Si
dissolved in
the test solution per unit of time.
Protocol for Determining Calculated Shelf Life
[0413] The calculated shelf life values reported in the working
examples are determined
by extrapolation of the total silicon measurements and average dissolution
rates,
respectively determined as described in the Protocol for Total Silicon
Measurement and the
Protocol for Determining Average Dissolution Rate. The assumption is made that
under the
indicated storage conditions the SiOxCy primer coating or layer will be
removed at the
average dissolution rate until the coating is entirely removed. Thus, the
total silicon
measurement for the vessel, divided by the dissolution rate, gives the period
of time required
for the test solution to totally dissolve the SiOxCy coating. This period of
time is reported as
the calculated shelf life. Unlike commercial shelf life calculations, no
safety factor is
calculated. Instead, the calculated shelf life is the calculated time to
failure.
[0414] It should be understood that because the plot of ppb Si versus
hours decreases
in slope with time, an extrapolation from relatively short measurement times
to relatively
long calculated shelf lives is believed to be a "worst case" test that tends
to underestimate
the calculated shelf life actually obtainable.
CA 03183219 2022- 12- 16
